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Sumana Posritong 
REGULATION OF OSTEOBLAST ACTIVITY BY PYK2-TARGETED 
APPROACHES 
 
The hormonal and cellular mechanisms controlling bone formation are not 
completely understood. The proline-rich tyrosine kinase 2 (Pyk2) is important for 
osteoblast (OB) activity and bone formation. However, female mice lacking Pyk2 
(Pyk2-KO) exhibit elevated bone volume/total volume. Previously, our laboratory 
found ovariectomized Pyk2-KO mice supplemented with 17β-estradiol (E2) 
exhibited a greater increase in bone volume than WT mice treated with E2. The 
overall hypotheses of our studies are that Pyk2 regulates OB activity by modulating 
the E2-signaling cascade and that a Pyk2-inhibitor will promote OB activity and be 
suitable for bone regeneration applications. In Aim1, we determined the 
mechanism of action of Pyk2 and E2 in OBs. Pyk2-KO OBs showed significantly 
higher proliferation, matrix formation, and mineralization than WT OBs. In the 
presence of E2 or raloxifene, a selective estrogen receptor (ER) modulator, both 
matrix formation and mineralization were further increased in Pyk2-KO OBs, but 
not WT OBs. Consistent with a role of Pyk2 in E2 signaling, Pyk2-depletion led to 
the proteasome-mediated degradation of ERα, but not ERβ. Finally, we found 
Pyk2-depletion and E2 have an additive effect on ERK phosphorylation, known to 
increase cell differentiation and survival. In Aim2, we developed a Pyk2-inhibitor 
loaded hydrogel and evaluated its viscosity, gelation time, swelling, degradation, 
and release behavior. We found that a hydrogel composed of PEGDA1000 plus 
10% gelatin exhibited viscosity and shear-thinning behavior suitable for use as an 
injectable-carrier. Importantly, the Pyk2-inhibitor-hydrogel was cytocompatible, 
retained its inhibitory activity against Pyk2 leading to an increase in OB activity. In 
conclusion, therapeutic strategies targeting Pyk2 may improve systemic bone 
formation, while Pyk2-inhibitor loaded hydrogels may be suitable for targeted bone 
regeneration in craniofacial and/or the other skeletal defects. 
 
Angela Bruzzaniti, Ph.D., Chair  
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1.1 Bone Cells and Bone Remodeling 
 
Bone is a highly specialized connective tissue that provides protective, 
mechanical, and metabolic functions. Bone tissue consists of three different bone 
cell types; osteoclasts (OC) which degrade bone, osteoblasts (OB) which build 
bone, and osteocytes which mediate signaling to other osteocytes and to OCs and 
OBs on the bone surface in response to mechanical strain and hormonal cues 
(Burr and Allen 2013). Through the coordinated actions of the bone cell types, new 
bone is formed, grows in length and width, and is repaired throughout life through 
the processes of bone modeling and remodeling. However, during aging or as a 
result of certain metabolic diseases, drug usage, or trauma, bone quality and 
quantity is compromised, which can lead to an increase in bone fracture and 
breakage (Burr and Allen 2013; Henriksen et al. 2009; Nakahama 2010). 
1.1.1 Osteoclasts  
OCs are multinucleated cells derived from the hematopoietic stem cell 
lineage and function in bone resorption (Vaananen and Laitala-Leinonen 2008). 
Osteoclastogenesis is regulated by OBs and osteocytes via secretion of receptor 
activator of nuclear factor-κB ligand (RANKL), macrophage colony stimulating 
factor (MCSF), and osteoprotegerin (OPG) among other cytockines (Burr and Allen 
2013; Datta et al. 2008). MCSF induces the proliferation and commitment of OC 
precursors, which, under the control of RANKL, differentiate and fuse to form 
multinucleated OCs. OBs and osteocytes also secrete OPG which acts as a decoy 
receptor for RANKL to prevent osteoclastogenesis. Thus, the ratio of RANKL and 
OPG is a key determinant of OC numbers in vivo (Boyce and Xing 2008; Boyle et 
al. 2003; Burr and Allen 2013). 
1.1.2 Osteoblasts 
OBs are derived from mesenchymal stem cells (MSCs) and are responsible 
for new bone production (Aubin et al. 1995; Datta et al. 2008). OB formation or 
osteoblastogenesis involves multiple steps: proliferation, extracellular matrix 
(ECM) formation and maturation, mineralization, and subsequently apoptosis. 
Each step is controlled by different cytokines, growth factors, hormones, ECM 
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proteins, and transcription factors. Schemas of osteoblastogenesis and the 
osteoblastic genes expressed during this process are shown in Figures 1 and 2, 
respectively.  
MSCs proliferate and become committed to the OB lineage as 
osteoprogenitor cells, which requires the canonical Wnt pathway and associated 
proteins that stimulate osteoblast formation but inhibit adipogenesis of MSCs. In 
addition, the canonical Wnt pathway regulates the expression of transcription 
factors, such as Runt-related transcription factor 2 (Runx2) and osterix (Osx) 
(Kokabu et al. 2016). Transcription factors of the activator protein 1 complex (AP1) 
such as c-fos are also highly expressed during OB proliferation and in the initial 
stages of differentiation (Machwate et al. 1995; Wagner 2002). MSC pre-OBs 
begin to produce the ECM and enter into their differentiation phase (Aubin 1998). 
Mature OBs that are localized along active matrix production sites stain intensely 
for alkaline phosphatase (ALP) (Aubin 1998). Unlike pre-OBs, mature OBs are 
cuboidal in shape, and have a large nucleus, enlarged Golgi apparatus and 
extensive endoplasmic reticulum, which are characteristics of cells highly engaged 
in protein production. Following OB proliferation, mature OBs secrete osteoid 
which then is mineralized. The transition from pre-OBs to mature and mineralizing 
OBs is controlled by the specific expression pattern of key genes and proteins 
(Figure 2).   
Collagen type I, ALP, bone sialoprotein (BSP), osteocalcin (OCN), and 
osteopontin (OPN) (Burr and Allen 2013; Datta et al. 2008; Soares et al. 2008) are 
OB markers expressed during the matrix development. Collagen type I is the main 
component of the ECM in bone, constituting approximately 90% of the total organic 
matrix in bone. The combination of collagen type I and minerals determines the 
mechanical property and functional integrity of bone tissues. Collagen type I 
provides the flexibility of bone, while the mineral in bone is responsible for bone 
strength (Viguet-Carrin et al. 2006). Thus, collagen type I is an early indicator of 
OB differentiation (Liu et al. 1994). Although collagen type I is the most abundant 
organic matrix in bone, other ECM molecules, such as osteonectin and 
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thrombospondin-2, also promote collagen fiber assembly and modulate OB 
lineage progression (Alford et al. 2015).  
Bone-specific ALP is the most commonly used marker to evaluate OB 
activity (Rodan and Noda 1991). The up-regulation of ALP occurs after collagen 
type I production but is detected before the expression of non-collagenous matrix 
markers and prior to mineralization (Long 2001). The main role of ALP in bone is 
to mediate mineralization, hence its expression is correlated with increased 
collagen type I synthesis. In vitro studies found that ALP generates inorganic 
phosphate (Pi) from substrates such as β-glycerophosphate (β-GP) to facilitate 
mineralization (Fallon et al. 1980). In vivo studies have revealed that mineralization 
is facilitated by ALP-mediated elimination of pyrophosphate (PPi), which is a potent 
mineralization inhibitor (Hessle et al. 2002). BSP, a member of the Small Integrin-
binding Ligand N-linked Glycoprotein (SIBLING) family, is also present within the 
bone matrix. BSP contains the Arg-Gly-Asp (RGD) amino acid motifs which 
mediate cell integrin to ECM attachment (Roach 1994). Moreover, BSP can bind 
to hydroxyapatite via polyglutamic acid sequences (Ganss et al. 1999). The 
presence of BSP in bone matrix, combined with a nucleation factor for 
hydroxyapatite formation and deposition, suggests that BSP has a potential role in 
the early mineralization of OBs (Hunter and Goldberg 1993).  
Once the organic matrix or osteoid is deposited OBs secrete ECM vesicles 
which contain calcium apatite crystals and are highly enriched in ALP (Stein et al. 
2004). The alignment of collagen fibrils in osteoid controls the direction of growth 
of the calcium apatite crystals (Anderson et al. 2005; Nudelman et al. 2010). In 
addition to collagen fibrils, non-collagenous ECM proteins, including OCN also 
contribute to mineral crystal nucleation and propagation (Alford et al. 2015). OCN, 
or bone gamma-carboxyglutamic acid, is the most abundant non-collagenous 
protein in bone, and is expressed in mature OBs and osteocytes, and is therefore 
considered to be a marker of late OB differentiation. In addition, OCN serum levels 
are used as a marker for bone turnover in clinical settings (Seibel 2005; Szulc and 
Delmas 2008; Vasikaran et al. 2011). In vitro studies indicate that OCN plays a 
role in regulating mineralization through calcium and hydroxyapatite binding, which 
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may allow OCN deposition within the mineralized matrix (Hauschka et al. 1989; 
Nefussi et al. 1997; Patti et al. 2013; Razzaque 2011).  However, it is worth noting 
that the physiological role of OCN in vivo is still unclear and some studies suggest 
it may be involved in the interaction of OBs with OCs and in bone resorption to 
enhance bone loss. Consistent with this, it has been reported that OCs resorb bone 
poorly in the absence of OCN (Hauschka et al. 1989; Patti et al. 2013; Villafan-
Bernal et al. 2011).  
Another important non-collagenous protein found in mineralized tissue is 
the glycoprotein osteopontin (OPN), which is secreted in both mineralized and non-
mineralized tissues. Within bone tissue, OPN plays key functions including cell 
adhesion, migration and survival (Standal et al. 2004). In addition, OPN can serve 
as a cell-matrix/matrix-mineral mediator due to its intrinsic RGD sequence (McKee 
and Nanci 1996). Further, OPN may also play a mineralization role in non-skeletal 
tissue such as in teeth and epithelial lining tissues. (McKee and Nanci 1996). 
As our knowledge broadens, new markers of mineralization are being 
identified. Recent studies have led to the identification of two novel small leucine-
rich proteoglycans (SLRPs), asporin and keratocan, which also interact with 
collagen and minerals, and are known to promote mineralization (Igwe et al. 2011; 
Kalamajski et al. 2009). However, their mechanism of action is currently unclear. 
At the completion of bone formation, most OBs undergo programmed cell 
death or apoptosis. However, some mature OBs become entrapped in the 
mineralized matrix and differentiate into osteocytes. Alternatively, remaining OBs 
become flat, quiescent bone lining cells, which are mostly found on the non-
remodeling bone surfaces (Aubin et al. 1995; Datta et al. 2008; Harada and Rodan 
2003). The bone lining cells have the potential to be reactivated to form active OBs 
when required for bone repair or in response to physiological changes in hormone 
or mineral levels (Dobnig and Turner 1995). 
1.1.3 Osteocytes 
Osteocytes are the most abundant cells in mineralized bone and are 
important in bone structure maintenance. Osteocytes are terminally differentiated 
cells derived from OBs that have become embedded in the secreted bone matrix 
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(Burr and Allen 2013). Osteocytes are morphologically distinct to OBs and are 
stellate in shape due to the presence of membrane extensions known as dendrites. 
Within bone, osteocytes are enclosed within lacunae, and their dendritic processes 
run along narrow canaliculi within the mineralized matrix to communicate with other 
osteocytes as well as with OCs and OBs on bone surfaces (Burr and Allen 2013; 
Noble 2008). Concomitant with changes in their cell morphology, osteocytes 
exhibit significant decreases in the expression of several OBs-related proteins 
including: collagen type I, ALP, BSP, and OCN. However, osteocytes exhibit higher 
levels of proteins related to bone mineralization, such as dentin matrix protein 1 
(DMP1), matrix extracellular phosphoglycoprotein (MEPE) and fibroblast growth 
factor 23 (FGF 23) (Burr and Allen 2013; Zhu et al. 2001). In addition, osteocytes 
secrete sclerostin, the product of the SOST gene, which is important for controlling 
bone formation by OBs. 
Osteocytes function as mechanosensory cells and coordinate the time and 
location of bone remodeling units (Noble 2008). The osteocyte lacunar-canalicular 
network is present within the entire volume of bone which allows osteocytes to 
detect circulating factors i.e., hormones and ions, as well as mechanical signals 
such as fluid flow and mechanical strain (Noble 2008; van Oers et al. 2008). 
Osteocytes also produce MCSF, RANKL, and OPG and also stimulate OBs to 
secrete these factors, which controls osteoclastogenesis and therefore OC 
number (Simonet et al. 1997; Tatsumi et al. 2007). Furthermore, osteocytes 
secrete sclerostin, which is an antagonist of several members of bone 
morphogenic proteins (BMPs) (Krause et al. 2010) and low-density lipoprotein 
receptor-related proteins (LRP) 5/6 on OBs to counteract Wnt signaling (Li et al. 
2005). Both BMPs and Wnts are important for OB formation and activity. Thus, the 
inhibition of BMPs and Wnts by sclerostin can lead to the disruption of osteoblastic 
bone formation.  
Mechanical loading affects osteocytes by altering fluid flow along the 
lacuna-canalicular system, which leads to the activation of several intracellular 
signaling pathways (van Oers et al. 2008). Mechanical loading results in 
decreased sclerostin levels in bone, allowing activation of Wnt/β-catenin 
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signaling in OBs, which subsequently leads to increased bone formation. 
Conversely, in the absence of mechanical loading, such as when astronauts are 
exposed to weightlessness, and in skeletal unloading during extended bed rest, 
sclerostin expression in bone is increased, which antagonizes Wnt/β-catenin 
signaling in OBs leading to decreased bone formation (Moustafa et al. 2012; Tian 
et al. 2011; van Oers et al. 2011). Osteocytes also respond to mechanical forces 
by releasing prostaglandin E2 (PGE2), which stimulates OB recruitment from the 
bone marrow and activates the Wnt/β-catenin signaling pathway (Liu et al. 2010). 
Furthermore, mechanical loading increases nitric oxide secretion to stimulate bone 
formation.  In addition, skeletal unloading decreases the secretion of OC-inhibitory 
signals (such as OPG) while pro-osteoclastogenesis signals (such as RANKL) are 
increased leading to an increase in OC numbers, favoring overall bone resorption 
(You et al. 2008). Thus, bone formation is the physiological response to 
mechanical stress, while bone resorption is the reaction to skeletal unloading or 
skeletal disuse (Tan et al. 2007). 
1.1.4 The bone remodeling process  
Bone tissue dynamically changes through the processes of bone modeling 
and bone remodeling. Bone modeling occurs on the periosteal surface during 
skeletal growth to achieve the optimal bone geometry and strength, while bone 
remodeling occurs throughout life and is a bone renewal process that helps to 
retain bone strength. This complex process is carried out by a coordinated balance 
between OC bone resorption, OB bone formation, and osteocyte-mediated 
mechano-signaling (Xiong and O'Brien 2012).  
Bone remodeling occurs predominantly on the endosteal surfaces within 
basic multicellular units (BMUs) (Figure 3) (Burr and Allen 2013; Orwoll 2003; 
Parfitt 2001; Proff and Romer 2009). BMUs are located on bone surfaces and is 
covered by a canopy of bone lining cells and nearby marrow capillaries (Sims and 
Martin 2014). Within BMUs, bone remodeling begins with the resorptive phase, 
when OCs are stimulated by MCSF and RANKL and degrade bone. Next, the 
reversal phase begins which is characterized by the cessation of osteoclastic bone 
resorption due to OC apoptosis and the initiation of osteoblastic bone formation. 
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OBs are recruited to resorbed areas of bone by a process that is not yet clear, and 
begin the bone formation phase, which includes OB proliferation and 
differentiation, osteoid formation, and mineralization of bone. During the last phase 
in the bone remodeling cycle, the so-called “resting” phase, selected mature OBs 
become trapped in the mineralized matrix and differentiate into osteocytes, or they 
flatten on the bone surface to form bone lining cells. Matrix mineralization within 
the BMU continues over time until mineralization is complete and the bone surface 
is reestablished and maintained until the next bone remodeling episode (Burr and 
Allen 2013). 
 
1.2 Regulators of Osteoblast Activity 
 
1.2.1 The role of estrogen and SERMs in bone tissue 
Estrogen, a sex steroid hormone, plays a significant role in bone 
metabolism and provides an osteoprotective action in both males and females. 
The consequence of estrogen deficiency is increased bone turnover due to an 
increase in osteoclast activity, which can lead to osteoporosis, especially in post-
menopausal women (Compston 2001; Imai et al. 2010; Krum 2011). Published 
studies suggest that estrogen therapy, including selective estrogen receptor 
modulators (SERMs), can prevent bone loss and increase bone mineral density 
(BMD) in post-menopausal women (Riggs and Hartmann 2003). Furthermore, the 
fracture risk of hip, spine, and wrist in post-menopausal women can be decreased 
by estrogen therapy (Compston 2001).  
SERMs are a group of natural or synthetic non-steroidal substances that 
act as either tissue specific agonists or antagonists of the estrogen receptors 
(ERs). Structurally, SERMs adopt a conformational structure that is similar to 
estrogen which allows them bind to the ligand-binding domain of the ER (Riggs 
and Hartmann 2003) (Figure 4). Ideally, a SERM should have positive effects on 
the cardiovascular system and bone, without having adverse effects on the breast 
and endometrium and without causing an increase in cancer risks. To date, there 
are two SERMS approved for osteoporosis treatment, raloxifene and 
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bazedoxifene, both of which have estrogen activity in the bone and prevent bone 
loss, improve bone BMD, and are associated with a decrease in the risk of 
vertebral fracture (Russell 2015). Raloxifene exerts its estrogenic effects on bone 
by decreasing the remodeling rate, reducing OC activity, and maintaining OB 
activity (Hegde et al. 2015). Furthermore, raloxifene acts as a complete estrogen 
antagonist on the uterus. Unlike hormone replacement therapy, raloxifene does 
not cause an increase in vaginal bleeding, endometrial thickening, or uterine 
volume in human studies. Thus, raloxifene has not been associated with an 
increase in the risk of endometrial cancer in postmenopausal women (Cohen et al. 
2000; Goldstein et al. 2000). In addition, raloxifene has been shown to substantially 
decrease the risk of invasive breast cancer (Barrett-Connor et al. 2006). 
1.2.2 Effects of estrogen on OB activity 
The effects of estrogen on its target tissues are not fully understood. 
Published studies suggest that the actions of estrogen can be mediated either by 
genomic or non-genomic pathways (Imai et al. 2010; Krum and Brown 2008). The 
genomic pathway of estrogen occurs through its binding to nuclear ERs either by 
direct interaction of estrogen-ER complex with the estrogen response element 
(ERE) in transcription promoter regions or indirect binding of estrogen-bound ER 
to ERE via other transcription factors. In contrast, the non-genomic actions of 
estrogen or rapid estrogen responses occur via interaction of estrogen with ERs 
present at the cell membrane or in the cytoplasm, resulting in the activation of 
signal transduction pathways including calcium flux and kinase activation within 
target cells (Figure 5). It is to be noted that kinase activation does not only cause 
post-translational changes in proteins, but also leads to transcriptional changes 
mediated by kinase-activated transcription factors (Burr and Allen 2013; Carroll et 
al. 2006; Heldring et al. 2007; Hewitt et al. 2016; Imai et al. 2010; Marino et al. 
2006; Simoncini and Genazzani 2003). 
Published studies demonstrate that 17β-estradiol (E2), the most potent form 
of estrogen, increases OB proliferation and activity. Some studies have shown that 
17β-estradiol affects gene expression in OBs, including the induction of insulin 
growth factor-1 (IGF-1), transforming growth factor-beta (TGF-β), TIEG (a TGF-β-
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inducible gene that inhibits DNA synthesis) and BMP-6 (Compston 2001; Ernst 
and Rodan 1991; Oursler et al. 1991; Rickard et al. 1998; Tau et al. 1998). 
Estradiol also increases the effect of parathyroid hormone (PTH) on collagen 
synthesis and ALP mRNA expression in osteoblastic SaOS-2 cells (Nasu et al. 
2000), and enhances the expression of insulin-like growth factor binding protein 4 
(IGFBP-4), which regulates osteoblastogenesis and OB activity (Krum 2011). 
Furthermore, 17β-estradiol increases the expression of receptors for growth 
hormone, 1α,25-dihydroxy vitamin D3 (1,25(OH)2D3), and progesterone (Ishibe et 
al. 1995; Slootweg et al. 1997). ALP is also up regulated by 17β-estradiol (Krum 
et al. 2008b; Plant and Tobias 2001). Likewise, BMP-2 is increased with estrogen 
treatment (Zhou et al. 2003). However, the effects of 17β-estradiol on the 
expression of OB activity markers, ALP, OCN, and collagen type I, is still 
controversial. Some studies reported 17β-estradiol treatment increased ALP, 
OCN, and collagen type I mRNA, whereas other results showed no changes or 
decreased expression of these markers after 17β-estradiol treatment (Keeting et 
al. 1991; Majeska et al. 1994; Robinson et al. 1997).  
Several studies demonstrated that 17β-estradiol increases Fas ligand 
(FasL) secretion by primary OBs and MC3T3-E1 osteoblastic cells, which 
subsequently binds to the pro-apoptotic Fas receptor on OCs to promote OC 
apoptosis (Krum et al. 2008a; Wang et al. 2015). Estradiol treatment also 
increases the level of OPG, a decoy receptor for RANKL (Bord et al. 2003) as well 
as decreasing RANKL in human OBs (Eghbali-Fatourechi et al. 2003). Together, 
the increase in the OPG/RANKL ratio in response to 17β-estradiol reduces 
osteoclastogenesis.  
1.2.3 The role of estrogen receptors in bone formation 
ERs are members of the steroid hormone receptor family regulated 
transcription factors. The ERs contain several domains, which include the 
activation function sites 1 and 2 (AF-1 and AF-2). The AF-1 domain, a ligand-
independent site, is responsible for promotor-specific activation which can 
phosphorylate and activate the ERs, whereas AF-2 is a ligand-specific activation 
site. The C region consists of the DNA-binding domain (DBD). The D domain is a 
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hinge region and contributes to the specificity of DNA binding and nuclear 
localization of ERs. The ligand binding domain (LBD) is in the E region. The ERs 
consist of at least 2 subtypes, ER-alpha (ERα) and ER-beta (ERβ). ERα and ERβ 
exhibit close structural homology particularly in the DBD (>95% amino acid 
identity), and to a lesser extent in the LBD (~60% amino acid identity) (Figure 6.) 
(Compston 2001; Hewitt et al. 2016; Marino et al. 2006). Estrogen has similar 
binding affinities for both ERα and ERβ. Compared to estrogen, raloxifene shows 
lower binding affinities for both ERα and ERβ, and preferentially binds ERα 
(approximately 3.5 fold higher affinity for ERα than ERβ) (Zhu et al. 2006).  
ERs are expressed in many tissues such as the central nervous system, 
cardiovascular system, reproductive organs, bladder, kidney, intestine, and bone 
(Compston 2001; Kuiper et al. 1997). In skeletal tissue, both ERα and ERβ are 
detected in OBs, OCs, and osteocytes. In human cortical bone, 
immunohistochemistry revealed intense staining for ERα in OBs and osteocytes 
next to the periosteal surface, and OCs on the resorbing surface. It was reported 
that ERα expression is high in newly incorporated cortical bone osteocytes, but 
older osteocytes in the cortical mineralized matrix exhibit lower ERα levels (Bord 
et al. 2001; Braidman et al. 2001). In cancellous bone, OBs, OCs, and osteocytes 
strongly express ERβ, while ERα is present but at reduced levels compared to 
ERβ. The distinct pattern of expression of the ERs, with ERα predominantly 
expressed in the cortical bone, whereas ERβ is predominantly found in the 
trabecular bone, suggests they may exhibit unique cellular functions and be 
responsible for differential regulation of cortical and cancellous bone tissues 
directly by estradiol and less specifically through non-genomic actions in the cells. 
Although OBs express both ER subtypes, ERα and ERβ are differentially 
expressed during OB differentiation. In SV-HFO cells, a human OB cell line, it was 
shown that ERα mRNA levels slightly increase until day 10 of culture, and then 
remain constant. In contrast, ERβ mRNA levels increase steadily throughout the 
10 day culture (Arts et al. 1997). In another study using MG-63 human 
osteosarcoma cells cultured for up to 25 days, ERβ mRNA expression remained 
at a constant high level whereas ERα mRNA was barely identified. However, ERα 
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mRNA expression in human primary OBs was much greater than ERβ mRNA 
levels during the same culture duration (Chen et al. 2004). In rat calvarial OBs, 
ERα mRNA expression was increased during matrix maturation and then 
decreased during mineralization phase, while ERβ mRNA levels were relatively 
constant throughout differentiation and revealed more constitutive expression 
(Bord et al. 2003; Onoe et al. 1997; Wiren et al. 2002). ERs are also regulated by 
estrogen, and one study reported that ERα mRNA is increased after estradiol 
treatment of human primary OBs for 24 hours, but no data regarding the effect of 
estradiol on ERβ mRNA levels was shown (Bord et al. 2003).  
An additional mode of regulation of the ERs is by intracellular degradation. 
Several studies suggest that ERα undergoes ubiquitin-proteasome mediated 
degradation (Chai et al. 2015; Lu et al. 2010; Petrel and Brueggemeier 2003; Zhou 
and Slingerland 2014). The ubiquitin-proteasome pathway is a major pathway of 
selective protein degradation. Cytosolic and nuclear proteins are first labeled for 
degradation by the attachment of ubiquitin, an amino acid that is highly conserved 
in all eukaryotes. Polyubiquinated proteins are then recognized and degraded by 
the proteasome, a large and multi-subunit protease complex. Lu et al. (Lu et al. 
2010) found that a decrease in ERα after docosahexaenoic acid treatment of MCF-
7 breast cancer cells was reversed in the presence of MG-132, a proteasome 
inhibitor. Another study reported that ERα protein levels in an adenocarcinoma 
breast cell line (BT474) were reduced after treated with TGF-β1 for 6 hours. MG-
132 abolished all effects on ERα protein by TGF-β1, which suggests ERα protein 
degradation occurs through a proteasome-dependent pathway (Petrel and 
Brueggemeier 2003). A recent study found that REGγ, a member of proteasome 
coactivator family, plays a role in ERα protein degradation in MCF-7 and BT474 
cell lines via the ubiquitin–proteasome pathway (Chai et al. 2015). Evidence 
suggests that ERα-binding ligands such as 17β-estradiol and fulvestrant (ER 
antagonist) also affect ERα degradation through the proteasome pathway (Callige 
and Richard-Foy 2006). There is also evidence that ERβ protein in MCF-7 cells 
undergoes ubiquitin-proteasome degradation through the activation of the AKT 
pathway (Sanchez et al. 2013). In addition, it was found that ERβ ubiquitination 
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and degradation in MDA-MB231 breast cancer cells occurs in an estrogen 
dependent manner (Tateishi et al. 2006). Collectively, these studies suggest ERα 
and ERβ can in part be regulated through the proteasome pathway, although if this 
occurs in all cells is unclear. 
1.2.4 Effect of genetic deletion ERα and/or ERβ on the murine skeleton  
Genetic mouse models have been used to examine the role of the ERs in 
skeletal bone. Female and male mice with global knockout (KO) of ERα (ERα-KO) 
exhibit an increase in trabecular BMD and bone volume/total volume (BV/TV) when 
compared to WT mice. In contrast, deletion of ERβ leads to different responses in 
male and female mice. ERβ-KO female mice exhibit an increase in trabecular BMD 
and BV/TV, whereas trabecular bone of male mice is unaffected (Lindberg et al. 
2001; Sims et al. 2002).  Although several labs have investigated the skeletal 
effects of deletion of both ERα and ERβ, differences in phenotype were found; one 
study reported that ERαβ-double KO female mice showed an increase in 
cancellous BMD (Lindberg et al. 2001), while another study showed a profound 
decrease in trabecular BV/TV, with a decrease in bone turnover in females. On the 
other hand, trabecular BMD was found to be unaffected in ERαβ-double KO male 
mice (Sims et al. 2002). This suggests that bone remodeling in male mice involves 
predominantly ERα, whereas in female mice, ERα and ERβ may play a 
compensatory effect to influence bone remodeling (Sims et al. 2002).  
In contrast to the reduced bone mass observed in post-menopausal women 
and ovariectomized (OVX) rodents, an impairment of bone development or low 
bone mass was not reported in female ERα-KO or ERβ- KO mice, which have high 
bone mass, while global ERαβ double KO mice have normal bone mass. A 
possible explanation may be differences in the levels of estradiol, the most 
important form of circulating estrogen. OVX rodents and post-menopausal women 
have circulating estradiol deficiency, while ERα-KO female mice exhibit high levels 
of circulating estradiol, which may be able to interact with ERβ, leading to higher 
bone mass (Harada and Rodan 2003; Imai et al. 2010; Sims et al. 2002; Zaidi 
2007).	Similarly, the elevation of circulating estradiol and testosterone in these 
mice may increase the activation of other receptors such as the androgen receptor 
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(Imai et al. 2010; Lindberg et al. 2001; Sims et al. 2002) and prevent loss of 
trabecular BMD in ERα-KO and/or ERβ-KO mice. An alternative explanation is that 
the osteoprotective actions of estrogen occur through endocrine or paracrine 
factors that may be secreted from bone marrow or other extra-skeletal tissues and 
cells. For example, hepatic IGF-1 is known to stimulate osteoblastogenesis; IGF-
1 modulates the action of growth hormone (GH) in bone development. Thus, the 
elevated estradiol in global ERα-KO and/or ERβ-KO mice may stimulate hepatic 
IGF-1 production, which can promote bone formation. Nevertheless, the molecular 
basis behind this mechanism remains unclear (Imai et al. 2010; Sims et al. 2000). 
Recently, cell-specific mouse models of ERα-KO and ERβ-KO were 
generated to better understand the bone-specific effects of estrogen signaling 
without the confounding physiological changes that likely affect global ERα and/or 
ERβ mice. However, no change in bone mass was observed either in cortical or 
cancellous bone in OB-specific ERα knockout mice in which Cre-mediated deletion 
was driven by the collagen type 1α promoter. However, when ERα was deleted in 
OB progenitors by crossing with osterix1 (Osx-Cre) or paired-related homeobox 1 
(Prx1-Cre) mice, BMD and cortical thickness in the femur were decreased in 
female mice, but no change in cancellous bone was observed (Almeida et al. 
2013). In contrast, ERβ deletion in osteoprogenitors (Prx1-Cre) enhanced 
cancellous bone mass in female mice, but had no effect on cortical bone (Nicks et 
al. 2015). In mice in which ERα deletion was driven by the OCN-Cre promoter, 
cortical and cancellous BV/TV were reduced in young female mice (Maatta et al. 
2013; Melville et al. 2014). However, this phenotype disappeared in adult mice 
(Maatta et al. 2013). Furthermore, in mice with osteocyte-specific deletion (Dmp1-
Cre) of ERα, a decrease in cancellous bone was observed only in male mice, and 
cortical bone was unaltered in both males and females (Windahl et al. 2013). On 
the contrary, another study found that osteocyte ERα deletion (Dmp1-Cre) female 
mice exhibited a significant decrease in trabecular BMD, but not in male mice 
(Kondoh et al. 2014). The discrepancies between these 2 studies maybe from the 




1.2.5 Pyk2 and its effects on bone cells and bone remodeling 
To understand the actions of the ERs and the function of bone cells in the 
bone remodeling process, it is important to understand the role of key signaling 
proteins. Our laboratory has focused on elucidating the role of the proline-rich 
tyrosine kinase 2 (Pyk2). Pyk2 is homologous to the focal adhesion kinase, FAK 
(Eleniste and Bruzzaniti 2012; Lipinski and Loftus 2010) and is expressed in OBs 
and OCs (Buckbinder et al. 2007; Eleniste et al. 2015; Gil-Henn et al. 2007; Kacena 
et al. 2012). Pyk2 consists of multiple protein domains: the FERM domain (N-
terminal), a catalytic kinase domain, several proline rich domains (PRD), and a 
focal adhesion targeting (FAT) domain at the C-terminus (Eleniste et al. 2012; Gil-
Henn et al. 2007). Pyk2 is stimulated by multiple extracellular cues including 
inflammatory cytokines, stress signals, intracellular calcium, and integrin-mediated 
cell adhesion (Gil-Henn et al. 2007). Pyk2 responds to integrin activation and 
intracellular calcium by autophosphorylation at tyrosine residue Y402 which is 
important for Pyk2 kinase activity. Phosphorylated Y402 also provides a binding 
site for SH2 domains of Src kinases (Eleniste et al. 2012; Kimble et al. 1996), thus 
acting as a protein scaffolding domain. Pyk2 is linked to a variety of cellular 
activities including proliferation and migration (Boutahar et al. 2004; Buckbinder et 
al. 2007; Gil-Henn et al. 2007; Kacena et al. 2012). Recently, it was reported that 
Pyk2 facilitates cell proliferation and survival by degrading p53, the tumor 
suppressor protein (Lim et al. 2008; Lim et al. 2010).  
Pyk2 has two isoforms, the full-length Pyk2 (118 kDa) and a mRNA spliced 
shorter form, Pyk2-S (106 kDa), which lacks a 42-amino acid motif compared to 
the full-length Pyk2 (Figure 7A). In addition, differences in the expression of Pyk2 
and Pyk2-S were observed during OB differentiation (Kacena et al. 2012) (Figure 
7B). We found that the ratio of Pyk2 to Pyk2-S decreases during OB differentiation, 
with Pyk2-S expression exceeding Pyk2 by day 14 and day 21. These findings 
suggest the transition from Pyk2 to Pyk2-S may control the transition from 
immature proliferating OBs to mature matrix mineralizing OBs, although this 
remains to be confirmed.  
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Recent studies have reported the importance of Pyk2 in the regulation of 
bone mass and in the function of OCs and OBs (Bruzzaniti et al. 2009; Buckbinder 
et al. 2007; Eleniste and Bruzzaniti 2012; Gil-Henn et al. 2007; Wang et al. 2003). 
Pyk2 has been shown to be a positive regulator of OC maturation and bone 
resorption in vitro. Pyk2 is localized to OC podosomes, which are actin-rich 
structures that facilitate cell attachment and migration (Buckbinder et al. 2007; 
Eleniste and Bruzzaniti 2012; Gil-Henn et al. 2007; Kacena et al. 2012). Pyk2-
deletion leads to OC impairment in part due to a disruption in the organization of 
podosomes and the formation of the actin ring (sealing zone) necessary for bone 
resorption (Bruzzaniti et al. 2009; Gil-Henn et al. 2007). Pyk2 is also expressed in 
OBs, and the deletion of Pyk2 affects the differentiation and migration of OBs. 
Deletion of Pyk2 in OBs also affects actin remodeling, which impacts the turnover 
of focal adhesion structures necessary for OB attachment to ECM proteins 
(Eleniste and Bruzzaniti 2012). Our studies and others demonstrated that OB 
differentiation and bone formation are enhanced in the absence of Pyk2 
(Buckbinder et al. 2007; Cheng et al. 2013; Eleniste et al. 2015; Kacena et al. 
2012). Furthermore, it has been reported that bone marrow cells of Pyk2-KO mice 
cultured in an osteogenic medium exhibit increasing levels of OB activity markers: 
ALP, OCN, and calcium deposition (Allen et al. 2009; Cheng et al. 2013). Pyk2-
KO mice exhibit an osteopetrotic phenotype, which is in part due to increased 
osteoblastic bone formation as well as decreased osteoclastic bone resorbing 
activity (Buckbinder et al. 2007; Gil-Henn et al. 2007). Pyk2-KO mice exhibit a 
139% increase in bone formation rate in the tibia compared to wild type (WT) mice. 
This increase was the result of both increased mineralizing surface per bone 
surface and increased mineral apposition rate (Gil-Henn et al. 2007).  
Unpublished observations from Dr. Bruzzaniti’s laboratory have revealed 
that global Pyk2-deletion in mice leads to an increase in bone mass in female mice, 
but not in male mice (Figure 8). Since the high bone mass of Pyk2-KO mice is sex-
specific, this suggests that Pyk2 may interact with estrogen, the major female sex 
hormone important for maintaining bone mass through the regulation of OC and 
OB numbers. To examine the potential role of estrogen in the regulation of bone 
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mass in Pyk2-KO mice, Dr. Bruzzaniti’s laboratory performed OVX surgery on 
female WT and Pyk2-KO mice, followed by 17β-estradiol supplementation. The 
bone morphometrics of estrogen-depleted (OVX) and estrogen-replete female 
mice (OVX + E2) was compared after 4 weeks. The results showed that female 
OVX Pyk2-KO mice exhibited a much greater increase in bone mass following 
estrogen supplementation than OVX WT + E2 mice (Figure 9). These findings 
indicate that Pyk2-KO mice may be more responsive to estrogen than WT mice, 
and therefore that Pyk2 may regulate bone mass in part by modulating estrogen 
signaling cascades. However, the molecular mechanism for the role of Pyk2 in 
estrogen signaling remains unknown. 
 
1.3 Osteoporosis and Systemic Bone Loss 
 
The bone remodeling process is regulated by many factors at both the 
systemic and local levels, which include hormones, growth factors, mechanical 
stimuli and transcription factors (Compston 2001). These factors affect the 
coupling between bone formation and bone resorption. The disruption in the 
coupling process can lead to high or low bone mass diseases such as 
osteopetrosis or osteoporosis, respectively. 
Osteoporosis is a systemic skeletal disease characterized by low BMD and 
bone architecture deterioration, which compromises bone strength and increases 
the risk of bone fractures. Risk factors for osteoporosis include genetic, behavioral, 
and nutritional in nature. The female sex, individuals with a petite skeletal structure, 
and being of Caucasian or Asian descent are all considered to be genetic factors. 
Aging, a sedentary lifestyle, smoking, and low body weight are also risk factors. 
Nutritional factors include low calcium or vitamin D intake, and alcohol abuse 
(Downey and Siegel 2006). Common metabolic diseases such as diabetes and 
certain drugs such as glucocorticoid therapy also lead to compromised bone mass 
and quality (Pisani et al. 2016; Rosen and Bouxsein 2006; Whittier and Saag 
2016). Osteoporosis is most commonly seen in post-menopausal women due to 
declining levels of the osteoprotective hormone, estrogen. Estrogen deficiency 
	 18 
promotes OC differentiation and survival, increasing OC numbers and bone 
resorption, which subsequently leads to decreases in bone mass and bone 
strength (Nakamura et al. 2007; Novack 2007). Long-term estrogen depletion is 
also associated with the induction of OB apoptosis, leading to a decrease in OB 
number and a subsequent disruption in bone formation (Almeida et al. 2007; 
Khosla et al. 2012). Recent studies have demonstrated that post-menopausal 
women show significantly higher serum levels of sclerostin, a key inhibitor of Wnt 
signaling in OBs, than pre-menopausal women, which can lead to inhibition of 
osteoblastic bone formation (Mirza et al. 2010). 
 
1.4 Periodontal Bone Loss: Correlation with Osteoporosis  
 
Bone remodeling in the oral cavity proceeds via the same series of 
osteoblastic and osteoclastic activity events as found in the rest of the skeleton. 
This process is considered essential in controlling tooth eruption, orthodontic tooth 
movement, tooth socket healing, alveolar bone healing after periodontal treatment 
or other surgical procedures, and osseointregation of dental implants. The 
uncoupled sequence of alveolar bone resorption and formation resulting in alveolar 
bone loss may occur from many causes including: infection, trauma, systemic or 
local alterations of the host response, pathological diseases, or multifactorial 
causes (Jeffcoat 1993).  
Periodontal disease is an inflammatory disease that leads to periodontium 
destruction; this disease can be classified into gingivitis and periodontitis. 
Periodontitis is characterized by loss of connective tissue and alveolar bone mass, 
and can eventually leads to tooth loss or loss of alveolar ridge height. Periodontitis 
is considered as the result of the interaction between pathogenic bacteria and the 
immune response of host. The primary etiology of periodontitis is dental plaque 
biofilm, which is formed by bacteria and toxins (Kinane and Marshall 2001; Varela-
Lopez et al. 2016). The host response to infection is another important factor to 
determine the extent and severity of periodontitis. Evidence suggests that systemic 
factors can modify the periodontitis through their effects on the immune and 
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inflammatory mechanisms. Systemic factors that enhance the extent and severity 
of periodontitis include a decrease in number or function of polymorphonuclear 
leukocytes, immuno-suppressive diseases such as HIV infection, smoking, and 
diabetes (Kinane and Marshall 2001; Loe 1993; Oliver and Tervonen 1994). 
Like osteoporosis, periodontitis is a bone-resorptive, host-dependent, and 
multifactorial disease. A correlation between skeletal BMD and the number of 
remaining teeth in post-menopausal women was observed in a 7-year longitudinal 
clinical study of Caucasian post-menopausal women (Krall et al. 1996). It was 
reported that in post-menopausal women experiencing a decrease in BMD of 1% 
per year, a significantly increase in the relative risks (4.83) of tooth loss was 
observed this indicating a link between systemic BMD and tooth loss. Recent 
studies also reported that post-menopausal women with osteoporosis had a 
greater chance of developing periodontitis and tooth loss when compared to those 
without osteoporosis (Gomes-Filho et al. 2007; Moedano et al. 2011; Pereira et al. 
2015). Patients with low systemic BMD also showed higher alveolar attachment 
loss than individuals with normal BMD (Iwasaki et al. 2013). Although the 
mechanisms are unknown, these findings suggest a link between osteoporosis and 
localized chronic bone destruction in the oral cavity. 
 
1.5 Pharmaceutical Approaches to Increase Bone Mass 
 
Current pharmaceuticals for the treatment of osteoporosis are classified into 
2 groups: anti-resorptive and anabolic medications. The examples of anti-
resorptive or anti-catabolic agents are bisphosphonates, calcitonin, hormone 
replacement therapy (estrogen), SERMs, and Denosumab, a RANKL antibody. 
Bisphosphonates and calcitonin directly inhibit OC activity and induce OC 
apoptosis (Bellido and Plotkin 2011). Published clinical studies reported that 
bisphosphonates and calcitonin treatment stabilized or improved spine BMD in 
post-menopausal women, resulting in a decrease in vertebral fracture in post-
menopausal women who received these two drugs compared to the non-treated 
group (Chesnut et al. 2000; Drake et al. 2008; Mehta et al. 2003). The FDA-
	 20 
approved anti-RANKL antibody, Denosumab, prevents RANKL from binding to the 
RANK receptor on OC precursors and as such inhibits osteoclastogenesis (Das 
and Crockett 2013). Thus Denosumab leads to an increase in bone mass, with a 
positive effect on cortical bone, and prevents fractures in post-menopausal 
osteoporosis patients (Cummings et al. 2009; Gifre et al. 2016; McClung et al. 
2006). As described in section 1.2.1, estrogen and SERMs can prevent bone loss 
and increase BMD in post-menopausal women, and lead to a decrease in fracture 
risk (Compston 2001; Riggs and Hartmann 2003). Estrogen and SERMs stimulate 
estrogen receptors leading to decrease in OC number, and consequently a 
decrease in the rate of bone loss (Pineda et al. 2012). Unlike estrogen, raloxifene 
does not cause negative effects on reproductive organs because it acts as a 
complete estrogen antagonist on these organs (Barrett-Connor et al. 2006; Cohen 
et al. 2000; Goldstein et al. 2000). 
In contrast to anti-resorptives, anabolic drugs induce bone formation by 
stimulating OB differentiation and restraining OB apoptosis (Jilka et al. 1999). 
Recombinant PTH (teriparatide) is the only FDA-approved bone anabolic 
medication (Riancho and Hernandez 2012), and it was found that teriparatide 
increased bone formation, bone volume, and BMD in post-menopausal women 
and anorexia nervosa patients (Eriksen et al. 2014; Fazeli et al. 2014). However, 
recombinant PTH still has some limitations, including parenteral administration and 
risk of osteosarcoma (Pazianas and Abrahamsen 2016). Currently in development 
is an anti-sclerostin antibody which is in clinical trials and is showing positive 
effects on bone anabolism (MacNabb et al. 2016).  
 
1.6 Pyk2 Inhibitors Increase Bone Mass in Mice 
 
Evidence has shown that Pyk2 plays a key role in the regulation of bone 
formation, so the chemical inhibitors of this kinase might have potential therapeutic 
effects on bone tissue regeneration. A combined Pyk2/FAK inhibitor, PF-431396 
(PF-43) or C22H21F3N6O3S · xH2O was developed by Pfizer, Groton, CT, having 
IC50 values of 11-32 nM of Pyk2 and 1.5 nM of FAK (Figure 10). The PF-43 has 
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been investigated for its effects on bone mass in OVX female rats, an animal model 
of post-menopausal osteoporosis (Buckbinder et al. 2007). It was reported that PF-
43 (10 and 30 mg/kg) administration for 21 days increased cancellous bone 
formation rate, and increased the mineralizing surface and mineral apposition rates 
in the proximal tibia of OVX rats. This suggests that PF-43 promotes OB activity 
(Allen et al. 2010; Allen et al. 2009; Buckbinder et al. 2007). In other studies, PF-
562-271, another dual FAK/Pyk2 inhibitor, inhibited tumor growth on lytic bone 
metastasis by decreasing bone resorption as well as increasing bone formation 
(Bagi et al. 2008; Roberts et al. 2008).  Taken together, these findings suggest that 
Pyk2 inhibitors may be alternatives for bone disease treatment and bone 
regeneration without increasing cancer risk. 
Another inhibitor which is specific to Pyk2, is PF-4618433 (PF-46) or 
C24H27N7O2 (Figure 10). PF-46 has IC50 values of 100 nM for Pyk2 and 10,000 nM 
for FAK. One study revealed that PF-46 also enhances ALP activity and 
mineralization in human MSCs in vitro, but no data was reported for the in vivo 
effects of PF-46 (Han et al. 2009).  
 
1.7 Use of Hydrogels for Bone Regeneration  
 
1.7.1 The bone regeneration process 
Bone regeneration is a complex and well-orchestrated process of bone 
formation and bone resorption, which can be seen during normal fracture healing, 
and it is involved in bone remodeling process throughout life. Bone fracture healing 
is a unique biological process which can restore both anatomy and function of bone 
to the normal condition. Bone fracture healing can be divided into primary healing 
and secondary healing. Primary or direct fracture healing occurs through 
intracortical remodeling without callus formation, and it occurs only in fractures that 
have been stabilized by rigid fixation. It normally requires a few months to a few 
years for complete primary healing. Secondary or indirect fracture healing involves 
a response of the periosteum and soft tissues at the fracture site. Normally, it 
occurs when some micro-movement still exists, and typically it is enhanced by 
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movement and inhibited by rigid fixation. We can see both intramembranous and 
endochondral ossification in this type of bone fracture healing. The new bone 
formed by intramembranous ossification is usually seen at the peripheral of the 
fracture site, and it does not contribute to bridging the fracture. Endochondral bone 
formation, which forms a callus, occurs at the fracture site and responds directly 
for fracture bridging (Aubin et al. 1995; Oryan et al. 2015).  
Bone fracture healing and regeneration consist of 4 stages; Inflammatory, 
soft callus, hard callus and bone remodeling. 1) The inflammatory stage usually 
happens within 24 hours and can last for a week. In this stage, the vessels will be 
disrupted and the hematoma will be formed. 2) In the soft callus formation stage, 
granulation tissues will be formed and replaced with fibrocartilage after hematoma 
formation; this usually takes about 7-10 days post fracture in a rodent model. 3) 
The hard callus or endochondral ossification stage usually occurs about 14 days 
post fracture in rodents. This stage includes the cartilaginous matrix formation by 
chondrocytes, and later the cartilage will be degraded by OCs then it will be 
replaced by the disorganized bone structure or woven bone produced by OBs. 4) 
During the bone remodeling stage, woven bone will be replaced by a more 
definitive bone tissue or lamellar bone by a coordinated balance between 
osteoclastic bone resorption and osteoblastic bone formation. This stage occurs 
around 3-4 weeks after fracture and may take years to be completed (Burr and 
Allen 2013; Marzona and Pavolini 2009; Oryan et al. 2015).  
Bone can spontaneously heal when minor bone defects occur. However, 
the large bony defects and cases of compromised bone regeneration such as 
avascular necrosis and in osteoporosis patients require large scale of bone 
regeneration (Dimitriou et al. 2011; Zomorodian and Baghaban Eslaminejad 
2012). Nowadays, standard approaches widely used in clinical setting to augment 
bone regeneration in extensive bone defects including distraction osteogenesis 
and bone grafting techniques. Autologous bone graft is considered the current gold 
standard because it has all required properties of a bone-graft material include: 
osteogenesis, osteoinduction, and osteoconduction. Furthermore, it is 
histocompatible and non-immunogenic, which decreasing immunogenic reactions 
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and transmission of diseases. Nonetheless, autologous bone graft requires an 
additional surgical procedure for graft harvesting that cause discomfort for patients 
and may increase complications. In addition, there is a limitation of graft quantity 
and grafts frequently associated with donor site morbidity. Alternative treatments 
are allogenic and xenogenic bone graftings, which exclude the problems of graft 
harvesting and the limitation of graft quantity. However, they possess a decrease 
in osteoinduction and no osteogenesis component. The addition disadvantages 
are immunogenicity, rejection reactions, and possibility of increasing the risk of 
infection and disease transmission (Amini et al. 2012; Dimitriou et al. 2011; Oryan 
et al. 2014). 
1.7.2 General principles of tissue engineering 
Bone tissue engineering has been extensively investigated to overcome the 
limitation of bone grafting and enhance bone healing (Mourino and Boccaccini 
2010; Romagnoli et al. 2013). Tissue engineering for bone regeneration requires: 
1) scaffolds with good biocompatibililty, biodegradation and mechanical properties, 
2) an appropriate cell source, and 3) biological factors (Amini et al. 2012; Li et al. 
2008; McCullen et al. 2009; Tollemar et al. 2016; Yoshimoto et al. 2003). The 
desirable physical and biological characteristics of bone tissue scaffolds include: 
1) be osteoinductive (the ability to recruit MSCs and stimulate them into pre-OBs) 
and osteoconductive (the ability to allow bone to grow on the surface of materials), 
2) promote osseointegration (the ability to stable anchorage of an implant to bone), 
3) provide adequate temporary mechanical support (10-1500 MPa), 4) 
demonstrate interconnected porous structures that allow vascularization, cell 
migration and adhesion, and mass transport, 5) exhibit controlled degradation, 6) 
create non-toxic degradation products, 7) allow sterilization without bioactivity loss, 
and 8) be capable of delivering bioactive molecules (Bose and Tarafder 2012; 
Janicki and Schmidmaier 2011; Li et al. 2014; Romagnoli et al. 2013). Currently, 
there is no all-inclusive material that meets the above requirements.   
1.7.3 Biomolecules for bone regeneration 
Several studies have focused on loading biomolecules such as growth 
factors, proteins or drugs into scaffolds to enhance their function (Mourino and 
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Boccaccini 2010; Romagnoli et al. 2013). The bone morphogenic proteins (BMP), 
especially BMP-2, have been the most extensively used due to their potent 
osteoinductive ability to recruit MSCs and stimulate pre-OB formation (Li et al. 
2014; Romagnoli et al. 2013). The osteoinductive effect of BMP-2 is well 
established for the regeneration of segmental bone defects, fractures, spinal 
fusion, aseptic bone necrosis, critical bone defects, and tooth socket healing (Chu 
et al. 2007; de Oliveira et al. 2013; Mont et al. 2004; Romagnoli et al. 2013). 
Recombinant human BMP-2 (rhBMP-2) is the form of BMP-2 that has been 
approved for limited clinical use. However, rhBMP-2 has been revealed to increase 
the risk of radicular pain, ectopic bone formation, osteolysis, premature epiphyseal 
fusion and poor global outcomes (Fu et al. 2013; Lewandrowski et al. 2007; Mesfin 
et al. 2013; Rodgers et al. 2013; Simmonds et al. 2013). Other published literature 
indicates that antiresorptive agents such as bisphosphonates and Denosumab 
cause a delay in bone remodeling process, but still enhance bone quality and 
quantity in the fracture repair site (Hegde et al. 2016). Although to date there are 
no reports on the effect of Pyk2 inhibitors for bone regeneration, the finding that 
genetic Pyk2-deletion increases OB activity and bone mass, and rats treated with 
the Pyk2-inhibitor (PF-43) showed an increase in bone formation rate and bone 
volume suggests that Pyk2 inhibitors may be an effective therapeutic agent for 
bone regeneration as well as for the treatment of systemic bone loss. 
1.7.4 Hydrogels in tissue engineering 
 Hydrogels are three-dimensional (3D) biopolymeric networks that exhibit 
the ability to absorb large amounts of water. The 3D networks occur through the 
polymeric crosslinking, which can arise from physical interactions, covalent 
bonding, hydrogen bonding or van der Waals interactions (Lin et al. 2015). 
Hydrogels can be fabricated using both natural and synthetic polymers that do not 
cause adverse biological responses, and they can be fabricated in various forms 
such as microparticles, nanoparticles, films, and slabs. In addition, hydrogels are 
able to encapsulate biomolecules, drugs or cells, and allow control of the release 
behavior by changing physical or chemical structure of gels (Lin and Anseth 2009). 
Consequently, hydrogels are widely used in biomedical applications including 
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regenerative medicine and tissue engineering. In bone tissue engineering, natural 
or synthetic hydrogels combined with biomolecules such as biotin, growth factors 
and BMP-2 have shown positive bone healing effects in various animal models 
(Park 2011; Shi et al. 2012).  
The controlled release behavior of hydrogels combines with their 
biocompatibility, biodegradability, and ability to mimic ECM structures ensue 
hydrogels are attractive materials for the carrier in drug delivery systems (Tronci 
et al. 2014). A crucial factor in the drug delivery system is the carrier must have 
the capacity to incorporate a drug, carry the drug to the specific target site and 
maintain an adequate drug concentration level for a desired period of time. In 
addition, a drug carrier should be gradually degraded without any toxicity in order 
to control drug release, deliver a drug at constant rates, and subsequently be 
replaced by tissue growth (Peppas et al. 2000). All these characteristics are well 
provided by hydrogels. Drugs or biomolecules can be incorporated into the gel 
networks by post-fabrication equilibrium partitioning or in situ encapsulation. 
Although the post-fabrication equilibrium partitioning method, which concentrated 
drug solutions are loaded through incubated gels, helps to preserve drug stability, 
it does not permit accurate control in the amount of drug loading. On the other 
hand, in situ encapsulation, which is a process to encapsulate drugs at the same 
time as network crosslinking, can be used to rapidly prepare hydrogels loaded with 
a more accurate amount of drugs. However, the drawback of in situ loading is the 
possibility that polymerization may cause undesired reactions with fragile 
biomolecules. The bioactivity of a drug released from hydrogels depends on 
numerous factors such as the drug loading technique, the molecular 
characteristics and size of the drug, the release profile of drugs, and the cellular/in 
vivo environment. The molecule release mechanisms from hydrogels are different 
from hydrophobic polymers due to their hydrophilicity, and they can be classified 
into 3 models; diffusion-controlled, swelling-controlled, and chemically controlled 
release (Lin and Anseth 2009). Many studies of drug release from hydrogels 
usually use only one mechanism to explain the release mechanism, which is not a 
realistic phenomenon. The coupled effects of diffusion and chemical matrix 
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degradation of hydrogels are more applicable and realistic to explain drug release 
from hydrogels (Lin and Metters 2006).   
1.7.5 Poly (ethylene glycol) (PEG) hydrogels 
PEG, one of the non-ionic hydrophilic synthetic polymers, has been 
extensively used for several decades for controlled drug delivery and cell delivery 
in tissue engineering applications due to the controllable material properties that 
enable hydrogels to be fabricated with the desired functions and properties. For 
example, the molecular weight of the polymer and crosslink density can be 
adjusted to obtain the desired degradation rate and release profile (Lin and Anseth 
2009; Lin et al. 2015). PEG-based macromers with reactive termini have been 
increasingly developed for hydrogel fabrication. Among these macromers, PEG-di 
(meth) acrylate (PEGDA or PEGDM) (Figure 11) is highly used in hydrogel 
fabrication because of the simplicity of synthesis and its availability from 
commercial sources (Hao and Lin 2014).  
PEG hydrogels can be formed by various methods including: physical, ionic 
and covalent interactions. Among these gelation methods, covalent or chemical 
crosslinking can produce stable hydrogels with tunable physicochemical properties 
such as permeability, diffusivity, and degradation rate.  Covalently crosslinked 
PEG hydrogels can be synthesized through chain-growth, step-growth, or mixed-
mode polymerization. Normally, chain-growth mechanism is developed from 
functional PEG molecules, such as PEGDA. The initiators for polymerization are 
free radicals, which propagate via unsaturated vinyl bonds on the PEG macromers. 
Then, chain-growth mechanism occurs and results in high molecular weight 
chains. One of the disadvantages of chain-growth polymerization is that non-ideal 
network hydrogels usually occur, and they may unfavorably affect drug release 
behavior and properties of materials (Lin and Anseth 2009). Step-growth 
polymerization occurs when at least two multifunctional monomers with reactive 
chemical groups are reacted together without free radical initiators. This 
mechanism creates fewer network defects, which allows accurate control of 
crosslink density and properties of hydrogels (Malkoch et al. 2006). This advantage 
is important in the drug delivery system because it allows precisely determined 
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drug dosing and release kinetics. Lastly, PEG hydrogels are also formed through 
mixed-mode polymerization, which presents both chain and step-growth 
polymerization characteristics (Lin and Anseth 2009). PEGDA hydrogels have also 
been used in bone regeneration as a carrier of biomolecules such as BMP-2. 
Evidence found that PEGDA hydrogel tethered with BMP-2 exhibits rapid bone 
healing in in vivo studies (Chen et al. 2011; Sonnet et al. 2013).  
1.7.6 Gelatin hydrogels 
Gelatin is a hydrocolloid protein derived from partial hydrolysis of collagen, 
usually from collagen type I, or denaturation at above 40°C. Gelatin has been 
widely used in biomedical applications because of its biocompatibility, 
biodegradability, and hydrogel characteristics, as well as its cost efficiency (Li et 
al. 2008). Furthermore, the presence of cell-recognition motifs such as the RGD 
sequence in gelatin structures improves its final biological characteristics over 
synthetic polymers. In drug delivery systems, gelatin has proven to be a versatile 
drug carrier because of its isoelectric point that enables charged biomolecule 
loading. In addition, release kinetics from gelatin can be tuned by the modification 
of its degradation (Santoro et al. 2014). Gelatin exhibits thermo-responsiveness, it 
forms gel at temperature below 35°C and becomes an aqueous solution at 
physiological temperature (37°C) (Bigi et al. 2004). Rapid degradation of gelatin is 
the factor limiting its applications in tissue engineering. However, this limitation has 
been improved by using covalent chemical crosslinking with various crosslinkers 
(Bigi et al. 2001; Chang et al. 2003).  
1.7.8 PEG and gelatin hydrogels 
Recently, the combination of PEG and gelatin has been investigated in 
order to overcome the limitations of PEG and gelatin hydrogels. PEGylation, the 
modification of gelatin with PEG for drug carriers has been developed to create 
slower drug clearance from the body and extended circulatory time (Santoro et al. 
2014). One study found that nano-encapsulation of ibuprofen within PEGylated 
gelatin nano-vehicle revealed a slow and sustained release of ibuprofen along with 
increased pharmacokinetics and bioavailability of drug, thereby increasing the 
duration of action, which could lead to prolonged pharmacological effects. This 
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helps reduce the dosage and frequency of drug administration, which minimizes 
the side effects of ibuprofen and enhances therapeutic drug benefits (Narayanan 
et al. 2013). A semi-interpenetrating network (sIPN), which contains of 
photocrosslinked PEG matrices and physically entrapped gelatin, has been 
developed as an effective drug delivery and tissue engineering scaffold (Fu et al. 
2012). sIPN of PEG matrices improve protein resistance and mechanical stability. 
The mesh size of sIPN depends on the amount of PEG in the system, which may 
impact the transportation of biomolecules out of the sIPN. Incorporating gelatin in 
matrices enhances elasticity and biodegradability of the system. Clearly, drug 
molecules can be directly added into the polymer solution prior to polymerization 
which allows for more accuracy in the amount of drug loaded rather than relying 
on equilibrium partitioning; thereby preventing drug overloading (Fu and Kao 
2009).  
 
1.8 Project Rationale, Hypotheses and Specific Aims 
 
As described above, bone mass is controlled by the coordinated actions of 
the bone cells. The mechanisms that control bone mass are still not completely 
understood. An imbalance in the bone cell coupling process can lead to systemic 
bone loss as in osteoporosis as well as localized bone loss associated with 
periodontitis or osteoarthritis. To date, many therapeutic approaches have been 
developed to improve these low bone mass conditions, but most of them have 
some clinical concerns; bisphosphonates can causes bisphosphonate-related 
osteonecrosis of the jaw (Ruggiero et al. 2004), and PTH has several limitations 
include, parenteral administration, and risk of osteosarcoma (Pazianas and 
Abrahamsen 2016). Likewise, bone tissue engineering as an alternative therapy 
for targeted bone regeneration still has limitations in term of biomaterial properties 
and the efficacy of biomolecules being used. For example, collagen sponges 
exhibit an initial uncontrolled burst release of a loaded biomolecule, which can 
cause adverse effects to surrounding tissues (Fu et al. 2013; Simmonds et al. 
2013). In addition, BMP-2, which is a well-established enhancer of bone 
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regeneration, is associated with increased risk of radicular pain, ectopic bone 
formation, and osteolysis (Fu et al. 2013; Mesfin et al. 2013; Rodgers et al. 2013; 
Simmonds et al. 2013). Therefore, a need for improved biomolecules and 
biomaterials for bone regeneration remains.  
Pyk2 is important for OB activity and bone formation as well as OC activity 
(Buckbinder et al. 2007; Eleniste et al. 2015; Gil-Henn et al. 2007; Kacena et al. 
2012). Pyk2-deletion and small molecule inhibitors of Pyk2 have been shown to 
increase OB activity and bone formation in vitro and in vivo. In addition, studies in 
Dr. Bruzzaniti’s laboratory showed that estrogen supplementation after OVX 
results in a greater increase in BV/TV in Pyk2-KO OVX mice than WT OVX mice. 
Furthermore, the Pyk2 inhibitor, PF-43, also increased bone mass and protected 
rats from OVX-induced bone loss (Buckbinder et al. 2007; Han et al. 2009). 
Together, these findings suggest that Pyk2-KO mice are more responsive to 
estrogen than WT mice. Although the molecular mechanism for the role of Pyk2 in 
estrogen signaling is still unknown, these findings suggest that Pyk2 and estrogen 
may be part of a common mechanism to regulate OB activity. Finally, therapeutic 
strategies that target Pyk2 activity may be effective for bone regeneration.  
The studies described in this thesis were undertaken with two overall goals; 
(1) To understand the actions of the tyrosine kinase Pyk2 as well as estrogen 
signaling through its cognate receptors to increase bone formation, and (2) to 
develop of a Pyk2-inhibitor loaded hydrogel which may be suitable for bone 
regeneration applications. The achievement of these aims required the integration 
of knowledge and skills related to both bone biology and biomaterial research. 
Experiments and results described in Chapters 3 and 4 are based on Specific Aims 
1 and 2, respectively. 
 
Specific Aim 1: To determine the mechanism of action of Pyk2 and estrogen in 
osteoblastic bone formation in vitro (Chapter 3). The effects of Pyk2 in combination 
with E2 on the expression of key OB markers were examined. In addition, the 
effects of Pyk2 with and without E2 or raloxifene on cell proliferation, ALP activity, 
and mineralization were determined. The reciprocal effects of E2 and Pyk2 on OB 
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activity were also investigated. Furthermore, the functional roles of the Pyk2 and 
Pyk2-S isoforms on OB differentiation were investigated. 
Hypothesis 1): Pyk2-deletion enhances OB differentiation and mineralization 
through modulation of the estrogen signaling cascade.  
.  
Specific Aim 2: To develop a Pyk2-inihbitor loaded hydrogel for bone 
regeneration applications (Chapter 4). Small peptide inhibitors of Pyk2 were 
examined for their efficacy in increasing OB proliferation, ALP activity, and 
mineralization in vitro, with minimal cytotoxicity. Next, we developed and tested 
different hydrogels composed of PEGDA and gelatin. Once the optimal properties 
of PEGDA-gelatin hydrogel combination were identified including viscosity, 
gelation time and the release profile, then the efficacy of released Pyk2 inhibitors 
on OB activity was evaluated in vitro.  
Hypothesis 2): A Pyk2-inhibitor loaded hydrogel will exhibit suitable properties for 
use as an injectable-carrier, and will retain its bioactivity against Pyk2 to promote 





MATERIALS AND METHODS 
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2.1 Materials and Methods for Studies Described in Chapter 3 
 
2.1.1 Media  
α-MEM with L-glutamine (HyClone Laboratories, Inc., South Logan, UT, 
USA), phenol red free α-MEM with L-glutamine (Life Technologies, Carlsbad, CA, 
USA) 
2.1.2 Chemicals, Solutions and Kits 
 Collagenase type IA (Sigma-Aldrich Co. LLC, St. Louis, MO, USA), Fetal 
Bovine Serum (FBS, Biowest, Kansas city, MO, USA), L-ascorbic acid and β-
glycerophosphate (Sigma-Aldrich), 0.25%Trypsin with 0.02% EDTA (Quality 
Biological, Gaithersburg, MD, USA), phosphate buffer saline (PBS, HyClone 
Laboratories, Inc.), SYBR® Green PCR Master Mix (Applied Biosystems, 
Warringtons, UK), Taq DNA Polymerase  (Thermo Fisher Scientific, Grand Island, 
NY, USA), agarose gel (Alkali Scientific, Pompano beach, FL, USA), ethidium 
bromide (Sigma-Aldrich), Tris-Chloride (Tris-Cl, Sigma-Aldrich) , sodium chloride ( 
NaCl, Sigma-Aldrich), Igepal CA 630 (NP-40,Sigma-Aldrich), sodium deoxycholate 
(Sigma-Aldrich), leupeptin hydrochloride (Thermo Fisher Scientific), aprotinin 
(Thermo Fisher Scientific), pepstatin (Thermo Fisher Scientific), 
Phenylmethanesulfonyl fluoride (PMSF, Sigma-Aldrich) sodium fluoride (NaF, 
Sigma-Aldrich), sodium orthovanate (Thermo Fisher Scientific), p-nitrophenol 
phosphate and alkaline buffer (Sigma-Aldrich), Alizarin Red-S (Sigma-Aldrich), 
acetylpyridinium chloride (Sigma-Aldrich), X-tremeGENE HP DNA Transfection 
Reagent (Roche Applied Science), Nupage® Gels (Novex, Thermo Fisher 
Scientific), Nitrocellulose membranes (Protran®, Sigma-Aldrich), the enhanced 
chemiluminescence reagent (SuperSignal West Pico Chemiluminescent 
Substrate, Thermo Fisher Scientific), Oneshot Top10® (Life Technologies, 
Carlsbad, CA, USA), and Luria-Bertani (LB) (DOT Scientific Inc., Burton, MI, USA), 
EDTA (Thermo Fisher Scientific). 17β-estradiol (E2, Sigma-Aldrich), raloxifene 
hydrochloride (Sigma-Aldrich), Penicillin/Streptomycin (P/S, Lonza, Allendale, NJ, 
USA, Z-Leu-Leu-Leu-al (MG-132, Sigma-Aldrich), propyl-pyrazoletriol (PPT, 
Sigma-Aldrich), diarylpropionitrile (DPN, Sigma-Aldrich), RNeasy® Mini Kit 
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(Qiagen, Valencia, CA, USA), DNase I enzyme (Fisher Scientific, Pittsburgh, PA, 
USA), Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, 
Indianapolis, IN, USA), MTS assay kit (CellTiter 96® AQueous Non-Radioactive 
Cell Proliferation Assay kit, Promega Life Science), PierceTM BCA protein assay 
kit (Thermo Fisher Scientific), QIAGEN plasmid maxi kit (QIAGEN).  
2.1.3 Antibodies 
Anti-Pyk2 polyclonal antibody (Upstate™, Thermo Fisher Scientific), anti-
ERα polyclonal antibody (MC20) and anti-ERβ monoclonal antibody (1531) (Santa 
cruz biotechnology, Dallas, TX), anti-p-Y402 monoclonal antibody (Alexis, 
Farmingdale, NY), anti-p-ERK, anti-p-AKT, and AKT rabbit monoclonal antibodies 
(Cell signaling, Beverly, MA), anti-V5 monoclonal antibody (Promega Life Science, 
Madison, WI, USA), anti-actin monoclonal antibody (Millipore, Bellerica, MA, USA), 
an anti-mouse antibody conjugated with horseradish peroxidase (HRP) and anti-
rabbit HRP (Promega Life Science). 
2.1.4 Preparation of calvarial-derived OBs from WT and Pyk2-KO mice  
C57BL/6 mice (WT) were obtained from Jackson Laboratories. Pyk2-KO 
mice were provided by Pfizer, Groton, CT.  Pyk2-KO mice were generated by 
creating a mutation into the murine Pyk2 gene as described previously (Buckbinder 
et al. 2007; Okigaki et al. 2003). Pyk2-KO mice have been back-crossed for more 
than 10 generations and maintained on a C57BL/6 background. Mice were bred 
as heterozygotes and crossed to generate Pyk2-KO mice and WT littermates 
(Cheng et al. 2013; Kacena et al. 2012). WT littermate mice were used as controls. 
All mice used in this project were handled according to the guidelines of the 
American Association for Laboratory Animal Science using Institutional Animal 
Care and Use Committee (IACUC) approved protocols (IACUC approval: 
DS000885R) and in according with the NIH (Guide for the Care and Use of 
Laboratory Animals, 1996). 
Murine calvarial cells were prepared using the previously described protocol 
(Cheng et al. 2013; Kacena et al. 2012). Briefly, calvaria from neonatal mice 2-3 
days old were pretreated with 10 mM EDTA in PBS for 30 minutes. Next, the 
calvaria were subjected to sequential collagenase digestions with 0.1% 
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collagenase type IA from Clostridium histolyticum in serum-free α-MEM media with 
1% (v/v) P/S for 30 minutes in each digestion at 37°C under shaking conditions 
(200 rpm). Cells were collected following incubation in collagenase from fractions 
3–5, which consist of about 95% OBs or OB precursors (Kacena et al. 2012). 
Calvarial OBs were passaged twice and expanded prior to use.  For passage 1, 
calvarial WT and Pyk2-KO OBs were seeded at 3×106 cells in a 10 cm2 petri-dish 
in α-MEM with L-glutamine supplemented with 10% (v/v) FBS and 1% (v/v) P/S in 
an incubator at 37ºC with 5% CO2.  OBs were grown for 2 days and then were 
passaged a second time and 5×106 cells were expanded into a T175 cm2 flask for 
2 additional days. All experiments used OBs from the second passage.  
2.1.5 Culturing of MC3T3-E1 osteoblastic cells 
The MC3T3-E1 mouse osteoblastic cell line was originally purchased from 
the American Type Culture Collection (ATCC). Frozen cells were thawed and 
grown in α-MEM with L-glutamine supplemented with 10% (v/v) FBS and 1% (v/v) 
P/S in an incubator at 37ºC with 5% CO2. Aliquots of MC3T3-E1 cells were stored 
frozen in liquid nitrogen. Cells were thawed and passaged once before being used 
for experiments.  
2.1.6 Estrogen and raloxifene treatment of cells 
WT and Pyk2-KO calvarial OBs were seeded in culture plates. The numbers 
of cells per well were as follows: 1) 2 × 103 cells/well in a 96-well culture plate, 2) 
5 × 104 cells/well in a 12-well culture plate, and 3) 2 × 105 cells/well in a 6-well 
culture plate. After 24 hours of calvarial OBs seeding and MC3T3-E1 transfected 
with Pyk2 and Pyk2-S, cells were treated from 12 hours – 28 days with either 17β-
estradiol (E2) or raloxifene in osteogenic medium, which contained 50 μM of 
ascorbic acid (AA) and 5 mM of β-GP in phenol red free α-MEM with L-glutamine 
supplemented with 2% (v/v) FBS and 1% (v/v) P/S. We used phenol red free media 
and low serum concentration in order to eliminate the estrogenic actions of phenol 
red and serum (Berthois et al. 1986). The medium was replaced every 2 days. The 
concentration 100 nM of E2 was used in all experiments based on our preliminary 
studies and literature that primary OBs and osteoblastic cell lines show the highest 
response at this concentration (Cheng et al. 2002; Taranta et al. 2002; Zhou et al. 
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2001). The vehicle control for E2 was 100% ethanol. For raloxifene, the 
concentration from 0.1 -10 nM was used and the vehicle control was DMSO.  The 
vehicle controls were used to determine whether the vehicles alone cause any 
effects to cells (Johnson and Besselsen 2002). The number of cells seeded, the 
duration of each drug treatment, and subsequent analyses are shown in Table 1. 
2.1.7 Transient expression of Pyk2 and Pyk2-S cDNA in MC3T3-E1 cells    
MC3T3-E1 cells 6.7 × 104 were plated per well in a 24-well culture plate for 
24 hours before transfection. Two micrograms of Pyk2 or Pyk2-S cDNA were used 
for one reaction and diluted in a 200-μL serum free α-MEM media and completely 
mixed by pipetting. Next, 6 μL of X-tremeGENE HP DNA Transfection Reagent 
was added into the diluent cDNA mixture (3:1 reagent to cDNA ratio) and then 
pipetted to mix thoroughly. The mixture of cDNA and transfection reagent was 
incubated for 20 minutes at room temperature to allow complex formation. After 
this, the complexes of cDNA and transfection reagent were added to the cells in a 
dropwise manner, and the culture plate was gently swirled and shaken to ensure 
the even distribution of the cDNA and transfection complexes. Following 
transfection, cells were incubated for 24 hours prior to the subsequent treatment 
and assays.  
2.1.8 Plasmid purification 
Pyk2 and Pyk2-S cDNA expression constructs were previously generated 
in Dr. Bruzzaniti’s laboratory by PCR cloning (Figure 12). Briefly, the pEF6/V5-His-
TOPO® vector was used. The pEF6/V5-His-TOPO® construct contains 5840 
nucleotides including a EF-1α promoter, a T7 promoter/priming site, a TOPO® 
cloning site, a V5 epitope, a C-terminal polyhistidine (6xHis) tag, a bovine growth 
hormone (BGH) reverse priming site, a BGH polyadenylation signal, an f1 origin, 
an SV40 promoter and origin, an EM-7 promoter, a blasticidin resistance gene, an 
SV40 early polyadenylation signal, a pUC origin, a bla promoter, and an ampicillin 
resistance gene.   The primers used for cloning are as follow: 5’-GATATG TCT 
GGG GTG TCC GAG CCC CTG AGC CGA GTA A, and 5’- CTC TGC AGG TGG 
GTG GGC CAG ATT GGC CAG AAC. Pyk2 and Pyk2-S cDNA was generated by 
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RT-PCR using human Pyk2 cDNA. The PCR product was then cloned into the 
pEF6/V5-His-TOPO® vector, amplified and purified.   
In the current study, we started with amplifying plasmid cDNA expressing 
Pyk2 or Pyk2-S. Each plasmid cDNA (5 μL) was added into a tube of Oneshot 
Top10®, which is commercial Escherichia coli with high efficiency cloning and 
plasmid propagation. The mixture was incubated for 30 minutes on ice, then heat 
shocked in a 42°C water bath for 30 seconds and immediately placed on ice for 2 
minutes. Next, 250 μL of Super Optimal broth with Catabolite repression (S.O.C) 
was added into the mixture and incubated at 37°C for 1 hour under shaking 
conditions at 225 rpm. The 200 μL of cultured mixture was spread on Luria-Bertani 
(LB) agar plates containing the 100 µg/mL ampicillin and incubated overnight at 
37°C. A single colony was selected and inoculated into 10 mL LB broth with 
ampicillin (100 µg/mL) and incubated overnight at 37°C at 200 rpm in the shaker 
incubator. All 10 mL of the culture was transferred into a 250 mL fresh LB broth 
and cultured under the same conditions. Bacteria were then harvested by 
centrifugation (6000x g) at 4°C for 15 minutes, and all of the supernatant were 
removed.  
Plasmids were purified using a QIAGEN plasmid maxi kit. The pellet was 
thoroughly re-suspended into 10 mL of re-suspension buffer. Cells were lysed in 
10 mL of lysis buffer, mixed gently by inverting the tube 4-6 times, and then were 
incubated at room temperature for 5 minutes. Next, the mixture was mixed 
vigorously with 10 mL chilled neutralization buffer and incubated on ice for 30 
minutes to promote the precipitation of the genomic DNA, proteins, and cell debris. 
Then the solution was centrifuged at 20,000x g for 30 minutes at 4°C, and the 
supernatant containing plasmid DNA was transferred to a new tube. The columns 
were prepared by adding 10 mL equilibration buffer through the column to reduce 
surface tension. The filter sheets were placed on top of the column, then the 
supernatant was loaded into the column and filtrated, then all contaminants were 
washed out with 60 mL wash buffer. The DNA was eluted using 15 mL elution 
buffer, and the precipitation of DNA was achieved by adding 10.5 mL isopropanol 
at room temperature to the eluted DNA and mixed vigorously, then centrifuged at 
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15000x g for 30 minutes at 4°C. The DNA pellet was washed with 5 mL room 
temperature 70% ethanol and centrifuged at 15000x g for 10 minutes. Lastly, the 
pellet was dissolved using Tris-EDTA (TE) buffer (10 mM Tris base, 1mM EDTA, 
pH 8.0) at 4°C overnight and kept at -20°C.   
2.1.9 RNA isolation  
Cell pellets of OBs were disrupted and homogenized in 350 μL of buffer 
RLT in RNeasy® Mini Kit. The lysate was centrifuged at 13000x g for 3 minutes at 
4°C. The supernatants were transferred into new Eppendorf tubes, and 350 μL of 
70% ethanol was added and mixed well by pipetting. All of the sample (700 μL) 
was transferred to an RNeasy Mini spin column placed in a 2 mL collection tube 
and centrifuged at 10,000 rpm for 15 seconds at 4°C, and the flow-through was 
discarded. Next, 700 μL of buffer RW1 was added to the column and centrifuged 
at 10,000 rpm for 15 seconds at 4°C, and the flow-through was discarded. Then, 
500 μL of buffer RPE was added to the column twice and centrifuged at 10,000 
rpm at 4°C for 15 s and 2 minutes, respectively. All of the flow-through was 
discarded. The column was placed in a new 2 mL collection tube and centrifuged 
at the maximum speed in order to dry the spin column membrane. After this, the 
column was placed in a new 1.5 mL collection tube and 30-50 μL of RNase-free 
water was added directly to the column membrane, and then centrifuged at 10,000 
rpm for one minute at 4°C to elute RNA. The purity and quantification of RNA were 
measured using a nanodrop spectrophotometer. The purity of RNA is evaluated 
using the ratio of the absorbance at 260 and 280 nm (A260/280), and the A260/280 of 
pure RNA is approximately two. The remnant genomic DNA in RNA samples were 
removed by digestion with DNase I enzyme. One unit of DNase I enzyme and 10x 
DNase buffer were used to clean up remnant DNA from RNA up to 1 μg. The 
reaction of DNase I enzyme was activated by incubation at 37°C for 30 minutes, 
and then the reaction was inactivated with 50 mM EDTA at 65°C for 10 minutes. 
2.1.10 Synthesis of cDNA by reverse transcription reaction 
Complementary DNA (cDNA) was synthesized using the Transcriptor First 
Strand cDNA Synthesis Kit, which used the reverse transcriptase and random 
hexamer (pd(N)6) primers to convert mRNA to cDNA. One µg of RNA was used 
	 38 
for each reaction. The RNA mixture with random hexamer primers was incubated 
at 65°C for 10 minutes in order to denature the RNA secondary structure. Next, 
the reverse transcriptase reaction with dNTPs was activated by incubating at 25°C 
for 10 minutes followed by 60 minutes at 50°C. The reaction was stopped by 
heating at 85°C for 5 minutes and at 4°C continually until the cDNA was stored at 
-20°C. 
2.1.11 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
The RT-PCR was done using the two-step technique. The first step was 
cDNA generation by reverse transcription reaction as previously described. The 
second step was a standard PCR that amplified a region of the interested cDNA. 
The PCR mixture was set up by mixing nuclease-free water, 10x Taq buffer, 2mM 
dNTPs, 25mM MgCl2, forward and reverse primers, Taq DNA Polymerase and 
template cDNA. β-Actin and GAPDH were used as the internal controls for RT-
PCR experiments. A list of the primers examined is shown in Table 2. PCR was 
performed using thermocycling conditions as follows: 1) initial denaturation at 95°C 
for 3 minutes, 2) denaturation at 95°C for 30 seconds, annealing at melting 
temperature (Tm) – 5°C for 30 seconds, and extension at 72°C for 1 minute, all 
repeating for 30-45 cycles, 3) final extension at 72°C for 5 minutes. The PCR 
products were separated using 2% agarose gel electrophoresis with ethidium 
bromide and then imaged with a Bio-Rad Gel Doc XR system.  
2.1.12 Primers for QPCR and RT- PCR 
Details are in Table 2. 
2.1.13 Quantitative Real-time Polymerase Chain Reaction (QPCR)  
QPCR was used to quantify mRNA expression from WT and Pyk2-KO OBs. 
In order to complete QPCR, SYBR® green PCR Master Mix was used. A list of the 
genes examined is shown in Table 1. The 18S RNA housekeeping gene was used 
as an endogenous control. In each QPCR reaction, 100 ng of cDNA was used. All 
samples were run in the ABI Prism® 7000 sequence detection system using 
STEP1 Software Solutions in duplicate with the temperature profile as follows: 1) 
50°C for 2 minutes, 2) 95°C for 10 minutes, 3) 40 repeating cycles of 95°C for 15 
seconds and 56°C or 60 °C for 1 minute, and 4) dissociation stage included: 95°C 
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for 15 seconds, 56°C or 60°C for 20 seconds, and 95°C for 15 seconds. The 
threshold cycle (Ct) for each test gene was normalized against 18S. QPCR was 
analyzed as absolute mRNA quantification of Pyk2-KO and WT OBs with or 
without E2 supplement.  
2.1.14 Cell proliferation assay 
The cell proliferation assay was performed by examining the proliferation 
activity of OBs and also counting cell number in each treatment. For proliferation 
activity assay, the CellTiter 96® AQeous Non-Radioactive Cell Proliferation Assay 
kit, a colorimetric method for determining the number of viable cells, was used. 
This kit consists of a tetrazolium compound, which is called MTS, and an electron-
coupling reagent that is phenazine methosulfate (PMS). MTS was reduced into a 
soluble formazan product by cellular activity, and the amount of formazan product 
can be measured directly from the culture plate using a Thermomax 
spectrophotometer recording the absorbance at 490 nm. For each proliferation 
assay, one hundred μL of PMS solution was added to 2 mL of MTS and completely 
mixed with pipetting, then 20 μL of the combined MTS/PMS was pipetted into each 
well of the 96-well culture plate that contained the culture of WT and Pyk2-KO OBs 
in the presence or absence of E2 for 12 hours at 37°C in a humidified, 5% CO2 
atmosphere. After addition of the MTS solution (time 0), absorbance at 490 nm 
was read every hour from 1-6 hours.   
To determine changes in OB cell number, an equal number of WT and 
Pyk2-KO OBs were cultured in the same condition as in the MTS metabolic activity 
assay. OBs from each group were harvested on day 1 and day 4 by incubating 
with 0.05% trypsin and EDTA for 5 minutes at 37°C in a humidified, 5% CO2 
atmosphere. Cell number per well was counted using a hemocytometer under the 
light microscope.  
2.1.15 Western blot analysis 
OBs and MC3T3-E1 cells were lysed in a modified radio-
immunoprecipitation assay (mRIPA) buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 
1% NP-40, 0.25% Sodium deoxycholate) supplemented with 10 µg/mL leupeptin 
hydrochloride, 10 µg/mL aprotinin, 10 µg/mL pepstatin, 1 mM PMSF, 1mM sodium 
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fluoride, and 1mM sodium orthovanate, and then sonicated for 5 minutes. The 
lysates were centrifuged at maximum speed for 5 minutes, and the supernatants 
were collected. The protein amount was quantified using the PierceTM BCA protein 
assay kit, and 30 µg of protein was resolved by SDS-PAGE electrophoresis. The 
loading buffer (62.5 mM Tris HCl pH 6.8, 2% w/v SDS, 25% glycerol, and 0.01% 
bromophenol blue) was added to protein samples, and then boiled at 100°C for 5 
minutes to denature protein. The samples were loaded onto gradient (4%-12%) 
Nupage® Bis-Tris gels along with the molecular weight protein markers and 
subjected to electrophoresis. Proteins were resolved at 120 volts for approximately 
2.5 hours. The proteins from the gel were transferred to the nitrocellulose 
membrane in Nupage® transfer buffer with 20% methanol at 100 volts for 1 hour 
at 4°C.  
The non-specific proteins on the membrane were blocked with 5% skim milk 
in a TBST solution (0.2 M Tris Base and 0.6 M NaCl at pH 7.4 containing 0.1% 
Tween-20) for 1 hour under shaking condition at room temperature. The 
membrane was incubated with the primary antibody (section 2.1.3), which was 
diluted in the TBST buffer (1:1000) overnight at 4°C. Next, the membrane was 
washed with the TBST buffer for 15 minutes 3 times to remove unbound primary 
antibody. An anti-mouse antibody conjugated with horseradish peroxidase (HRP) 
and anti-rabbit HRP were used as secondary antibodies. The anti-mouse antibody 
HRP was diluted 1:20000, while anti-rabbit HRP was diluted 1:10000 in the TBST 
buffer and incubated with the membrane for 1 hour at room temperature with 
agitation. The membrane was washed 3 times for 15 minutes in the TBST buffer, 
and then proteins were detected using the enhanced chemiluminescence (ECL) 
reagent (SuperSignalTM West Pico Chemiluminescence Substrate, Sigma-Aldrich) 
for 5 minutes according to the manufacturer’s recommendations. A radiographic 
film was used to record the emitted signal from the membrane. 
2.1.16 Quantitative ALP activity assay 
OB and MC3T3-E1 cells were lysed in 100 µL of the mRIPA buffer 
supplemented with protease/kinase inhibitors as previously described. The lysate 
was sonicated for 5 minutes, and then centrifuged at maximum speed for 5 minutes 
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and the supernatant were collected. Five µL of the cell lysates was pipetted into 
each well of a 96-well plate. Then 100 µL of ALP substrate (40 mg of p-nitrophenyl 
phosphate (p-NPP), 10 mL of alkaline buffer, and 10 mL of dH2O) were added to 
each well, and the assay plate was incubated for 50 minutes at 37°C in a dark 
atmosphere. The reaction was stopped by adding 95 µL of 20 mM NaOH. ALP 
activity was determined by the colorimetric conversion of p-NPP to nitrophenol. 
Optical absorbance at 405 nm was recorded using a Thermomax 
spectrophotometer. ALP activity was normalized by total protein using a PierceTM 
BCA protein assay kit. 
2.1.17 Quantitative analysis of Alizarin Red S staining  
OB and MC3T3-E1 cells were washed with PBS and fixed with cold 70% 
ethanol for 1 hour at -20°C. The fixed cells were allowed to warm up to room 
temperature and washed twice with deionized water (dH2O). One mL of 40 mM 
Alizarin Red S (pH 4.2) was used to stain calcium in each well for 10 minutes with 
agitation. The Alizarin Red S stained samples were washed 5 times with dH2O, 
followed by 15 minutes of PBS washing on the shaker.  Next, the bound Alizarin 
Red S was extracted with 750 µL of 1% cetyl pyridinium chloride (CPC) in 10 mM 
sodium phosphate (pH 7.0) for 15 minutes on the shaker at room temperature. The 
extracted solution was collected and mixed thoroughly and then 150 µL were 
pipetted into a 96-well plate, and calcium deposition was measured by recording 
the absorption of extracted Alizarin Red S at 562 nm using a Spectramax 190 
spectrophotometer.   
 
2.2  Materials and Methods for Studies Described In Chapter 4 
 
2.2.1 Media  
α-MEM with L-glutamine (HyClone Laboratories, Inc.), phenol red free α-
MEM with L-glutamine (Life Technologies). 
2.2.2 Chemicals and solutions 
FBS (Biowest, Kansas city, MO, USA), AA and β-GP (Sigma-Aldrich), 
0.25%Trypsin with 0.02% EDTA (Quality Biological), PBS (HyClone Laboratories, 
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Inc.), p-nitrophenol phosphate and alkaline buffer (Sigma-Aldrich), collagen 
sponges (RCF, Surgical Supplies Co. Brockton, MA, USA), PEGDA 1000 Da and 
600 Da (Polysciences Inc, Warrington, PA, USA), dithiothreitol (DTT, Thermo 
Fisher), type B gelatin from bovine skin (Sigma-Aldrich), 7-amino-4-
methylcoumarin (Sigma-Aldrich), Penicillin/Streptomycin (P/S, Lonza). PF-43 
(Sigma-Aldrich), PF-46 (Adipogen, San Diego, CA, USA), PierceTM BCA protein 
assay kit (Thermo Fisher Scientific), Universal Tyrosine Kinase Assay Kit (Takara 
Bio, Mountain View, CA, USA). 
2.2.3 Antibodies 
Details are in section 2.1.3. 
2.2.4 Preparation and culturing of murine MSCs 
Murine MSCs were obtained from tibias and femurs of 10-14-weeks old 
C57BL/6 mice. Both proximal and distal ends of tibias and femurs were cut away 
from epiphysis, and the marrow was flushed out with PBS. The released cells were 
collected and cultured in a 35 mm2 petri-dish in α-MEM with L-glutamine 
supplemented with 10% (v/v) FBS and 1% (v/v) P/S in an incubator at 37ºC with 
5% CO2. The medium was changed after 24 hours in order to remove non-
adherent cells. Sub confluent MSCs were passaged and expanded into T75 cm2.  
All experiments used OBs from the second passage.  
2.2.5 MC3T3-E1 osteoblast cell line and human embryonic kidney 293 cells 
(293VnR) culturing 
MC3T3-E1 and 293VnR cells were grown in α-MEM with L-glutamine 
supplemented with 10% (v/v) FBS and 1% (v/v) P/S in an incubator at 37ºC with 
5% CO2. MC3T3-E1 and 293VnR cells were used for experiments after the first 
passage.  
2.2.6 Pyk2 inhibitors treatment 
WT MSCs were seeded in culture plates, and the number of cells per well 
was as follows: 1) 2 × 103 cells/well in a 96-well culture plate and 2) 4 × 104 
cells/well in a 12-well culture plate. After 24 hours of MSCs seeding, cells were 
treated from 1-28 days with PF-43, PF-46 or DMSO (vehicle control) in osteogenic 
medium. The medium was replaced every 2 days. The doses of PF-43 and PF-46 
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were 0.0125, 0.025, 0.05, 0.1 and 0.3 μM (Buckbinder et al. 2007; Han et al. 2009). 
The number of seeding cells, the duration for treatment of each drug, and 
subsequent analyses are shown in Table 3. 
2.2.7 Cell proliferation assay 
The cell proliferation assay of mouse MSCs treated with and without PF-43 
or PF-46 was performed using the CellTiter 96® AQeous Non-Radioactive Cell 
Proliferation Assay kit as described in section 2.1.14  
2.2.8 Quantitative ALP activity assay 
The quantitative ALP activity of mouse MSCs treated with and without PF-
43 or PF-46 was performed by the technique described in section 2.1.16.  
2.2.9 Quantitative analysis of Alizarin Red S staining  
The quantitative calcium deposition of mouse MSCs treated with and 
without PF-43 or PF-46 was performed by the technique described in section 
2.1.17.  
2.2.10 Preparation of Scaffolds  
1. Collagen sponge preparation   
 Collagen sponges, RCF, were purchased from Surgical Supplies Co, and 
then were cut into disks of 5 mm in diameter and 3 mm in thickness by using a 
hole-puncher and ready to be used.  
2. PEGDA-gelatin hydrogels fabrication 
PEGDA 600 Da or 1000 Da was dissolved in α-MEM at 37°C under stirring 
to form a 50% w/v solution overnight, and the other required components, which 
are 2% lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) photoinitiator, and 
0.1 mM DTT, were added and stirred for 8 hours. Type B gelatin was also dissolved 
in α-MEM at 37 °C under stirring to form 10% or 20% v/v solution overnight. Next, 
PEGDA solution was mixed with gelatin solution at ratio 1:1 by volume under 
stirring to get gel formulations as follows: 1) 25% PEGDA1000 and 10% gelatin 
(P1000:G10), 2) 25% PEGDA600 and 5% gelatin (P600:G5), 3) 25% PEGDA1000 
(P1000), and 4) 25% PEGDA600 (P600). All the concentrations indicated were the 
final concentration in the prepolymer solution. The prepolymer solution 150 μL was 
pipetted into the disk-shaped silicone mold of 5 mm in diameter and 3 mm in 
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thickness and exposed under LED light 450-470 nm and 1000 J/cm2 for 2-6 
minutes in order to get complete photopolymerization.  
2.2.11 Dynamic viscosity test 
P600, P600:G5, P1000, and P1000:G10 prepolymer solutions were 
prepared as previously described in section 2.2.10. Dynamic viscosity of the 
prepolymer solutions (1 mL) from every group was measured on a Bohlin CVO 100 
digital rheometer (viscometry mode) using 4° cone/plate geometry in controlled 
continuous shear rate from 100 to 600 s−1 with a gap size of 150 µm at room 
temperature (Lin et al. 2011).  
2.2.12 Measurement of gelation time 
P600, P600:G5, P1000, and P1000:G10 prepolymer solutions were 
prepared as previously described in section 2.2.10. We determined the gelation 
time of hydrogels by using 2 techniques as follows: 
1.  Probing technique 
Gelation times of all groups were determined using a technique as 
described previously (Lemon et al. 2003; Murata et al. 2004). Briefly, the 
prepolymer solution 150 μL was pipetted into the disk-shaped silicone mold of 5 
mm in diameter and 3 mm in thickness and exposed under visible LED light 450-
470 nm and 1000 J/cm2 for 20 seconds; then a periodontal probe was used to 
contact the surface. This contact was repeated at 20-second intervals after light 
exposure. Gelation time was defined as the time when the surface of the material 
hardened and the material did not adhere to the tip of the periodontal probe. This 
experiment was carried out at the room temperature (N=5/group). 
2.  In situ photorheometry test 
To monitor gelation kinetics, in situ photorheometry by shear oscillation 
measurements were performed using a Bohlin CVO 100 digital rheometer with a 
light cure attachment. Four groups of prepolymer solutions were prepared as 
previously described in section 2.2.10. A hundred μL of each prepolymer solution 
was pipetted on a quartz plate in the light cure cell and irradiated with light through 
a flexible light guide using Omnicure S1000 system (1000J/cm2). Light was turned 
on at 10 s after starting time-sweep mode, using 25 mm parallel plate geometry 
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with 10% strain, 1 Hz frequency, and a gap size of 90 μm. Gel points or gelation 
times were defined as the time when storage modulus (G′) crossed over loss 
modulus (G″) (Greene and Lin 2015). 
2.2.13 Swelling and degradation of PEGDA-gelatin hydrogels  
P1000:G10 and P600:G5 gels were prepared as previously described in 
section 2.2.10 (N=5/group), and were dried under the vacuum for 48 hours to 
completely remove remaining water. The initial dry weight of hydrogel was 
measured. Hydrogels were immersed in 1 mL of pH 7.4 PBS in Eppendorff tubes 
and stored at 37°C. Hydrogels were removed from the tubes and dried with 
Whatman paper to remove excess water from hydrogel surfaces and then weighed 
every 30 minutes for the first four hours, and then at 24, 48, 72, 120, 240, 360, 
480, and 600 hours. One mL of PBS was replaced at every time point to keep the 
volume constant. The percentage of swelling ratio (Q) was calculated as:  𝑄 = 𝑊𝑡𝑊𝑑×100% 
where Wt is wet weight at time t, and Wd is dried weight of hydrogels.  
For degradation, we performed hydrolytic degradation by using the same 
method as swelling experiment. The extent of degradation (D) was calculated on 
day 1, 2, 3, 5, 10, 15, and 25 as following equation:  𝐷 = 1 −𝑚𝑡𝑚𝑖 ×100% 
where mt is the gel mass at a particular time point and mi is the original gel mass. 
2.2.14 In vitro release behavior of the PEGDA-gelatin hydrogel 
7-amino-4-methylcoumarin was used as a representative of PF-46 for the 
study of release behavior of hydrogel due to its easily detectable by using simple 
equipment. P1000:G10, P600:G5, and collagen sponge disks were fabricated as 
previously described in section 2.2.10 (N=5/group), and 50 μg of 7-amino-4-
methylcoumarin were added to collagen sponge and the prepolymer solution 
before photopolymerization. The loading efficacy was evaluated to determine the 
amount of 7-amino-4-methylcoumarin that was successfully loaded into the 
scaffolds. Samples from each group were soaked in 1 mL of PBS and stored in an 
incubator at 37ºC for 24 hours, and samples from all groups were sonicated. The 
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total amount of 7-amino-4-methylcoumarin in the samples was measured by using 
a Biotek Synergy HTX multi-mode reader. Fluorescence was measured using 370 
nm excitation and 460 nm emission wavelengths. The loading efficacy will be 
calculated as follows:  
                              % loading efficacy =  	/01234	15	6728	93	4:;	<=/551>66728	/66;6  × 100 
For the release profile of 7-amino-4-methylcoumarin, the samples were also 
soaked in 1 mL of PBS at 37°C, and the soaking solution was collected 500 μL on 
day 0, 1, 2, 3, 5, 10, 15, 20 and 25 to measure the 7-amino-4-methylcoumarin 
amount using a Biotek Synergy HTX multi-mode reader (n=5/group). The samples 
were replaced with fresh 500 μL of PBS at every time point in order to keep a 
constant volume of medium. We have chosen to perform a release profile using 
this time frame based on rhBMP-2 studies, in which a drug vehicle with sustained 
rhBMP-2 of at least 10% of the initial dose after 5 weeks has been shown to be 
sufficient for inducing callus formation in rabbit bone defects (Seeherman et al. 
2003). The concentration of release 7-amino-4-methylcoumarin was calculated 
from a standard curve of 7-amino-4-methylcoumarin.  
2.2.15 In vitro cytotoxicity test  
P600:G5, P1000:G10, and collagen sponge gel disks (N = 5/group) were 
prepared as previously described in section 2.2.10. All samples were sterilized by 
UV light for 30 minutes per each side. Each sample was immersed in 1 mL of α-
MEM with L-glutamine supplemented with 10% (v/v) FBS and 1% (v/v) P/S in an 
incubator at 37ºC for 24 hours. P600:G5, P1000:G10, and collagen sponge eluates 
were then collected. 
The cytotoxicity of eluates was evaluated on MC3T3-E1 cells using the 
CellTiter 96® AQeous Non-Radioactive Cell Proliferation Assay kit.  MC3T3-E1 
were seeded at 1.5 × 103 cells per well in a-96-well culture plate and incubated 
overnight at 37°C with 5% CO2. Thereafter, the medium was replaced with 150 μL 
of P600:G5, P1000:G10, or collagen sponge eluates. For the control group, a fresh 
medium was replaced. After incubation for 24 hours, the CellTiter 96®AQeous 
Non-Radioactive Cell Proliferation Assay kit was used as described in the section 
2.1.14.  
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2.2.16 In vitro tyrosine kinase activity assay 
P1000:G10 gels were prepared as previously described in section 2.2.10, 
and 20 μg of PF-46 were added to the prepolymer solution before 
photopolymerization. The representative dosage 20 μg of PF-46 was used in the 
in vitro experiment based on the effective ratio of rhBMP-2 using in vitro and local 
approach in vivo studies (30 ng/mL: 10 μg) (Chu et al. 2007; Jikko et al. 1999).  
 All samples were sterilized by UV light for 30 minutes per each side. Each 
sample was immersed in 1 mL of α-MEM with L-glutamine supplemented with 10% 
(v/v) FBS and 1% (v/v) P/S under shaking conditions (50 rpm) at 37ºC for 24 hours. 
Pyk2 catalytic activity depends on its autophosphorylation on tyrosine 
residues (Bruzzaniti et al. 2009; Eleniste and Bruzzaniti 2012; Eleniste et al. 2012). 
293VnR cells (Bruzzaniti et al. 2005) were cultured and then transiently transfected 
with Pyk2 cDNA for 72 hours, and incubated with or without fresh PF-46 or the 
released PF-46 at the concentration of 0.1, and 0.3 μM (N=5/group) for 45-120 
minutes (Tse et al. 2009). Changes in Pyk2 kinase activity were evaluated using 
the Universal Tyrosine Kinase Assay Kit (Takara Bio). Cells were washed with 
PBS, 1 mL of extraction buffer was added to the culture plate, and cells were 
scraped. The samples were spun at 10,000x g for 10 minutes at 4°C. The 
supernatant which contains the total protein extract was transferred to a new tube. 
Next, the specific protein tyrosine kinase activity assay was performed using 
immunoprecipitation (IP). The Protein G agarose (50 μL) (Roche Applied Science) 
was added into 1 mL of total protein extracts. Non-specific binding proteins in the 
Protein G agarose were removed by shaking gently for 20 minutes, and then spun 
at 10,000x g for 10 minutes at 4°C. The supernatant was transferred to a new tube, 
and 3 μg of Pyk2 antibody (polyclonal antibody) were added into the supernatant 
and incubated at 4°C overnight. Protein G agarose (40 μL) was added again into 
the supernatant and incubated for 1 hour at room temperature, then spun for one 
minute at 10,000x g and the supernatant was discarded. The precipitate was 
washed 3 times with 1 mL of PBS on the shaker for 10 minutes and spun at 
10,000x g for 1 minute at 4°C, and the supernatant was removed. The kinase 
reacting solution (150 μL) with 2-mercaptoethanol was added to the precipitate, 
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and then the sample was diluted 2 times with the kinase reacting buffer. Forty μL 
of the diluent was added into each well of a 96-well plate with 10 μL of 40 mM ATP-
2Na, and the sample was incubated for 30 minutes at 37°C. The sample was 
washed with the washing buffer 4 times, and blocked with 100 μL of the blocking 
solution and incubated for 30 minutes at 37°C. The blocking solution was removed, 
and 50 μL of anti-phosphotyrosine (PY20)-HRP was added into each well and 
incubated for 30 minutes at 37°C. The content in each well was washed 4 times 
with the washing buffer, and 100 μL of HRP substrate solution was added into 
each well and incubated at 37°C for 15 minutes. The reaction was stopped by 
adding 100 μL of the stop solution. The absorbance at 450 nm was measured.  
2.2.17 Quantitative ALP activity assay of mouse MSCs treated with the 
released PF-46  
PF-46 loaded P1000:G10 were prepared, sterilized, and extracted the 
released PF-46 as described in section 2.2.16. Mouse MSCs 4 × 104 were cultured 
for 7 days under osteogenic conditions with and without fresh PF-46 or the 
released PF-46 at the concentration of 0.1 and 0.3 μM (N=5/group). After this, 
quantitative ALP activity assay was performed as described in section 2.1.16.  
 
2.3 Statistical Analyses for All Studies in Chapter 3 and Chapter 4 
 
All data from specific aim 1 and 2 were analyzed by one-way analysis of 
variance (ANOVA) and/or two-way ANOVA or multifactorial ANOVA followed by 
post hoc multiple comparisons where appropriate. Data was analyzed by using 
SPSS 24 software (IBM Corporation, Armonk, NY, USA). Data is presented as 
means ± standard error of means (SEM), and a significant difference was 





MECHANISM OF ACTION OF PYK2 AND ESTROGEN IN  





The bone remodeling occurs throughout life to maintain bone mass. This 
process involves a coordinated balance between osteoclastic bone resorption and 
osteoblastic bone formation, which are regulated by many factors at both the 
systemic and local levels. These factors include hormones, growth factors, 
transcription factors, and mechanical stimuli (Compston 2001). When an 
imbalance occurs in this process, excessive osteoclastic bone resorption and/or 
decreased osteoblast function leads to low bone mass diseases such as 
osteoporosis. The risk of osteoporosis increases with age, and it is common in 
post-menopausal women due to declining levels of the osteoprotective hormone 
estrogen. Evidence suggests that estrogen therapy, including SERMs, can prevent 
bone loss and increase BMD in post-menopausal women (Riggs and Hartmann 
2003). Moreover, the risk of fracture of the hip, spine, and wrist in post-menopausal 
women is decreased by estrogen therapy (Compston 2001).  
The actions of estrogen on target tissues are mediated by genomic and non-
genomic mechanisms (Imai et al. 2010; Krum and Brown 2008). The ERs consist 
of at least 2 subtypes, ERα and ERβ, which exhibit close structural homology 
(Compston 2001; Hewitt et al. 2016). Estrogen has high binding affinity for both 
ERα and ERβ, and its binding affinities for these two ERs are quite similar. 
However, the SERM raloxifene shows lower binding affinity for the ERs than 
estrogen, and it preferentially binds ERα with an approximately 3.5-fold higher 
affinity for ERa than ERβ (Zhu et al. 2006). 
The proline-rich tyrosine kinase, Pyk2, is important for the regulation of 
bone mass and for the function of OBs and OCs (Bruzzaniti et al. 2005; Buckbinder 
et al. 2007; Eleniste and Bruzzaniti 2012; Gil-Henn et al. 2007). Our studies and 
others demonstrated that OB differentiation and bone formation are enhanced in 
the absence of Pyk2 (Buckbinder et al. 2007; Cheng et al. 2013; Eleniste et al. 
2015; Kacena et al. 2012). Pyk2-KO mice exhibit an osteopetrotic phenotype, 
which is in part due to increased osteoblastic bone formation as well as decreased 
osteoclastic bone resorption (Buckbinder et al. 2007; Gil-Henn et al. 2007). 
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Unpublished observations from Bruzzaniti et al. reveal that the high bone mass is 
predominantly seen in female Pyk2-KO mice. Notably, OVX Pyk2-KO mice 
exhibited a much greater increase in bone density with 17β-estradiol 
supplementation than OVX WT mice. Together these data suggest that Pyk2 may 
regulate bone mass through estrogen signaling in bone cells.  
The aim of studies described in this thesis was to understand the 
mechanism of action of Pyk2 and estrogen in osteoblastic bone formation in vitro. 
First, the effects of Pyk2 and 17β-estradiol (E2) or the SERM, raloxifene, on OB 
activity were determined by examining the expression of key osteoblast markers, 
OB proliferation activity, ALP activity, and mineral deposition levels. Next, the 
reciprocal effects of E2 and Pyk2 signaling cascades in OBs were investigated 
using Western blot analysis. Finally, we examined the effect of the Pyk2 and Pyk2-
S isoforms on the proliferation, ALP activity, and mineralizing activity of MC3T3-




3.2.1 Estrogen increases the proliferation of Pyk2-KO and WT OBs. 
First, we determined the culture conditions for our in vitro OB studies. 
Standard culture media is supplemented with 10% FBS and contains phenol red 
as a pH indicator, both of which have estrogenic effects (Berthois et al. 1986; 
Ganguly et al. 2008). Therefore, we compared the effects of α-MEM and phenol 
red free α-MEM media containing either 10% or 2% FBS on WT and Pyk2-KO 
OBs.  Cells were plated at the same cell density and the total number of viable 
cells (excluding Trypan blue) were counted after 4 days (Figure 13). When cultured 
in α-MEM or phenol red free α-MEM with 10% FBS, no difference was found 
between the number of Pyk2-KO OBs and WT OBs. However, when cells were 
cultured in 2% FBS in either α-MEM or phenol red free α-MEM, Pyk2-KO OB 
numbers were significantly higher than WT OB numbers. These findings indicate 
that type of media does not affect OB number, but the concentration of serum is 
important for distinguishing differences between Pyk2-KO and WT OBs. There was 
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a significant interaction between genotype and serum concentration (p=0.04). 
Furthermore, these findings suggest that WT OBs seem to be more sensitive to 
reduced serum than Pyk2-KO OBs.  
Based on these findings, we examined the effects of estrogen on WT and 
Pyk2-KO cell number. WT and Pyk2-KO calvarial OBs were cultured in phenol red 
free α-MEM with 2% FBS in the presence or absence of 100 nM E2 for 1 or 4 days 
and then counted.  E2 at 100 nM was used which was based on published literature 
showing that human primary OBs, mouse MSCs, calvarial OBs and osteoblastic 
cell lines show a peak response to E2 at this concentration (Cheng et al. 2002; 
Taranta et al. 2002; Zhou et al. 2001). As expected, Pyk2-KO OBs showed 
significantly higher numbers than WT OBs on both days (p<0.05) (Figure 14A). 
After 4 days of E2 supplementation, a significant increase in the number of WT 
OBs was observed, compared to untreated WT OBs (p<0.05). In contrast, E2 had 
no effect on the number of Pyk2-KO OBs. 
We also examined the effect of short-term E2 on OB proliferation using an 
MTS cell proliferation activity assay. An equal number of WT and Pyk2-KO OBs 
were cultured in the presence or absence of 100 nM E2 for 12 hours prior to MTS 
assay. As shown in Figure 14B, Pyk2-KO OBs had a significantly higher level of 
proliferation activity compared to WT OBs (p<0.05), indicating that OB proliferation 
was increased in the absence of Pyk2. However, WT or Pyk2-KO OBs cultured 
with E2 showed no significant increases in proliferation activity.  
To further examine proliferation, we examined the expression level of c-fos, 
which is a transcription factor highly expressed during cell proliferation (Figure 
15A). WT and Pyk2-KO OBs were cultured for 4 days in the presence or absence 
of E2. QPCR analysis revealed significantly higher c-fos mRNA levels in Pyk2-KO 
OBs, compared to WT OBs (2.5 fold, p=0.01). However, E2 supplementation of 
either Pyk2-KO or WT OBs did not lead to a statistical significant change in c-fos 
mRNA. Together with Figure 13, these findings suggest that Pyk2-deletion 
increases OB proliferation and that E2 does not significantly alter the proliferation 
of Pyk2-KO OBs.  
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3.2.2 Estrogen treatment of Pyk2-KO OBs increases ALP activity and 
mineralization. 
To examine the effect of Pyk2-deletion and E2 on OB differentiation, WT 
and Pyk2-KO calvarial OBs were cultured under osteogenic conditions containing 
50 μM ascorbic acid and 5 mM β-GP in the presence or absence of 100 nM E2 for 
4 and 28 days. Several genes involved in matrix formation and maturation, and 
mineralization of OB, including ALP, collagen type 1, and OCN were examined 
using QPCR. In addition, quantitative ALP activity and Alizarin Red S staining, 
which stains bound calcium on the collagen matrix were determined.  
After 4 days of treatment, Pyk2-KO OBs exhibited significantly higher 
collagen type 1 mRNA expression than WTs (1.9 fold, p=0.03) (Figure 15B). 
Notably, E2 supplementation significantly increased collagen type 1 mRNA 
expression in Pyk2-KO (p=0.04), but not WT OBs. However, ALP and OCN mRNA 
expressions in Pyk2-KO were not significantly different from WT OBs (Figure 15C 
and 15D). Moreover, E2 had no effect on the expression of ALP or OCN mRNA in 
4-day E2-treated WT or Pyk2-KO OBs.  
Next, we examined whether mature OBs cultured for 28 days in the absence 
or presence of E2 showed differences in ALP or OCN expression. Similar to our 
findings after 4 days, ALP mRNA levels in 28-day cultures were not significantly 
different between WT and Pyk2-KO OBs. Further, E2 treatment for 28 days had 
no effect on ALP expression in either WT or Pyk2-KO OBs (Figure 15E). In 
contrast, Pyk2-KO OBs showed increased expression of OCN mRNA more than 
WT OBs, (8.75 fold, p=0.007), although E2 supplementation did not increase OCN 
mRNA levels in either genotype (Figure 15F).  
Since Pyk2-deletion and E2 did not appear to affect ALP mRNA expression, 
we next examined if ALP enzymatic activity was altered in these OBs. WT and 
Pyk2-KO OBs were cultured in osteogenic media with or without E2 
supplementation for 4, 14, 21 or 28 days, and ALP activity was assayed using a 
quantitative biochemical assay and normalized for total protein as a measure of 
cell number (Section 2.1.16). Although ALP activity was not significantly changed 
in either WT or Pyk2-KO OBs cultured for 4 and 14 days (Figures 16A and 16B), 
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a robust increase in ALP activity was seen in Pyk2-KO OBs cultured for 21 days 
(12.1±1.52 nM/mL/μg) and 28 days (13.8±1.7 nM/mL/μg) compared to WT OBs 
(5.4±0.31 and 6.8±0.7 nM/mL/μg, respectively) (p<0.05). Furthermore, ALP activity 
in Pyk2-KO OBs was additionally increased when cells were cultured in the 
presence of E2 for 21 (1.5 fold, p=0.009) and 28 days (2 fold, p=0.005). WT OBs 
did not show an increase in ALP activity at any of the time points tested in the 
presence of E2. Our results suggest that Pyk2 deletion and E2 affect ALP activity 
but not ALP mRNA expression in mature differentiated OBs. 
Similarly, calcium deposition, which is one of the markers of mature OB 
activity, was evaluated by culturing WT and Pyk2-KO OBs with ascorbic acid and 
b-glycerolphosphate in 2% FBS with phenol red free α-MEM. In the presence or 
absence of E2 supplementation for 14, 21 or 28 days, and quantitative Alizarin 
Red S staining was assayed (section 2.1.17). We found that calcium deposition 
levels in Pyk2-KO OBs were markedly higher than WT OBs at every time point 
tested (p <0.05, Figure 17). In addition, calcium deposition levels in Pyk2-KO OBs 
were significantly increased when cells were supplemented E2 for 14, 21, and 28 
days (1.35 fold, 1.37 fold, and 1.62 fold, respectively, p<0.05). WT OBs did not 
show an increase in mineralization in the presence E2 at any of the time points 
tested. This suggests that calcium deposition levels in OBs were affected by Pyk2 
deletion and E2 supplementation. 
3.2.3 Raloxifene increases ALP activity and mineral deposition in Pyk2-KO 
OBs. 
Raloxifene is an FDA-approved SERM for the treatment of post-
menopausal osteoporosis. We examined if raloxifene affects the activity of WT and 
Pyk2-KO OBs, in a similar manner to E2. We cultured WT and Pyk2-KO OBs in 
osteogenic media with or without raloxifene (0.1, 1 and 10 nM) for 28 days. The 
time of treatment was based on the most robust effects observed for E2. The 
raloxifene concentration used was determined based on the literature (Lin et al. 
2004; Matsumori et al. 2009) and our pilot studies (data not shown). After 28 days, 
we performed quantitative ALP activity and calcium deposition (mineralization) 
assays. As shown in Figure 18A, Pyk2-KO OBs exhibited significantly higher ALP 
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activity than WT OBs in the absence or presence of raloxifene (p<0.05). Notably, 
1 nM and 10 nM raloxifene further increased ALP activity only in Pyk2-KO OBs 
(1.4 fold and 1.7 fold, respectively) (p<0.05); ALP activity in WT OBs was not 
changed by raloxifene, similar to our findings with E2. Interestingly, raloxifene (0.1, 
1 and 10 nM) enhanced calcium deposition in Pyk2-KO OBs (p<0.05) compared 
to vehicle controls. Although raloxifene increased mineral deposition by WT OBs, 
this was not observed with the lowest concentration of raloxifene (0.1 nM) (Figure 
18B). Moreover, the overall percentage increase in calcium deposition by 
raloxifene was greater in Pyk2-KO OBs than WT OBs (116% vs 44%, respectively, 
at 1 nM, p<0.05). Together, these findings suggest that both E2 and raloxifene 
exert a significant osteogenic effect on Pyk2 OBs.  In contrast, E2 has no effect on 
and raloxifene exerts only a minimal effect on calcium deposition in WT OBs. 
3.2.4 Pyk2-deletion regulates ERα protein levels.  
To begin to determine the mechanism of action of Pyk2 in the estrogen 
signaling cascade, we first determined if Pyk2 regulates the expression of the 
estrogen receptors, ERα and ERβ, in early and mature OBs. WT and Pyk2-KO 
calvarial OBs were grown under osteogenic conditions in the presence or absence 
of 100 nM E2 for 4 and 28 days. QPCR analysis revealed that ERα and ERβ mRNA 
expression was similar in Pyk2-KO OBs and WT OBs, and that ERα or ERβ mRNA 
expression was unchanged in cells treated with E2 for 4 or 28 days (Figure 19A-
19D).  
Next, we examined if Pyk2-deletion affects ERα and ERβ protein levels.  
Total cell lysates were resolved by SDS-PAGE and Western blotting was 
performed using antibodies specific to ERα or ERβ (section 2.1.3). Protein loading 
in all wells was confirmed by blotting with antibody to β-actin. ERα and ERβ protein 
levels, normalized to β-actin, were quantified by densitometry using ImageJ 
software. Of interest, we found a decrease in ERα protein levels in Pyk2-KO OBs 
when compared to WT OBs after 4 and 28 days of culture (Figure 20A and 20C). 
In contrast, we found that ERβ protein levels in Pyk2-KO OBs were not different 
from WT OBs (Figure 20B and 20D). Moreover, the addition of E2 for 4 or 28 days 
had no further effect on ERα or ERβ protein levels in either Pyk2-KO or WT OBs. 
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Together, these findings suggested that Pyk2 regulates the expression ERα in 
early (day 4) and late (day 28) stages of OB differentiation, whereas E2 stimulation 
has no effect on ERα or ERβ in either WT or Pyk2-KO. In addition, the data suggest 
that Pyk2 may regulate OB activity in part by regulating ERα protein levels. 
3.2.5 Pyk2-KO OBs promote ERα protein degradation through the ubiquitin-
proteasome pathway. 
Several studies suggest that ERα can undergo proteasome-mediated 
degradation (Chai et al., 2015; Zhou and Slingerland, 2014;(Levi-Montalcini et al. 
1996; Petrel and Brueggemeier 2003). Therefore, the decreased ERα in Pyk2-KO 
OBs could potentially be due to degradation of ERα. To demonstrate this, we 
examined the effect of the proteasome inhibitor, MG-132, on the distribution of 
ERα protein levels in cytosol and the plasma membrane. WT and Pyk2-KO OBs 
were cultured for 4 days and then treated with or without MG-132 (20 μM) for the 
final 3 hours of culture. Cells were lysed with mRIPA lysis buffer and pelleted by 
centrifugation. The soluble fraction, which contains the cytosolic proteins, was 
separated from the insoluble pellet fraction that contains proteins associated with 
the plasma membrane, nucleus, and cytoskeleton (pellet fraction). We found that 
ERα (after normalization with β-actin control) in WT OBs was more abundant in 
the pellet fraction than in the soluble fraction. However, in Pyk2-KO OBs, ERα was 
more abundant in the soluble fraction when compared to the pellet fraction. 
Consistent with section 3.2.4, we found that Pyk2-KO OBs exhibited a decrease in 
ERα protein when compared to WT OBs, and this occurred in the pellet fraction 
(Figure 21). In WT OBs, MG-132 surprisingly enhanced ERα protein degradation 
in both fractions. This may suggest that MG-132 stabilizes an unknown protein 
which can promote the degradation of ERα in WT OBs under certain cellular 
condition. Conversely, we found that OBs may be regulated by E2 via a non-
genomic pathway through translocation of ERα protein to the cytosol (Levi-
Montalcini et al. 1996; Petrel and Brueggemeier 2003). Therefore, the decreased 
ERα in Pyk2-KO after MG-132 showed an increase in ERα protein in soluble 
fraction compared to non-treated Pyk2-KO OBs. Our findings suggest that MG-
	 57 
132 prevents ubiquitin-proteasome mediated ERα protein degradation in Pyk2-KO 
OBs, leading to an accumulation of ERα in the cytosol.  
3.2.6 An ERβ agonist promotes mineralization in Pyk2-KO OBs.  
As we found a decrease in ERα protein in Pyk2-KO OBs, we examined 
whether decreasing ERα protein expression was related to changes in OB activity. 
WT and Pyk2-KO calvarial OBs were cultured under osteogenic conditions for 21 
days. In addition, an ERα-specific agonist (propyl-pyrazoletriol (PPT)) at the 
concentrations of 0.04, 0.1, and 0.4 μM was added for the whole time of culture. 
The time of treatment was based on our previous experiments and PPT 
concentration was determined based on the literature (Galea et al. 2013; Somjen 
et al. 2011). Quantitative Alizarin Red S staining was then performed as described 
in section 2.1.17. We found that PPT had no effect on the mineralization or either 
WT or Pyk2-KO OBs, although in Pyk2-KO OBs there was a trend towards 
increasing mineralization at 0.1 μM PPT (Figure 22A). This finding was not 
unexpected given that WT OBs did not show an increase in mineralization with E2, 
and Pyk2-KO have reduced levels of ERα and potentially do not respond efficiently 
to PPT. Alternatively, it is possible, we did not achieve the optimal PPT 
concentration to observe a statistically significant increase in mineralization, as we 
observed with raloxifene (Figure 18).  
Pyk2-deletion did not result in a change in ERβ protein levels, suggesting 
that ERβ was likely to be active in Pyk2-KO OBs. We used an ERβ-specific agonist 
(diarylpropionitrile (DPN)) to examine if WT and Pyk2-KO OBs were cultured with 
0.1 µM  and 0.4 µM  DPN for 21 days. WT OB treated with DPN showed no change 
in mineralization, whereas DPN (0.4 μM) increased mineralization in Pyk2-KO OBs 
(Figure 22B). This finding suggests that ERβ signaling could potentially contribute 
to the increase in ALP activity and mineralizing activity observed in Pyk2-KO OBs. 
3.2.7 Pyk2-deletion and E2 activate the ERK pathway.  
OB proliferation and differentiation are controlled by signaling pathways 
such as mitogen-activated protein kinases/extracellular signal-regulated kinases 
(MAPKs/ERKs) (Ge et al. 2012; Lai et al. 2001) and protein kinase B (AKT) (Ayala-
Pena et al. 2013; Burr and Allen 2013; Ge et al. 2012; Lai et al. 2001; Mandal et 
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al. 2016). ERK1 (44 KDa) and ERK2 (42 KDa) are expressed in OBs and have 
relevant functions in bone metabolism. ERK activation was reported to increase 
ALP activity (Jaiswal et al. 2000), OCN mRNA levels and mineralization during OB 
differentiation (Ge et al. 2007; Matsushita et al. 2009). The activation of AKT is 
also associated with cell growth, proliferation and survival. AKT in concert with 
BMP-2 can mediate OB differentiation from MSCs (Ghosh-Choudhury et al. 2002). 
It was also found that the OBs with disrupted AKT1, a major AKT in OBs and OCs, 
showed increased susceptibility to apoptosis and decreased the expression of 
Runx2, an early OB differentiation regulator (Kawamura et al. 2007). In addition, 
E2 binding to ER promotes the rapid interaction of ER with the SRC kinase leading 
to ERK and AKT activation (Marino et al. 2006).  
Our results indicate that Pyk2-KO OBs have significant increases in 
proliferative activity, matrix maturation and mineralization, which were further 
increased with E2 or raloxifene. Therefore, we investigated if Pyk2-deletion and/or 
stimulation with E2 affected downstream signaling of ERK or AKT.  WT and Pyk2-
KO calvarial OBs were cultured alone or in the presence of 100 nM E2 for 4 days. 
Cell pellets were lysed with mRIPA lysis buffer. Proteins were resolved by SDS-
PAGE, then blotted with anti-phospho-ERK (p-ERK) and anti-phospho-AKT (p-
AKT) antibodies and subsequently re-blotted with ERK and AKT antibodies, 
respectively.  
As shown in Figure 23A, Pyk2-KO OBs enhanced ERK phosphorylation 
when compared to WT OBs. Moreover, E2 further increased ERK phosphorylation 
in Pyk2-KO and WT OBs, suggesting an additive effect of E2 in both genotypes. 
However, total ERK phosphorylation in E2-treated Pyk2-KO OBs was still higher 
than in E2-treated WT OBs. A non-specific band approximating the molecular 
weight of p38 and p-p38 was also detected as indicated. These findings suggest 
that Pyk2-deletion combined with E2, activates the ERK pathway to promote OB 
activity. We did not detect a difference in AKT phosphorylation or total AKT 
between WT and Pyk2-KO OBs, either with or without E2 treatment (Figure 23B).  
Since we found increases in ERK phosphorylation in Pyk2-KO OBs, we 
further investigated if Pyk2-deletion and/or E2 stimulation affected ERK signaling 
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in mature OBs, after 21 days of culture. We cultured WT and Pyk2-KO calvarial 
OBs in the presence or absence of 100 nM E2 for 21 days, and then performed 
Western blot analysis as described above. Our results revealed no differences in 
ERK phosphorylation or total ERK protein levels between WT and Pyk2-KO OBs 
(Figure 24). E2 stimulation also had no effect on ERK phosphorylation or total ERK 
after 21 days of treatment. These results suggest that Pyk2-deletion and E2 
increase the mitogenic activity of early OB through ERK, whereas ERK activation 
does not appear to be required for mature OBs function. Whether other signaling 
pathways may be involved requires further investigation.  
3.2.8 Pyk2 and Pyk2-S inhibit ALP and mineralization. 
We previously identified two isoforms of Pyk2, which represent full length 
Pyk2 and the shorter mRNA splice variant, Pyk2-S; Pyk2-S lacks a 42-amino acid 
insert compared to Pyk2 (Figure 25A). Furthermore, differences in the ratio of Pyk2 
and Pyk2-S expression were observed during OB differentiation (Figure 7B and 
25B) (Kacena et al. 2012). This suggests that Pyk2/Pyk2-S may have different 
roles in OB activity. To examine the roles of Pyk2 or Pyk2-S in OB activity we 
chose to transiently express each isoform in pre-osteoblastic cell line, MC3T3-E1, 
since primary OBs are difficult to transfect. We had previously determined and 
confirmed herein (Figure 25B) that MC3T3-E1 cells do not express Pyk2/Pyk2-S, 
making them a suitable Pyk2-deficient cell model. MC3T3-E1 cells were transiently 
transfected with cDNA expression constructs for Pyk2, Pyk2-S or a vector cDNA 
control (Figure 26A) and were incubated for 24 hours. Consistent with our finding 
that primary Pyk2-KO OBs exhibit increased proliferation (Figure 14B), expression 
of Pyk2 or Pyk2-S decreased the proliferation of MC3T3-E1 cells to a similar 
extent, compared to the vector control. (Figure 26B).  
We next examined if Pyk2 or Pyk2-S affect ALP activity and mineral 
deposition of MC3T3-E1 cells. Expression of either Pyk2 or Pyk2-S decreased ALP 
activity to a similar extent (Figure 26C). We also examined the effect of Pyk2 
versus Pyk2-S on mineral deposition in MC3T3-E1 cells. We found that Pyk2 and 
Pyk2-S expressing cells decreased to a similar extent mineral deposition after 3 
days, compared control MC3T3-E1 cells (Figure 26D). Our findings suggest that 
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Pyk2 and Pyk2-S appear to have redundant activities in OBs since both decrease 
OB activity in pre-OB MC3T3-E1 cells, differentiated for 3 days. However, given 
that the ratio of Pyk2 to Pyk2-S varies during OB differentiation, it is likely that the 
actions of Pyk2 and Pyk2-S are temporally separated and/or that they play distinct 
roles in other unidentified signaling effects in OB.  
3.2.9 Estrogen regulates Pyk2 and Pyk2-S protein expression and 
phosphorylation.  
The use of transiently transfected MC3T3-E1 cells precluded our ability to 
examine long-term effects of E2 of Pyk2 and Pyk2-S. Therefore, as an alternative 
approach, we compared undifferentiated OBs (predominately express Pyk2) and 
calvarial OBs differentiated for 14 days (predominately express Pyk2-S). Pyk2 
Y402 phosphorylation is critical for Pyk2 activity and downstream signaling 
(Eleniste et al. 2012) as discussed in Section 1.1.8. Therefore, we examined if E2 
altered the Y402 phosphorylation of Pyk2 or Pyk2-S in undifferentiated and mature 
primary OBs, respectively. WT calvarial OBs were grown without (day 0) or with 
osteogenic media for 14 days and stimulated with 100 nM E2 or vehicle (ethanol) 
for the 6 hours prior to harvesting. As expected, we observed a shift in the 
molecular weight of Pyk2 from full length (118 KDa) on day 0 to the shorter Pyk2-
S isoform (106 KDa) after 14 days of culture (Figure 27), which is consistent with 
our previous publication (Kacena et al. 2012) and Figure 7B. In undifferentiated 
OBs, which primarily express full-length Pyk2, E2 treatment for 6 hours had no 
effect on Pyk2 Y402 phosphorylation. Similarly, differentiated OB which primarily 
express Pyk2-S showed no change in Y402 phosphorylation after 6 hours of E2 
treatment.  
Next, we examined whether longer E2 treatment times might alter Pyk2 or 
Pyk2-S phosphorylation. We cultured WT calvarial OBs alone or in the presence 
of 100 nM E2 for 4 or 28 days. We confirmed that after 4 and 28 day cultures, OBs 
predominately express Pyk2 and Pyk2-S, respectively (Figure 28A and 28B). After 
4 days treatment with E2, the ratio of pY402/Pyk2 was decreased when compared 
to non-treated OBs and the total level of Pyk2 (relative to actin) was increased 
(Figure 28A). The converse was seen in day 28 cultures. That is, E2 treatment for 
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28 days led to an increase in the ratio of pY402/total Pyk2-S which was correlated 
with a decrease in Pyk2-S levels (relative to actin) (Figure 28B). Together, our 
findings suggest that in early and mature OBs, E2 has differential effects on Pyk2 





Osteoblastic bone formation is essential for bone remodeling as well as 
fracture repair. Our studies and others have shown that Pyk2-KO mice have higher 
bone mass compared to WT mice and that OBs from these mice show increased 
bone formation activity (Buckbinder et al. 2007; Gil-Henn et al. 2007). In this study, 
we focused on the role of Pyk2 and estrogen on OB activity. We found that Pyk2-
KO OBs exhibited higher proliferation and differentiation than WT OBs as 
determined by an increase in proliferation, cell number and c-fos mRNA levels in 
Pyk2-KO OBs compared to WT OBs in low serum conditions. These results are 
different from our previously publication (Cheng et al. 2013), in which it was 
reported that Pyk2-KO OB proliferation was not different between Pyk2-KO and 
WT OBs. The reason for this discrepancy was found to be the percentage of serum 
present during the cultures; 10% FBS versus 2% FBS. In the current study, we 
found a decrease in total cell number for both WT and Pyk2-KO OBs in 2% FBS, 
compared to 10% FBS. Nevertheless, Pyk2-KO OBs showed higher proliferation 
compared to WT OBs. These findings suggest that WT OB proliferation is more 
affected by reduced serum levels than Pyk2-KO OBs.  
During the early stage of differentiation, collagen type I mRNA expression 
levels, an early indicator of OB differentiation, was higher in Pyk2-KO OBs than 
WT OBs. At later stages of the OB differentiation process, Pyk2-KO OBs exhibited 
higher OCN mRNA expression, which is a marker of mature OBs. In addition, ALP 
activity and calcium deposition in Pyk2-KO OBs were greater than WT OBs. These 
findings reproduced our previously published studies (Cheng et al. 2013; Eleniste 
et al. 2015) which were performed in 10% FBS, confirming that our current findings 
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were not simply the result of reduced serum levels. Generally, matrix formation 
precedes mineralization in OBs (Anderson et al. 2005; Nudelman et al. 2010; Stein 
et al. 2004). Interestingly, in Pyk2-KO OBs we found that the matrix formation, 
maturation and mineralization phases appeared to be overlapping. Specifically, we 
found an increase in ALP activity in Pyk2-KO OBs when cultured for 21 and 28 
days compared to WT OBs. However, the calcium deposition levels in Pyk2-KO 
OBs were markedly higher than WT OBs started from day 14 to day 28. These 
findings suggest that the matrix formation and mineralization phases may be 
maintained for longer periods in Pyk2-KO OBs than in WT OBs. Overall, our results 
confirm that Pyk2 is a negative regulator of OB activity, which is consistent with 
our previous data as well as other published studies (Buckbinder et al. 2007; 
Cheng et al. 2013; Eleniste et al. 2015; Kacena et al. 2012).  
We examined the role of Pyk2 and estrogen in OB proliferation and 
differentiation, and found that E2 had no effect on OB proliferation on day 1 of 
treatment, either in WT or Pyk2-KO OBs. However, we demonstrated that 4 days 
of E2 supplementation significantly increased the number of WT OBs, but did not 
show a corresponding increase in proliferation assessed using the MTS assay. 
The explanation for the different results may be from the duration of E2 
supplementation. In the cell counting experiment, OBs were treated with E2 for 1 
and 4 days, while for the MTS assay, cells were cultured in E2 for only 12 hours. 
Although E2 did not affect Pyk2-KO OBs number, E2-treated Pyk2-KO OBs still 
exhibited higher cell number than E2-treated WT OBs due to the high basal OB 
number compared to WT OBs, which was likely due to the decreased sensitivity of 
Pyk2-KO OBs to low serum. Thus, our data indicates that E2 maintained WT OBs 
in a proliferative state, most likely in the G1 phase of the cell cycle (Bonnelye et al. 
2001; Wakeling et al. 1991), whereas Pyk2-KO OBs likely enter the differentiation 
phase at a faster rate than WT cells. The increase in the ratio of mineralizing to 
proliferating Pyk2-KO OBs, compared to WT OBs may also explain the increase 
in ALP activity and mineralization in E2-treated Pyk2-KO OBs compared to E2-
treated WT OBs (Figure 16 and 17). In support of this, in differentiated Pyk2-KO 
OBs but not in WT OBs, we found that E2 augmented collagen type I mRNA 
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expression levels, and collagen is known to be necessary for mineralization. 
Moreover, we observed an additive effect of Pyk2-deletion and E2 on ALP activity 
and calcium deposition levels. Interestingly, there was a strong trend for decreased 
ALP mRNA expression with 28 days of E2 treatment in both WT and Pyk2-KO 
OBs. This suggests that long term E2 treatment may accelerate OBs enter to 
mineralization phase faster than non-treated group. These findings suggest that 
differentiated Pyk2-KO OBs are influenced by E2 to a greater extent than WT OBs, 
resulting in increased osteogenesis. This finding may also in part explain our 
unpublished in vivo data in which we observed a greater increase in trabecular 
BV/TV in E2-supplemented OVX Pyk2-KO mice than in E2-treated OVX WT mice 
(Figure 9).  
We investigated the mechanism of action of Pyk2 in the estrogen-signaling 
cascade and found that ERα protein levels were reduced in Pyk2-KO OBs, 
compared to WT OBs, whereas ERβ protein levels were similar for the two 
genotypes. Our studies suggested that the decrease in ERα in Pyk2-KO OBs was 
likely to be the result of ubiquitin-proteasome mediated degradation of ERα in the 
cytosol compartment, although other mechanisms for protein degradation (such as 
lysosomal) cannot yet be ruled out. However, the percentage of ERα in cytosolic 
compartment versus membrane/nucleus compartments were not so skewed that 
significant genomic regulation could still occur. In addition, it is known that 
regulation by ERs in OBs occurs through translocation from cytosol to nucleus in 
response to certain stimuli such as strain. The evidencealso showed that estrdiol 
had little effect upon β-catenin location in the cell (Armstrong et al. 2007). 
Furthermore, it is known that ERα mRNA is highly expressed during matrix 
maturation and then decreases during mineralization, while ERβ mRNA levels 
remain relatively constant throughout differentiation (Bord et al. 2003; Onoe et al. 
1997; Wiren et al. 2002). Therefore, the increased degradation of ERα in Pyk2-KO 
OBs may also reflect the increased differentiation state of these cells, compared 
to WT OBs. Unexpectedly, MG-132 treatment enhanced ERα protein degradation 
in WT OBs, and although the mechanism is still unclear, the evidence has shown 
that ER degradation depends on ubiquitin-activating E1 enzyme (UBA) and 
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ubiquitin-conjugating E2 enzymes (UBCs), as well as other co-
activators/repressors and MG132 may also block their protein degradation in vitro 
(Ismail and Nawaz 2005; Nawaz et al. 1999).   
Our studies demonstrated decreased ERα levels in Pyk2-KO OBs, 
suggesting that the in vitro phenotype may be related to the reduction in ERα. It 
has been reported that ERα-KO calvarial OBs exhibit normal mineralization when 
compared to WT OBs (McCauley et al. 2003). On the contrary, Almeida et al. 
showed that OBs from mice with Prx-targeted or osterix-targeted deletion of ERα 
showed significantly decreased differentiation when compared to controls 
(Almeida et al. 2013). This effect may be from the reduced ability of MSC to enter 
the OB lineage. Unexpectedly, it has been shown that 17β-estradiol can stimulate 
osteogenic differentiation of bone marrow cells derived from ERα-KO mice, which 
was demonstrated by an increase in collagen type I synthesis, ALP activity, and 
mineralization. Interestingly, the increased ALP activity in 17β-estradiol -treated 
ERα-KO OBs was even higher than 17β-estradiol -treated WT OBs (Parikka et al. 
2005), similar to our findings in 17β-estradiol-treated Pyk2-KO OBs (Figure 16). In 
another study, it was reported that 17β-estradiol treatment significantly enhanced 
ALP activity and collagen type I mRNA expression in MG-63 osteosarcoma cells 
with reduced levels of ERα, but not ERβ (Cao et al. 2003). These findings suggest 
that the additive effect of 17β-estradiol on ALP and mineralization in our Pyk2-KO 
OBs, compared to WT OBs, may be mechanistically linked with the decrease in 
ERα in Pyk2-KO OBs. However, our studies do not rule out the possibility that E2 
signaling via ERβ may also contribute to the increase in mineralization of Pyk2-KO 
OBs. Indeed, we found that DPN, which is an ERβ agonist increased the 
mineralization of Pyk2-KO OBs (Figure 22B), suggesting that the ERβ signaling 
pathway can be activated in these cells.  
Together, our findings suggest that Pyk2 may regulate OB activity in part by 
modulating ERα and/or ERβ signaling. It is also possible that Pyk2-KO OBs 
respond to E2 by mechanisms other than ERα and/or ERβ, such as through the 
N-terminal truncated ERα isoform, or the orphan nuclear ER–related receptor α 
(ERRα) which was reported to affect bone formation and is differentially expressed 
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relative to ERα and ERβ in OBs (Bonnelye and Aubin 2002; Bonnelye et al. 2001; 
Parikka et al. 2005). In addition, Pyk2 may play a role in the regulation of male sex 
steroid hormone receptors, androgen receptor.  In support of this, a recent study 
found that Pyk2 promoted the expression and phosphorylation of the androgen 
receptor (Hsiao et al. 2016). Further studies are needed to investigate the role of 
Pyk2 and these receptors in OB activity.  
To examine if Pyk2-deletion potentially affects signaling cascades that are 
common to ERα and/or ERβ, we examined ERK and AKT phosphorylation, which 
are important of mitogenesis and anti-apoptotic activity, respectively.  Although 
AKT levels were similar in WT and Pyk2-KO OBs, Pyk2-KO OBs exhibited 
enhanced ERK phosphorylation compared to WT OBs.  
It is well-established that MAPKs are activated by phosphorylation of 
tyrosine/threonine residues in signal transduction cascades, which include ERK, 
leading to the activation of nuclear transcription factors such c-jun, which is highly 
expressed during early OB differentiation (Marie 2008). Consistent with this, ERK 
activation was also reported to increase ALP activity (Jaiswal et al. 2000), OCN 
mRNA and OB mineralization (Ge et al. 2007; Matsushita et al. 2009). Similarly, 
mice lacking ERK1/ERK2 exhibited substantially reduced bone mineralization 
when compared to WT mice (Matsushita et al. 2009). Given the increased 
proliferation and differentiation of Pyk2-KO OBs, we speculate that Pyk2-deletion 
leads to an increase in ERK phosphorylation, and subsequently leads to increases 
in collagen type I and OCN mRNA levels, ALP activity and mineralization. We also 
found that E2 had an additive effect on ERK phosphorylation in both WT and Pyk2-
KO OBs. This finding is consistent with published evidence that 17β-estradiol 
supplementation enhances ERK phosphorylation via ERα in MC3T3-E1 cells, and 
leads to inhibition of OB apoptosis (Yang et al. 2013). Thus, estrogen stimulation 
augment ERK phosphorylation signaling in Pyk2-KO OBs, which already exhibit 
high basal ERK phosphorylation, resulting in an overall increase in OB 
differentiation and possibly survival as seen by the marked increase in matrix 
formation and mineralization in 17β-estradiol treated Pyk2-KO OBs. In addition, it 
will be interesting to see whether an increase in OB activity with Pyk2 deletion 
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involves other signaling pathways such as p38 pathway, which is part of the MAPK 
subfamily, similar to ERK and is involved in cell proliferation. Published evidence 
shows that the activation of p38 plays important roles in differentiation of calvarial 
OBs, bone marrow cells, and some OB cell lines (Hu et al. 2003; Rodriguez-
Carballo et al. 2016; Wang et al. 2007).  
Similar to our findings with E2, we found that raloxifene, which is an 
activator of ERa and ERb, had a significant osteogenic effect on both WT and 
Pyk2-KO OBs. However, the osteogenic effect on Pyk2-KO OBs was markedly 
greater than on WT OBs. The mechanism of action of raloxifene on target tissue 
is not well understood, but it is believed that its actions are mediated by genomic 
and non-genomic pathways through ERα and ERβ (Jordan et al. 2001; Tee et al. 
2004). It has been shown that raloxifene exerts its estrogenic effects on bone by 
decreasing the remodeling rate, reducing OC activity, and maintaining OB activity 
(Hegde et al. 2015). In addition to its antiresorptive activity, several studies suggest 
that raloxifene may act as an anabolic agent by increasing proliferation activity, 
and Runx2 and collagen type I mRNA expression in primary human OBs and this 
effect was found to be partly mediated via ERK1 and ERK2 activation (Noda-Seino 
et al. 2013; Taranta et al. 2002). This suggests that raloxifene may promote Pyk2-
KO OB activity via a similar mechanism as E2. 
The Pyk2 and Pyk2-S isoforms were previously identified (Kacena et al. 
2012)  and shown to be differentially expressed during OB differentiation, with 
Pyk2 levels decreasing during differentiation while Pyk2-S levels progressively 
increase (Figure 25B). This suggests that Pyk2 and Pyk2-S isoforms potentially 
exert unique roles in OB activity. Contrary to our expectations, we found that Pyk2 
and Pyk2-S exert similar effects in MC3T3-E1 cells, and reduce OB proliferation, 
ALP activity, and mineralization levels to the same extent (Figure 26). These 
results indicate that both Pyk2 and Pyk2-S are negative regulators of OB activity, 
which is consistent with our results that Pyk2-KO OBs have enhanced activity. 
However, it is possible that Pyk2 and Pyk2-S may affect OBs at different stage of 
differentiation due to their differential expression; Pyk2 may inhibit OB activity in 
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the early stage of OB differentiation, while Pyk2-S may affect later stages of OB 
differentiation or be active in mature OBs.  
The phosphorylation of residue Y402 in Pyk2, and presumably Pyk2-S, is 
critical for its tyrosine kinase activity and the recruitment of other signaling proteins, 
such as c-Src (Eleniste et al. 2012; Kimble et al. 1996). Therefore, we examined if 
E2 affects the phosphorylation of Pyk2 or Pyk2-S in early or mature OBs, 
respectively. In OBs treated with E2 for 4 days, which primarily express full-length 
Pyk2, E2 led to a small decrease in the ratio of phosphorylated Y402 to total Pyk2, 
as well as a significant increase in total Pyk2 levels (Figure 28A). Conversely, in 
OBs cultured for 28 days, which primarily express Pyk2-S, E2 significantly 
increased the ratio of phosphorylated Y402 to total Pyk2-S, and decreased total 
Pyk2-S levels (Figure 28B). Thus, we speculate that E2 likely increases 
downstream signaling in early OBs via Pyk2 through proteins other than Y402-
mediated recruitment of Src. In contrast, E2 is likely to promote the recruitment of 
Src to Pyk2-S in mature OBs. Currently, only one published study has reported an 
increase in Pyk2 protein levels in MCF-7 cells, a human breast cancer cell line, 
when stimulating with E2 for 30 minutes at the concentration of 0.4, 40, and 400 
nM. Although the mechanism of regulation of Pyk2 or Pyk2-S protein levels is 
unknown, one possibility is through the regulation of microRNA species. miRNAs 
are a class of short, non-protein coding RNAs that serve to post-transcriptionally 
regulate gene expression through either translational repression or mRNA 
degradation. In addition, miRNAs also play important roles in cell proliferation, 
differentiation, apoptosis, and tumorigenesis (Cai et al. 2009; Loftus et al. 2012; 
Maillot et al. 2009). It was reported that a set of miRNAs, which include miR-23b, 
are down regulated by E2 in a number of human breast cancer cell lines (Maillot 
et al. 2009). In addition, it was shown that decreased miR-23b expression in glioma 
cells enhanced Pyk2 expression, which was correlated with an increase in glioma 
cell migration in vitro (Loftus et al. 2012). Therefore, it is possible that E2 
stimulation of early OBs may increase miR-23b which leads to the increase in 
Pyk2.  In contrast in mature OBs, perhaps miR-23b levels are upregulated, leading 
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to a decrease in Pyk2-S. Whether miR-23b levels are temporally altered during OB 
differentiation and by E2 remains to be determined. 
 
3.4 Summary and conclusions 
 
We examined the effect of E2 on Pyk2-KO OBs.. We found a decrease in 
ERα protein levels in Pyk2-KO OBs compared to WT OBs which was due to ERα 
degradation in the cytosol through the ubiquitin proteasome pathway. In contrast, 
ERβ protein levels in Pyk2-KO OBs were similar to WT OBs. For OB activity, our 
results indicated that during early differentiation (4 days) Pyk2-KO OBs exhibit 
significant increases in c-fos and collagen type I mRNA expression levels, and up-
regulated basal ERK phosphorylation compared to WT OBs. Moreover, we found 
an additive effect of estrogen on collagen type I mRNA in Pyk2-KO OBs, and on 
ERK phosphorylation in both WT and Pyk2-KO OBs. Mature Pyk2-KO OBs (14-28 
days) also showed higher OCN mRNA levels, ALP activity, and calcium deposition 
levels compared to WT OBs. Estrogen stimulation led to a further increase in both 
ALP activity and calcium deposition in Pyk2-KO OBs, but not in WT OBs. Likewise, 
raloxifene supplementation markedly enhanced ALP activity and calcium 
deposition levels in Pyk2-KO OBs, whereas a minimal effect on mineral deposition 
was observed in WT OBs.  Although both Pyk2 and PyK2-S isoforms were found 
to negatively regulate OB activity, we found that the Y402 phosphorylation of Pyk2 
or Pyk2-S, which is necessary for tyrosine kinase activation, is differentially 
regulated by E2 in early and mature OBs, respectively, suggesting that functional 
differences between these isoforms in OBs may exist. Whether the actions of Pyk2 
or Pyk2-S in early or mature OBs, respectively, are interchangeable, or whether 
our observed differences reflect the different stages of the OB differentiation 
process is currently unknown.  
In conclusion, our results indicate that Pyk2 (and Pyk2-S) is a negative 
regulator of OBs. Furthermore, Pyk2 stabilizes ERα protein levels by preventing 
its proteasome-mediated degradation. Pyk2-deletion and E2 have an additive 
stimulatory effect on ERK signaling suggesting that Pyk2 is integrated into the E2-
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ERα/ERβ signaling cascade via ERK, which leads to inhibition of OB differentiation 
and mineralization. Thus, we speculate that Pyk2-deletion promotes bone 
formation and potentiates the effects of estrogen (and raloxifene) on OB matrix 
formation and mineralization, resulting in an increase in bone mass. Figure 29 
describes our current working model for the action of Pyk2 and E2 signaling in 










Bone can regenerate in response to injury or pathological diseases, as well 
as during the remodeling process that occurs throughout life. Bone regeneration is 
a well-orchestrated process of bone formation and bone resorption, involving a 
number of biological events in an effort to repair bone damage and eventually 
restore skeletal function. Bone can spontaneously repair in cases of minor bone 
damage. However, clinical intervention for large scale bone regeneration such as 
reconstructive surgery and bone transplantation are required in cases of extensive 
bone damage including large bony defects resulting from trauma, infection, tumor, 
and skeletal abnormalities, or cases of compromised bone regeneration such as 
avascular necrosis and in osteoporosis patients, which result in a decrease in bone 
quality (Dimitriou et al. 2011; Zomorodian and Baghaban Eslaminejad 2012). The 
current gold standard clinical therapy for the regeneration of large bone defects is 
the use of autologous grafts because they possess inherent osteoconductivity, 
osteoinductivity, and osteogenicity. However, there is a limited supply of grafts and 
grafts frequently associated with donor site morbidity. An alternative treatment 
incorporates the use of allogenic or xenogenic bone grafts, which exhibit no donor 
site morbidity and supply limitations. Even though advantageous, they still have 
drawbacks associated with increasing the risk of infection and disease 
transmission (Amini et al. 2012; Oryan et al. 2014).  
Bone tissue engineering has been extensively investigated as an alternative 
therapy for bone grafting (Chu et al. 2007; Li et al. 2014; Romagnoli et al. 2013). 
In order to enhance bone healing, a tissue engineering technique using 
biomolecules or drugs incorporated into scaffolds have been investigated (Mourino 
and Boccaccini 2010; Romagnoli et al. 2013). Among these biomolecules, BMP-2 
is a well-established enhancer used in bone regeneration for orthopedic and 
maxillofacial applications (Chu et al. 2007; de Oliveira et al. 2013; Mont et al. 2004; 
Romagnoli et al. 2013). Nevertheless, BMP-2 still has some clinical concerns that 
should not be overlooked which include: increasing risk of radicular pain, ectopic 
bone formation, osteolysis, and poor global outcomes. These suggest that a need 
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for alternative biomolecules for bone regeneration and bone tissue engineering 
remains (Fu et al. 2013; Mesfin et al. 2013; Rodgers et al. 2013; Simmonds et al. 
2013). 
Our studies and others suggest that Pyk2 deletion increases OB 
differentiation and enhances bone formation, resulting in a high bone mass 
phenotype in global Pyk2-KO mice (Buckbinder et al. 2007; Cheng et al. 2013; Gil-
Henn et al. 2007; Kacena et al. 2012). Importantly, Buckbinder et al. reported that 
PF-431396 (PF-43), which is a dual FAK/Pyk2 inhibitor, increased bone mass and 
protected rats against OVX-induced bone loss (Buckbinder et al. 2007). In addition, 
PF- 461-8433 (PF-46), which is more specific to Pyk2, has been shown to enhance 
ALP activity and mineralization in human MSCs, but has not been investigated for 
in vivo studies (Han et al. 2009). These findings suggested that a Pyk2-inhibitor 
loaded scaffold may promote OB activity, and may therefore be useful for future 
studies to regenerate bone defects. 
Bone healing and regeneration consist of several phases including 
inflammatory phase, soft callus formation phase, hard callus or endochondral 
ossification phase, and bone remodeling phase (Burr and Allen 2013; Marzona 
and Pavolini 2009; Oryan et al. 2015). Drug delivery systems for bone regeneration 
usually target osteoblastic bone formation, and the systems  that increase the 
availability of proteins, growth factors, or drugs have been proven for safety and 
efficiency for bone regeneration such as rhBMP-2 and collagen sponge (Ratko et 
al. 2010). Nevertheless, the collagen sponges loaded with rhBMP-2 often exhibits 
an initial uncontrolled burst release of rhBMP-2, which can cause side effects to 
surrounding tissues such as osteolysis around the bone graft (Fu et al. 2013; 
Simmonds et al. 2013). Therefore, the need for a drug carrier system that allows 
for local sustained release of biomolecules is still required to achieve a therapeutic 
efficacy. Nowadays, hydrogels are widely used in biomedical applications 
including bone tissue engineering due to their biocompatibility, biodegradability, 
and ability to mimic ECM structures. In addition, the controlled release behavior 
ensures hydrogels may be good carrier materials for drug delivery systems (Park 
2011; Shi et al. 2012; Tronci et al. 2014). 
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Poly (ethylene glycol) (PEG), a non-ionic hydrophilic synthetic polymer, has 
been extensively used for several decades for controlled drug delivery and cell 
delivery in tissue engineering applications due to the controllable material 
properties that enable hydrogels to be fabricated with the desired functions and 
properties (Lin and Anseth 2009; Lin et al. 2015). PEG-diacrylate (PEGDA), a 
PEG-based macromers with reactive termini, is highly used in hydrogel fabrication 
because of the simplicity of synthesis and its availability from commercial sources 
(Hao and Lin 2014). PEGDA hydrogels have also been used in bone regeneration 
as carriers of biomolecules such as BMP-2. It has been reported that PEGDA 
hydrogel tethered with BMP-2 promotes bone healing in vivo (Chen et al. 2011; 
Sonnet et al. 2013).  
A semi-interpenetrating network (sIPN), which contains photocrosslinked 
PEG matrices and physically entrapped gelatin, has been developed as an 
effective drug delivery and tissue engineering scaffold (Fu et al. 2012). sIPN of 
PEG matrices improves protein resistance and mechanical stability. The mesh size 
of sIPN depends on the amount of PEG in the system, which may impact the 
transportation of biomolecules out from the sIPN. Incorporated gelatin in matrices 
enhances biological characteristics because gelatin contains cell-recognition 
motifs such as the RGD sequence, and gelatin can be cleaved by various 
proteases such as matrix metalloproteinase 2 (MMP-2) and MMP-9, which can 
improve the biodegradability of the system. Furthermore, drug molecules can be 
directly added into the polymer solution prior to polymerization, which can prevent 
drug overloading (Fu and Kao 2009; Santoro et al. 2014).  
In the current study, we hypothesized that PEGDA-gelatin hydrogel would 
be an effective candidate carrier for Pyk2 inhibitors to increase osteoblastic activity 
in terms of material handling, release behavior, retained bioactivity of inhibitors, 
and hydrogel biodegradability. This chapter describes the development of a Pyk2-







4.2.1 A Pyk2-targeted inhibitor (PF-46) enhances matrix formation and 
mineralization of OBs. 
First, we examined the effects of the Pyk2 inhibitors, PF-43 and PF-46, on 
the proliferation of OB precursors and on the activity of differentiated mature OBs. 
For these studies, we mostly used bone marrow derived MSC as these cells more 
closely replicate an in vivo bone healing environment in which a Pyk2-scaffold 
would potentially be used. In addition to the use of undifferentiated MSCs for 
proliferation studies, MSCs and calvarial OBs were cultured in osteogenic media 
for 7-21 days to induce OB differentiation, maturation and matrix deposition.  
 To examine the effect of PF-43 and PF-46 on OB precursor proliferation, 
mouse MSCs were plated overnight and then cultured in the presence or absence 
of 0.1 or 0.3 μM of each inhibitor for an additional 24 hours. A MTS assay was then 
performed to compare cell proliferation rates. As shown in Figure 30A, PF-43 (0.1 
and 0.3 μM) and PF-46 (0.3 μM) significantly increased cell proliferation when 
compared to the untreated or control group (p<0.05).  Moreover, 0.1 μM PF-46 
exhibited the highest proliferation activity among the groups (p<0.05).  
Bone marrow derived MSCs were then differentiated into mature OBs with 
50 μM ascorbic acid and 5 mM β-GP in the presence or absence of PF-43 or PF-
46. ALP activity assay and mineralizing activity were assayed at 7 and 21 days, 
respectively. Our results revealed that both PF-43 and PF-46 at 0.1 and 0.3 μM 
significantly increased the differentiation of OBs as assessed by increased ALP 
activity (Figure 30B). However, only PF-46 (0.1 and 0.3 μM) enhanced calcium 
deposition, a marker of mineralizing activity of OBs (Figure 30C).  
We also examined the effect of PF-46 on the differentiation of calvarial OBs.  
Similar to MSCs, calvarial OBs treated with lower concentration of PF-46 for 21 
days significantly promoted ALP activity (0.0125 and 0.05 μM) and mineral 
deposition levels (0.05 μM) in calvarial OBs when compared to control group 
(p<0.05) (Figure 31A and B).  
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These data suggest that PF-46, a Pyk2-targeted inhibitor, promotes ALP 
activity and mineralization to a greater extent than PF-43, the dual Pyk2/FAK 
inhibitor. Thus, we used PF-46 in all subsequent experiments. In addition, since a 
long-term goal of our studies is to identify a hydrogel suitable for in vivo bone 
regeneration applications, bone marrow derived MSCs were used to more closely 
approximate the bone microenvironment in which the scaffold will likely be used. 
4.2.2 Characterization of PEGDA-gelatin hydrogels  
4.2.2.1 P1000:G10 prepolymer solution reveals the highest viscosity and 
shear-thinning effect.  
PEGDA and gelatin were chosen as the polymers for hydrogels since 
PEGDA properties can be tailored through the adjustment of molecular weight and 
PEGDA polymer concentration, which may influence the release behavior and 
degradation of hydrogels (Parlato et al. 2014). Gelatin incorporation has been 
shown to improve biodegradability and elasticity of the network (Burmania et al. 
2003). We performed preliminary studies using PEGDA 400, 600, and 1000 Da 
with various w/v% of PEGDA and gelatin in prepolymer solutions and found that 
25% PEGDA600 (P600), 25% PEGDA1000 (P1000), 25% PEGDA600 and 5% 
gelatin (P600:G5), and 25% PEGDA1000 and 10% gelatin (P1000:G10) showed 
the optimal consistency and did not form complete physical gels at room 
temperature for 5 minutes, which allowed us to have enough material working time. 
Thus, P600, P1000, P600:G5, and P1000:G10 prepolymer solutions were the 
candidate prepolymer solutions used in subsequent studies.  
To measure the dynamic viscosity of the prepolymer solutions, all 
prepolymer solutions were prepared and examined for the controlled shear rate 
viscometry using a digital rheometer (viscometry mode) at room temperature. The 
viscometry was performed because we postulated that gelatin incorporated into 
PEGDA prepolymer solution could enhance the prepolymer solution viscosity, 
which would improve the handling of prepolymer solution. Our pilot results 
demonstrated that all groups exhibited a decrease in viscosity when shear rate 
was increased; this is the shear-thinning behavior. Furthermore, the addition of 
gelatin enhanced the shear-thinning effect in both P1000 and P600 prepolymer 
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solutions (Figure 32A). After prepolymer solutions reached Newtonian fluid 
behavior and exhibited a constant viscosity, P1000:G10 revealed the highest 
viscosity (44.8 mPa.s), followed by P600:G5 (39.1 mPa.s), P1000 (28.5 mPa.s) 
and lastly P600 (16.4 mPa.s). 
Yield stress is the applied stress that needs to be exceeded in order to make 
materials flow. A material with this property is called a yield stress fluid, which is 
fully elastic when the stress value is below the yield stress, but it flows at stresses 
above yield stress (Moller et al. 2009).  The presence of yield stress in the solution 
indicates that fluid will not be self-flowing. Regarding the plot of shear stress vs. 
shear rate or the flow curve (Figure 32B), incorporating gelatin in PEGDA 
prepolymer solutions allowed P1000:G10 solution to demonstrate a yield stress of 
about 16 Pa. This properly allows the gel to stay within the defect site when applied 
and not free-flowing before the prepolymer solution is polymerized by light curing.  
4.2.2.2 Determination of hydrogel gelation times 
The gelation times of P600, P1000, P600:G5, and P1000:G10 prepolymer 
solutions were determined using two methods; the probing technique and in situ 
photorheometry test. For the probing method, all prepolymer solutions were 
prepared and the disk-shaped gels (5x3 mm) were fabricated under visible light 
(LED dental curing light: 450-470 nm and 1000 J/cm2) at room temperature 
(N=5/group). A periodontal probe was used to determine gelation time, which was 
the time when the surface of materials hardened and materials did not adhere to 
the tip of the periodontal probe. The gelation times of the four groups of hydrogels 
from the probing method are shown in Figure 33A. The statistical analysis 
indicated significant differences in the gelation times among the groups (p<0.05). 
The shortest mean gelation time (2.17±0.17 minutes) was recorded for P600. No 
significant difference in the gelation time was found between P600 and P600:G5. 
However, both P1000 and P1000:G10 showed a significantly higher gelation time 
than P600 and P600:G5. P1000:G10 exhibited the longest gelation time when 
compared to the other groups (5.4±0.15 minutes, p<0.05). 
For the in situ photorheometry test, all prepolymer solutions were subjected 
to shear oscillation measurement using the digital rheometer with a light cure 
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attachment (Omnicure S1000: UV and visible light system: 320-500 nm and 
1000J/cm2). The photorheological analysis provides more accuracy in a gelation 
profile of hydrogels. Information about the gelation behavior of the gels is gained 
in terms of the measured storage or elasticity modulus (G’) and loss or viscous 
modulus (G”). We observed that the moduli of P600, P600:G5, and P1000 that 
started from G” were greater than G’ because the hydrogels exhibited a liquid 
behavior. Then, G’ increased as the polymerization proceeded to a crossover point 
with G”, which is recorded as the gelation time. Our results showed that P600 was 
cured fastest (2.4±0.04 minutes) followed by P1000 (5.71±0.01 minutes), and 
P600:G5 (6.8±0.13 minutes). Interestingly, we could not obtain the gel point for 
P1000:G10 by this method because G’ of P1000:G10 exceeding G” at the starting 
point, so no crossover of G’ and G” occurred. The plots of log G’ and G” vs. time 
of a representative sample from each group are shown in Figure 33B-33E. The G’ 
after curing of P600, P600:G5, P1000, and P1000:G10 were at 202.3×103, 
327.8×103, 151.4×103, and 760 Pa, respectively.  
Overall, different gelation times were found using the probing method and 
in situ photorheometry test, which will be discussed in greater detail in the 
discussion section of this chapter.  Furthermore, both P600:G5 and P1000:G10 
exhibited a gelation time between 2-6 minutes.  Regarding the viscosity, the 
addition of gelatin enhanced the viscosity of P600 and P1000 prepolymer 
solutions. Thus, the gelation time and viscosity of our hydrogels would allow for 
sufficient handling time and fluid flow for future applications. Therefore, P600:G5 
and P1000:G10 hydrogels were chosen for all subsequent experiments due to its 
viscosity and gelation which would make it useful as a carrier for drug delivery. 
4.2.2.3 P600:G5 shows a greater swelling behavior and degradation than 
P1000:G10. 
The swelling behavior of hydrogels can greatly affect the pore size of the 
network and the release behavior of gels. We evaluated the swelling ratio (Q) of 
PEGDA-gelatin hydrogels by fabricating P1000:G10 and P600:G5 gels 
(N=5/group), then soaking gels in PBS at 37°C and weight measuring up to 25 
days. Both P1000:G10 and P600:G5 gels revealed rapid water absorption and 
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swelling and reached a maximum swelling ratio (Qmax) within 1 and 1.5 hours, 
respectively (Figure 34A). P1000:G10 showed significantly lower Qmax than 
P600:G500 (p<0.05).  
Polymer degradation also affects drug release characteristics. Therefore, 
the extent of hydrogel degradation was examined by soaking P1000:G10 and 
P600:G5 hydrogels in PBS and measuring mass of samples up to 25 days 
(N=5/group). We found that P600:G5 gels exhibited greater degradation than 
P1000:G10 gels at days 3, 10, 20, and 25 (Figure 34B, p<0.05).  
4.2.2.4 P1000:G10 hydrogels exhibit the highest loading efficiency and the 
slowest release behavior. 
The loading efﬁciency mostly depends on the drug or substance solubility in 
the scaffold matrix material, the composition and molecular weight of the polymer, 
and the drug–polymer interaction (Asghar et al. 2012). To determine the loading 
efficacy, we used a fluorescent dye to mimic drug delivery of small molecule, PF-
46. 7-amino-4-methylcoumarin was chosen because its excitation and emission 
spectrums (370 nm and 460 nm, respectively) are well defined and easily 
detectable. The 7-amino-4-methylcoumarin (2 mM) was loaded into P1000:G10 
and P600:G5 prepolymer solutions before light curing and once set the hydrogels 
were immersed in PBS at 37 °C. In addition, we compared the loading efficacy of 
the hydrogels with 7-amino-4-methylcoumarin loaded collagen sponges, which are 
the control group. After 24 hours, all samples were completely disrupted using a 
sonicator (N=5/group). The total amount of fluorescent dye released into PBS was 
measured using fluorescence spectrophotometry. The 7-amino-4-methylcoumarin 
loaded collagen sponges had a loading efﬁciency of 100%. The loading efﬁciencies 
in P1000:G10 and P600:G5 were 99% and 83%, respectively (Figure 35).  
To determine the release behavior of PEGDA-gelatin hydrogels, the in 
vitro release kinetics of 7-amino-4-methylcoumarin was measured in P1000:G10 
and P600:G5 hydrogels, and collagen sponges (control). To replicate the 
physiological environment, the loaded hydrogels and collagen sponge with 7-
amino-4-methylcoumarin were incubated in PBS at 37°C up to 25 days 
(N=5/group). The released fluorescent dye was measured using fluorescence 
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spectrophotometry over time. The total amount of 7-amino-4-methylcoumarin 
released from all candidate carriers is shown in Figure 36A. The percentage of 
cumulative in vitro release patterns of 7-amino-4-methylcoumarin loaded 
PEGDA-gelatin hydrogels and collagen sponges are shown in Figure 36B. On 
day 3, the cumulative initial burst of dye released from P1000:G10, P600:G5, and 
control were approximately 84%, 88%, and 93% of the loading amount, 
respectively. Approximately 100% of the loaded fluorescent dye was released 
from the control group by day 5, followed by P600:G5 at day 10 and P1000:G10 
at day 15. 
Generally, diffusion, erosion, and degradation are the mechanisms involved 
in molecule release from hydrogels (Fu and Kao 2009; Lin and Anseth 2009). A 
simple mathematical method to determine the release kinetics of molecules from 
a polymer matrix is derived by plotting the first 60% of cumulative drug release 
data vs. square root of time (Figure 36A, and insert figure), then fitting data in the 
Higuchi equation: 𝑄4 = 𝐾𝑡@/B 
where Qt is the amount of drug released at time t, and K is the release constant 
rate. This equation is based on the Fickian diffusion and applicable to the diffusion 
of drugs that dispersed homogeneously in a polymer matrix (Dash et al. 2010; 
Grassi and Grassi 2005). By applying this model to our hydrogels, we found that 
data from all groups acceptably fit this equation (R2 > 0.96). This finding indicated 
that the drug release mechanism of P1000:G10, P600:G5, and collagen sponge 
followed Fickian diffusion with the K values at 46.68±1.28, 48.68±1.27, and 
49.59±1.73, respectively. 
4.2.3  P1000:G10 and P600:G5 hydrogels are non-cytotoxic carriers.  
According to the ISO 10993-5 guidelines (ISO-10993-5 1993), the  materials 
that exhibit equal or more than 70% of the relative cell viability compared to the 
control group are considered as non-cytotoxic materials. We evaluated the 
cytotoxicity of P1000:G10 and P600:G5 hydrogels against MC3T3-E1 osteoblastic 
cells by following ISO 10993-5 guidelines (ISO-10993-5 1993). P1000:G10 and 
P600:G5 hydrogels, and collagen sponges were prepared, sterilized by sterilized 
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by UV light for 30 minutes per each side, and then soaked in α-MEM with 10% 
FBS and 1% P/S at 37ºC for 24 hours. Next, P1000:G10, P600:G5, and collagen 
sponge eluates were collected and used for the cytotoxicity tests. MC3T3-E1 
osteoblastic cells were cultured with P1000:G10, P600:G5 or collagen sponge 
eluates (N=5/group) for 24 hours, and then cells were assayed for cell viability by 
performing an MTS assay.  MC3T3-E1 cell viability was similar between 
P1000:G10 and P600:G5 eluates; cell viability after 24 hours was found to be 70% 
and 80%, respectively (Figure 37). MC3T3-E1 cell viability was found to be 100% 
in control media and collagen sponge eluates, which were used as positive 
controls. These data suggest that both P1000:G10 and P600:G5 hydrogels are 
non-cytotoxic hydrogels, with cell viability equal or greater than 70% after 24 hours. 
4.2.4 The released PF-46 retains its efficacy to inhibit Pyk2 kinase activity. 
P1000:G10 hydrogels were chosen to use as a carrier for PF-46 due to their 
viscosity, acceptable gelation time, release behavior, and cytocompatibility. PF-46 
was reported to inhibit Pyk2 kinase activity with an IC50 value of 100 nM (Han et 
al. 2009). Since Pyk2 catalytic activity depends on its phosphorylation at key 
tyrosine residues (Bruzzaniti et al. 2009; Eleniste and Bruzzaniti 2012; Eleniste et 
al. 2012), we examined if the released PF-46 inhibited Pyk2 kinase activity by 
performing Pyk2 immunoprecipitation (IP) and tyrosine kinase activity assay. 
PF-46 loaded P1000:G10 hydrogels were prepared, sterilized, and then 
soaked in α-MEM with 10% FBS and 1% P/S at 37ºC for 24 hours. Next, the 
released PF-46 was collected and the concentration estimated based on the 
release of 7-amino-4-methylcoumarin loaded P1000:G10 hydrogels after 24 hours. 
Three days prior to conducting the kinase assay, 293VnR cells were transfected 
with Pyk2 cDNA. 293VnR cells were used in this assay because they do not 
express Pyk2 and reveal high efficiency in transfection (Bruzzaniti et al. 2009). 
Pyk2-transfected 293VnR cells were then treated for 2 hours with released PF-46 
at the estimated concentration of 0.1, 0.3, and 0.5 μM. Fresh PF-46 at 0.1 and 0.3 
μM were used as positive controls and non-treated was used as a negative control 
group. In addition, Pyk2-expressing 293VnR cells were IP with a Pyk2 antibody to 
confirm that all groups had the same level of Pyk2. After this, the tyrosine kinase 
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activity assay was performed following the manufacturer’s protocol (Takara Bio). 
(Figure 38A). As shown in Figure 38B, we found that all concentrations of the 
released PF-46 significantly inhibited Pyk2 kinase levels when compared to non-
treated group (p<0.05). The ability of released PF-46 to inhibit Pyk2 kinase activity 
was comparable to fresh PF-46. This suggests that PF-46 released from 
P1000:G10 hydrogels retains its efficacy against the kinase activity of Pyk2.  
4.2.5 The released PF-46 enhances ALP activity of stromal OBs. 
To examine the bioactivity of PF-46 released from P1000:G10 hydrogels, 
bone marrow derived MSCs were differentiated into mature OBs under osteogenic 
conditions for 7 days in the presence or absence of the released PF-46 at the 
estimated concentrations of 0.1, 0.3, and 0.5 μM, and then ALP activity was 
examined. We used untreated stromal OBs as the negative control group. For the 
additional control, we used PF-46 incubated at 37°C for 24 hours as an additional 
control because we found that there was not statistical significant between fresh 
PF-46 and the one that incubated for 24 hours. The concentrations of PF-46 
released from P1000:G10 were estimate values as described previously in section 
4.2.4. As shown in Figure 39, released PF-46 at 0.1 and 0.5 μM markedly 
enhanced ALP activity as compared to the negative control group and the non-
loaded P1000:G10 group (p<0.05). Furthermore, the ALP activity of OBs treated 
with released PF-46 at 0.1 and 0.5 μM was not statistically different from the 37°C-
incubated PF-46 group. These findings indicate that the bioactivity of PF-46 





An ideal biomolecule carrier should not induce inflammatory or immune 
reactions. Furthermore, it should be absorbed concomitantly with bone healing 
without toxic residues, but still providing a slow delivery of biomolecules. Carriers 
should also be simply and cost-effectively fabricated, easily sterilized, and should 
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be stable for storage (Peppas et al. 2000; Seeherman and Wozney 2005). In 
addition, carriers should remain at their initial placement site.  
We evaluated the viscosity, gelation time, swelling, degradation, and 
release behavior of several hydrogels and found a hydrogel composed of 
PEGDA1000 plus 10% gelatin exhibited viscosity and shear-thinning behavior 
suitable for use as an injectable-carrier. In addition, the P1000:G10 hydrogel was 
cytocompatible and PF-46 released from it retained its inhibitory activity against 
Pyk2, leading to an increase in OB activity. We found that P1000:G10 solution 
exhibited the most obvious shear-thinning behavior. Furthermore, the P1000:G10 
solution exhibited the highest viscosity when it reached the Newtonion fluid 
behavior. These characteristics of P1000:G10 solution make it suitable as a drug 
delivery carrier because its viscosity is reduced when stress is applied and is 
rapidly recovered upon removal of the stress; then it can form the drug release gel 
depot (Choi et al. 2015) The viscosity of P1000:G10 solution can be affected by 
both increasing gelatin weight and PEGDA molecular weight (Hoch et al. 2012). 
As we can see that P1000 exhibited higher viscosity than P600, and the greater 
amount of gelatin also enhanced the viscosity of prepolymer solution. In addition, 
P1000:G10 solution is a yield stress fluid, which indicates that the solution will 
remain stationary after injection, allowing it to be cured without the concern of a 
free-flowing solution. This has the potential to prevent undesirable leakage of 
solution into neighboring tissues or blood circulation. This is important for one of 
our future applications, bone fracture healing application, that want to deliver the 
solution to the open surgical site, and the solution will stay in place next to the 
regeneration site. 
As can be seen from our results, gelation times of our gels were increased 
when the molecular weight of PEGDA and the amount of gelatin were increased. 
This is true for both in situ photorheometry and probing techniques that we used 
to determine gelation time. However, the gelation times from in situ 
photorheometry were higher than the probing technique. The possible explanation 
may be from the probing technique examined only the surface of the gels, while 
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the oscillatory rheometry measured the entire gels. Another reason may be due to 
the difference in thickness of specimens in the two methods. 
The thickness of specimens in the oscillatory measurement was 90 μm, 
while we used thicker specimens (3 mm) in the probing technique because it was 
the thickness of specimens that we used for all experiments in our project, and 
heat could be generated in the thick specimens during the curing process which 
may have accelerated the polymerization. These may have shortened the gelation 
times in the probing technique when compared to the in situ rheometry. 
Interestingly, the gelation time of P1000:G10 could not be detected by the 
rheometry. In contrast, we did not encounter difficulty in determining the gelation 
time in P600:G5. Our results are consistent with Fu et al. (Fu et al. 2012) that both 
covalently and physically crosslinked PEGDA-10%gelatin hydrogels exhibited a 
significantly higher value of G’ than G” at both room temperature and 37 °C. The 
potential cause may be due to gelatin already in part forming a physical 
thermoreversible gel at room temperature, so that the rheometry could not detect 
the G” in P1000:G10. Using a temperature-adjusted rheometer may solve this 
problem. We also found that P1000:G10 showed a significantly lower swelling ratio 
than P600:G5. This suggests that higher PEGDA molecular weight exhibit lower 
water absorption and Qmax, and needs more time to reach Qmax, which is consistent 
with the previous publication (Fu et al. 2012). Additionally, we found that the higher 
amount of gelatin decreased the swelling ratio, which corresponds with published 
studies showing that when the gelatin concentration is more than 6%, the swelling 
degree of gels tends to decrease because of a significant increase in the network 
chains density. This can lead to decreases in water absorption and polymer 
relaxation, resulting in a decrease in the degree of hydrogel swelling (Liu and 
Ballada 2014).  
The degradation results reveal that P1000:G10 exhibited lower mass loss 
when compared to P600:G5. Our PEGDA-gelatin hydrogels consist of PEGDA 
chains with DTT to form (−PEG−DTT−) n PEG polymer chains, which are 
hydrolytically labile chains. Thus, the formed hydrogels can undergo hydrolytic 
degradation over time (Hudalla et al. 2008; Parlato et al. 2014). In addition, we 
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used gelatin, which is a natural polymer that is responsive to enzymatic 
degradation and can be degraded in vivo by several enzymes, such as 
collagenase and lysozyme (Bae et al. 2015; Hutson et al. 2011). This suggests 
that our PEGDA-gelatin hydrogels can be tailored to get desirable degradation time 
through the adjustment of the concentration of DTT and gelatin. 
Although we used the same gelatin and PEGDA polymers for the synthesis 
of both PEGDA-gelatin hydrogels, we found that P600:G5 exhibited inferior loading 
efficiency than P1000:G10. This suggests that molecular weight of PEGDA and 
gelatin concentration may play a role in loading efﬁciency. As we know, the 
swelling and degradation of hydrogels in drug delivery applications facilitates local 
delivery of drugs through temporally modulated drug release. The release profile 
of 7-amino-4-methylcoumarin from PEGDA-gelatin hydrogels showed an initial 
burst release similar to what we found in collagen sponges, but the amount of dye 
release from PEGDA-gelatin hydrogels were slower than collagen sponges. 
P1000:G10 tended to exhibit the slowest release behavior even though we could 
not find the statistical significance, which resulted from P1000:G10 showing the 
lowest degree of swelling and degradation. Using released 7-amino-4-
methylcoumarin we estimated the concentration of released PF-46. However, one 
limitation of this approach is that the detection of released 7-amino-4-
methylcoumarin may differ from the released Pyk2 inhibitor due to differences in 
molecular weight, structure, and solubility between these two molecules, 
Nevertheless, the fluorescent dye was a cost-effective and amenable approach to 
examine molecule release kinetics of the PEGDA-gelatin hydrogels.As described 
above, several of our experiments suggested that P1000:G10 may make an 
appropriate carrier for delivery of small-molecule inhibitor of Pyk2. Overall, we 
selected P1000:G10 due to its viscosity and gelation because the long-term 
application of this technology will be as a drug-delivery system to promote OB bone 
formation, which does not require high mechanical properties. In load bearing area, 
we need to combine this gel with the other solid scaffolds to enhance mechanical 
properities. To identify an appropriate Pyk2 inhibitor, we examined the efficacy of 
two commercially available small molecule inhibitors of Pyk2, PF-43 and PF-46. 
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We found that both PF-43 and PF-46 enhanced the proliferation of mouse MSCs 
(OB precursors) and ALP activity in mature OBs. However, when OBs were 
differentiated for 21 days under osteogenic conditions, only PF-46 increased 
calcium deposition compared to the control group. These observations were 
consistent with our findings that Pyk2-KO OBs exhibit higher proliferation, ALP 
activity and mineralizing activity than WT OBs (Chapter 3). Furthermore, our 
results are consistent with published studies showing that both PF-43 and PF-46 
can increase ALP activity of OBs, but only PF-46 enhances mineralization levels 
of OBs (Han et al. 2009). The possible reason for this is that PF-43 is a dual 
FAK/Pyk2 inhibitor, which is 20-fold more potent against FAK than Pyk2, whereas 
PF-46 is a Pyk2-targeted inhibitor with 100-fold more potent against Pyk2 than 
FAK. It has been reported that inhibition of FAK significantly reduces calcium 
deposition by human MSCs after 28 days of culture (Salasznyk et al. 2007). This 
suggests that FAK may play a role in the osteogenic mineralization process of 
OBs. Thus, the Pyk2-targeted inhibitor, PF-46, was used in subsequent in vitro 
experiments. Importantly, we found that the P1000:G10 hydrogel was 
cytocompatible. Importantly, the release PF-46 from P1000:G10 retained its 
efficacy against Pyk2 kinase activity and still effective in promoting ALP activity of 
OBs differentiated for 7 days. In addition, the ability to inhibit Pyk2 kinase activity 
and enhance OB activity was similar to the positive control, which was the PF-46 
group. These signify that the bioactivity of PF-46 was not obliterated during 
PEGDA-gelatin hydrogel preparation. 
 
4.4 Summary and conclusions 
 
In summary, our results indicate that PF-46, a Pyk2-targeted inhibitor, 
enhances OB activity in vitro. Furthermore, P1000:G10 is appropriate to use as a 
carrier for PF-46 based on several physical characteristics as follows: 1) 
P1000:G10 prepolymer solutions exhibit a shear-thinning effect, 2) P1000:G10 
prepolymer solutions exhibit high viscosity which can prevent undesirable leakage 
of the solution into neighboring tissues or blood circulation, 3) P1000:G10 can form 
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gel in situ by photopolymerization with a reasonable gelation time; allowing for 
sufficient handling time prior to light curing, 4) The P1000:G10 hydrogel is 
biodegradable and can be degraded by both hydrolytic and enzymatic degradation, 
5) P1000:G10 is cytocompatible and exhibited the slowest drug-release behavior. 
Notably, the PF-46 released from P1000:G10 retained its inhibitory activity against 
Pyk2 kinase activity and enhanced ALP activity in OBs in vitro. The schema 
presentation of Pyk2-inhibitor loaded hydrogel preparation and utilization is shown 
in Figure 40. All of these findings strongly support the use of PEGDA-gelatin 











The mechanisms that control bone mass and bone formation are not 
completely understood. Low bone mass diseases such as osteoporosis and 
periodontitis result from an imbalance in the bone resorption and bone formation 
processes. Therapeutic approaches have been developed to improve these low 
bone mass conditions in both systemic and local levels, but they still have some 
disadvantages. Therefore, a need for suitable approaches including biomolecules 
and biomaterials for both systemic and local levels still remains. The overall goals 
of this dissertation were to better understand the cellular mechanism of bone 
formation by OBs, and to develop novel therapies to increase bone mass.  
Pyk2 is important for OB activity as well as OC activity (Buckbinder et al. 
2007; Gil-Henn et al. 2007). While female Pyk2-KO mice exhibit increased BV/TV, 
unpublished studies from Dr. Bruzzaniti reveal that male Pyk2-KO mice exhibit a 
bone phenotype similar to WT mice. In addition, our unpublished studies indicate 
that E2 supplementation of OVX female Pyk2-KO mice resulted in a greater 
increase in BV/TV in Pyk2-KO OVX mice than in WT OVX mice. This suggests that 
Pyk2-KO mice may regulate OB activity and bone formation in part through 
estrogen signaling pathway.  
In chapter 3 of this dissertation, we examined whether Pyk2 regulate bone 
mass in part by modulating the estrogen signaling in OBs. This is the first study to 
examine the role of Pyk2 and E2 in OB activity. A number of earlier studies 
examined only the role of Pyk2 in OB and OC activities (Buckbinder et al. 2007; 
Cheng et al. 2013; Eleniste et al. 2015; Gil-Henn et al. 2007; Kacena et al. 2012). 
Our results revealed that Pyk2-KO OBs showed significant increases in 
proliferation (cell number and metabolic activity), matrix formation and maturation, 
and mineralization. The addition of E2 or raloxifene led to a further increase in both 
matrix formation and maturation, and mineralization in Pyk2-KO OBs, but not in 
WT OBs. Consistent with a role of Pyk2 in OB activity, we found a decrease in ERα 
protein levels in Pyk2-KO OBs due to the degradation of cytosolic ERα via the 
ubiquitin proteasome pathway. These findings are consistent with published 
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reports that ERα can undergo proteasome mediated degradation (Chai et al. 2015; 
Lu et al. 2010; Petrel and Brueggemeier 2003; Zhou and Slingerland 2014). 
Although several reports indicate that ERβ can also be degraded by this 
mechanism (Sanchez et al. 2013; Tateishi et al. 2006), we found that ERβ protein 
levels in Pyk2-KO OBs were similar to WT OBs, suggesting the ERa and ERβ are 
differentially regulated in OBs. In addition to the proteasome-mediated 
degradation, ERα degradation can occur through a lysosome-dependent pathway. 
(Cooper 2000; Zhou and Slingerland 2014). A recent publication reported that 
chloroquine, a lysosomal inhibitor, abrogated the estrogen-dependent ERα 
breakdown in MCF-7 cells (Totta et al. 2014). Whether ERα is also degraded by 
lysosomes in Pyk2-KO OBs remains to be determined. 
We also determined the role of Pyk2 and Pyk2-S isoforms and found they 
exhibit differential expression during OB differentiation.  We also found Pyk2 and 
Pyk2-S are both negative regulators of OB activity, suggesting they may affect 
OBs at different stage of differentiation; Pyk2 may be active in early OBs, while 
Pyk2-S may inhibit OB activity in the mature OBs. 
The results described in Chapter 3 strongly suggest that Pyk2 regulates OB 
activity and bone formation in part by modulating the estrogen signaling pathway. 
There are still many unanswered questions regarding the role of Pyk2 and 
estrogen in OB activity. For example, it will be interesting to determine if ERα 
degradation plays a role directly in OB differentiation and mineralization in the 
absence of Pyk2 or it is just a physiological coincidence. In addition, whether ERβ, 
plays a direct role in the regulation of OB activity in the absence of Pyk2 remains 
to be determined. Pyk2-KO OBs may also respond to E2 mechanisms other than 
ERα and/or ERβ, such as through the N-terminal truncated ERα isoform or ERRα. 
In addition, the role of Pyk2 in the regulation of the androgen receptor should not 
be overlooked especially in light of a recent publication which reported that Pyk2 
promoted the expression and phosphorylation of the androgen receptor (Hsiao et 
al. 2016).  
Pyk2-KO mice exhibit an osteopetrotic phenotype mostly from increasing 
cancellous bone volume. In this study, we found that Pyk2-KO OBs exhibited a 
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decrease in ERα protein levels compared to WT OBs. These in vitro findings 
correspond with what has been reported for the phenotype of global ERα-KO mice, 
which also exhibit high bone mass (Lindberg et al. 2001; Sims et al. 2002; Windahl 
et al. 1999). However, our findings are different from the phenotypes reported for 
bone-cell specific ERα-KO mice models. Controversy in the bone phenotypes of 
the bone-specific ERα-KO mice still exists due to the use of different Cre mice 
models, which affect different stages of OB differentiation. Almeida et al. (Almeida 
et al. 2013) found that cortical bone, not cancellous bone, was reduced in female 
mice when deleting ERα in MSCs (ERαf/f; Prx‐Cre) or OB progenitors (ERαf/f; Osx‐
Cre). However, this bone loss disappeared in female mice in which ERα deletion 
was driven by the Cola1-promoter (ERαf/f; Col1a1‐Cre). On the contrary, recent 
studies have reported that both cortical and cancellous bone volumes are 
decreased in the young female OB-specific deletion of ERα mice (ERαΔOB/ΔOB; 
OCN‐Cre) (Maatta et al. 2013; Melville et al. 2014). However, this phenotype 
disappeared when the age of mice was increased (Maatta et al. 2013). The bone 
phenotype of OB-specific ERα-KO mice suggests that deletion of ERα in OBs 
leads to a decrease in OB activity at least in young females. This conclusion 
contrasts with our results showing Pyk2-KO OBs which exhibit ERα protein 
degradation, exhibit a significant increase in OB activity, including proliferation, 
matrix maturation, and mineralization. Therefore, it is possible that decreased 
expression of ERα is unlikely to be the only mechanism involved in the regulation 
of OB activity in the absence of Pyk2.  
In the current studies, we focused the role of Pyk2 and E2 in OB activity. 
However, Pyk2 is also expressed in OCs and Pyk2-deletion leads to OC 
impairment and reduced bone resorption (Bruzzaniti et al. 2009; Gil-Henn et al. 
2007). In addition, it has been well established that estrogen promotes OC 
apoptosis (Hughes and Boyce 1997). Thus, it will be necessary to examine the 
combined effect of Pyk2 and estrogen on OC activity. To this end, we speculate 
that estrogen will enhance the effect of Pyk2-deletion on OCs as we found in OBs. 
Furthermore, the systemic effects such as the effect of hepatic IGF-1 which is 
known to stimulate OB formation (Imai et al. 2010; Sims et al. 2000) should be 
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evaluated in Pyk2-KO mice because it is known that estradiol can enhance the 
expression of IGF-1 and consequently promote bone formation (Bord et al. 2001). 
Thus, the high bone mass phenotype in Pyk2-KO mice with estradiol 
supplementation may also occur through this pathway.  
In chapter 4 of this dissertation, we developed a Pyk2-inihbitor loaded 
hydrogel for future bone regeneration applications. We used bone marrow derived 
MSCs because they more closely approximate the bone microenvironment in 
which the hydrogel will be used in future studies. We found that PF-46, a Pyk2-
selective inhibitor, enhanced OB proliferation, ALP activity, and mineral deposition 
in vitro. Importantly, our results support the hypothesis that our proposed drug 
carrier, P1000:G10, was cytocompatible and exhibited shear-thinning behavior, 
high viscosity and yield stress which would be favorable for a drug injectable carrier 
(Choi et al. 2015; Hoch et al. 2012). P1000:G10 also exhibited the slowest drug 
release behavior. Importantly, the released PF-46 retained its inhibitory activity 
against Pyk2 kinase activity and enhanced ALP activity in OBs in vitro.  
To the best of our knowledge, this is the first study to develop a Pyk2-
inihbitor loaded hydrogel for bone formation, and our in vitro results are promising 
and strongly support the therapeutic application of using a PEGDA-gelatin 
hydrogel incorporated with a Pyk2-selective inhibitor for bone regeneration in vivo. 
However, there are a number of limitations in our in vitro experiments that should 
not be overlooked. First, we used 7-amino-4-methylcoumarin, a fluorescent dye, 
as a representative of PF-46 because it is a small molecule that has the molecular 
weight quite close to PF-46 and the detection of this fluorescent dye can be 
performed by simple spectrophotometry.  However, the release profile of the 7-
amino-4-methylcoumarin may be different from the release profile of PF-46 due to 
the difference in molecular weight, structure, and solubility. Nevertheless, this still 
provides an approximation of the release behavior of PEGDA-gelatin hydrogels. 
Moreover, the released profile of 7-amino-4-methylcoumarin was a cost-effective 
method that can be useful for other carriers or scaffolds. However, it should be 
noted that there are the other methods that can be used to detect the release of 
PF-46 such as mass spectrometry or high performance liquid chromatography, 
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which require longer time to prepare and analyze. In future studies, we will 
examine the release profile of PF-46 using these techniques to obtain a more 
accurate release profile of PF-46 from PEGDA-gelatin hydrogels. Second, the 
gelation time of P1000:G10 could not be detected by the in situ photorheometry, 
which may be due to gelatin already forming physical gel at room temperature, so 
that the rheometry could not detect a crossover point of G” and G” in P1000:G10 
at room temperature. This problem may be solved using the temperature-adjusted 
rheometer. However, the temperature should be above 37°C because a study 
found that both covalently and physically crosslinked PEGDA-10%gelatin 
hydrogels exhibit a significantly higher value of G’ than G” at both room 
temperature and 37°C (Fu et al. 2012).  
Furthermore, the release behavior of our PEGDA-gelatin hydrogels need to  
be improved, so that it will provide a more sustained released than collagen 
sponges, which will allow for the lower dosages of drugs or biomolecules 
(Fassbender et al. 2014). Therefore, Pyk2-inhibitor loaded hydrogel could be more 
efficient for promoting bone formation and regeneration. Theoretically, the initial 
release of biomolecules during first 3-7 days should be approximately 60% to 
initiate bone healing and then the remaining 30% bound biomolecules should show 
sustained release for 3-4 weeks to maintain an osteoinductive effect (Woo et al. 
2001). The controlled and sustained release kinetics can be modified by various 
methods such as fabricating covalently PEGDA-gelatin hydrogels modification with 
cysteine (Fu et al. 2012) or incorporating methacrylate to retard drug release rate 
(Sutter et al. 2007). 
In addition to bone marrow derived MSCs, future studies elucidate the 
efficacy of Pyk2-inhibitor loaded hydrogel in calvarial OBs will be useful in order to 
expand the therapeutic applications to the craniofacial skeleton, for example, for 
use in cranial defect regeneration or palatal suture expansion.  
Given that deletion of Pyk2 increases OB activity and decreases OC 
resorption, Pyk2 inhibitors may have both anabolic and antiresorptive properties.  
However, to date, published studies have focused only on the anabolic effects of 
the Pyk2 inhibitors. Since OCs activity is decreased in the absence of Pyk2, 
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leading to a decrease in bone resorption, a possible concern regarding the use of 
a Pyk2-inihbitor based strategy for bone regeneration, especially in long bones, is 
whether the Pyk2 inhibitor will affect callus remodeling. Evidence shows that when 
antiresorptive agents such as bisphosphonates or Denosumab, which can impair 
OC activity, are used to enhance bone fracture healing, the quality and quantity of 
bone fracture repair is improved, although a delay in the time of bone healing may 
occur (Hegde et al. 2016). Another advantage of a hydrogel-based carrier is that 
the carrier and/or scaffold design can be tailored for timed release during the 
reparative phase of bone healing and be degraded prior to the remodeling phase, 
allowing for OC activity to proceed normally once the carrier and/or scaffold is 
degraded. 
As we found an additive effect of estrogen on bone formation in the absence 
of Pyk2, we speculate that our Pyk2-inihbitor loaded carriers may provide more 
pronounced bone healing results in females than males. Furthermore, 
incorporating estrogen or raloxifene into a Pyk2-inihbitor based carriers may 
potentially promote bone healing in post-menopausal women. Based on our 
findings and other studies, Pyk2-inhibitor strategies may be useful for the treatment 
of post-menopausal osteoporosis. To date, estrogen replacement and raloxifene 
therapy still remain as effective treatments to protect and treat post-menopausal 
osteoporosis, but concerns exist regarding the non-skeletal risks related to long-
term estrogen treatment, including the risk of uterine cancer, breast cancer and 
cardiovascular disease (Rosen 2005). One strategy to potentially reduce these 
risks is through the dual combination of estrogen or raloxifene with a Pyk2 inhibitor. 
This dual-combination drug approach could potentially reduce the dosage of 
estrogen or raloxifene and Pyk2 inhibitor being used, which may consequently 




Taken together, our results indicate that Pyk2 is integrated into the estrogen 
and ERα/ERβ signaling cascade, and negatively regulates OB activity by 
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controlling the levels of ERα and phospho-ERK. Additionally, PF-46, a Pyk2-
selective inhibitor, incorporated into P1000:G10 is cytocompatible and retains its 
ability to inhibit Pyk2, leading to an increase in OB differentiation in vitro. These 
findings strongly support that the inhibition of Pyk2 locally with PEGDA-gelatin 
hydrogel delivery may be a therapeutic tool for bone regeneration at sites of 
appendicular and/or craniofacial bone pathology. The schema presentation of the 
summary of key findings in this dissertation is shown in Figure 41. In the future, we 
will use the Pyk2 inhibitor incorporated into PEGDA-gelatin hydrogel for proof-of-
concept bone healing application using a non-critical bone defect in a rat model 
system.  Overall, our Pyk2-based strategy may be useful in the bone regeneration 
field, and may be valuable as a therapeutic treatment for those suffering from 
systemic bone loss, such as osteoporosis. Thus, targeting Pyk2 may be a novel 
strategy for bone regeneration at the local and systemic levels.  
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Table 1. Experimental design for cell studies described in Chapter 3 
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Table 2. Oligonucleotide primers used for QPCR and RT-PCR 































































Table 3. Experimental design for cell studies described in Chapter 4 











in 96-well plate 
0.0125, 0,025, 0.05, 
0.1 and 0.3 μM of 














in 12-well plate 
Osteogenic media 
comtaining 0.0125, 
0,025, 0.05, 0.1 and 






31 Calvarial OBs 4×104 cells/well 
in 12-well plate 
Osteogenic media 
comtaining 0.0125, 






37 MC3T3-E1 2×103 cells/well 







38 293 VnR 
cells 
1×106 cells/dish 
in 10 cm2-dish 
0.1 and 0.3 μM of 
released PF-46 
2 hours In vitro kinase 
activity 







in 12-well plate 
0.1 and 0.3 μM of 
released PF-46 


















Figure 1. Schema for osteoblastogenesis. 	
Osteoprogenitor cells differentiate from MSCs, and then differentiate into pre-OBs 
and then into mature OBs.  OB maturation is associated with an increase in 
collagen type I, ALP, BSP, OPN, and OCN expression. At the end of differentiation, 
mature OBs enter apoptosis or further differentiate into either osteocytes or bone 
lining cells.   
Mature OB 
	 	
Osteoprogenitor cell Pre-OB 
Osteocyte 
MSC 
Bone lining cell 
	 	
Collagen type I, BSP, OPN, 
ALP, and OCN 




















Figure 2. Gene expression during OB proliferation and differentiation. 	
OB proliferation is associated with cell-cycle progression and the induction of key 
transcription factors such as c-fos. The maturation of OBs requires the ECM-
related proteins including ALP and collagen type 1. The induction of OCN, OPN 
and other genes is required for the mineralization of the ECM. (Adapted from Stein 




Figure 3. Interplay of bone cells in the basic multicellular unit. 	
Bone remodeling process is carried out by the coupling between bone resorption 
and bone formation within BMUs. The BMU is located on bone surface and 
covered by a bone remodeling compartment (BRC). In the BRC, intercellular 
communication occurs among bone cells, endothelial and vascular cells. OCs are 
derived from the hematopoietic lineage, while OBs are originated from MSCs in 
the marrow cavity. The cytokines MCSF, RANKL, and OPG necessary for OC 
formation and are produced by OBs and osteocytes. Osteocytes also secrete 










Figure 4. Chemical structures of 17β-estradiol and raloxifene. 
17β-estradiol has a cyclophenanthrene structure, whereas raloxifene has a 
benzothiophene structure. Even though the raloxifene structure differs from 
estrogen, both have a conformation that allows them to bind to the ligand-binding 
domain of the ER (Riggs and Hartmann 2003). Unlike 17β-Estradiol that has 
similar binding affinity to both ERs, raloxifene has a preferential binding affinity to 





















Figure 5. Schema of the mechanisms of estrogen response. 
Estrogen actions are mediated by genomic and non-genomic pathways. The 
genomic pathway of estrogen (E2) occurs through its binding to nuclear estrogen 
receptors (ERs) either by direct interaction between E2-ER with the estrogen 
response element (ERE) in transcription promoter regions or by indirect binding of 
E2- ER to ERE via other transcription factors. In contrast, the non-genomic actions 
of E2 occur via the interaction of E2 with ERs present at the cell membrane or in 














Figure 6. ERα and ERβ protein structure and functional domains.  
ERα and ERβ shared a conserved domain structure. The N terminal A/B domain 
contains activation function sites 1 (AF-1). The C region consists of the DNA-
binding domain (DBD). The D domain, hinge region, contributes to the specificity 
of DNA binding and nuclear localization of ERs. The E domain is the ligand binding 
domain (LBD), and AF-2 is also in this domain. The F domain is at the C terminal. 
The percentage in the figure demonstrates the structural homology of each domain 
between ERα and ERβ; these are similar in mouse, rat, and human (Adapted from 

















Figure 7. The structures of Pyk2 isoforms and their expression during OB 
differentiation.   
(A) Pyk2 has two isoforms, the full-length Pyk2 (118 KDa) and Pyk2-S (106 KDa), 
which lacks 42 amino acids compared to the full-length Pyk2. Pyk2 and Pyk2-S 
can be autophosphorylated at tyrosine residue Y402, which is important for kinase 
activity and downstream signaling. (B) RT-PCR of OB differentiated for 3-21 days, 
OBs express full-length Pyk2 (370-bp PCR product) and Pyk2-S (250-bp PCR 
product). The ratio of Pyk2 to Pyk2-S decreases during OB differentiation with 





















Figure 8. μ-CT analyses of long bones in female and male mice. 
(A) Representative images of μ-CT at the distal femur of 32-week-old male and 
female WT and Pyk2-KO mice showing an increase in trabecular BMD in Pyk2-KO 
female mice compared to WT female mice, but not in male mice. (B) BV/TV% of 
female Pyk2-KO mice (20.98 ± 2.68) was significantly higher than female WT mice 
(3.28 ± 0.46%), whereas no difference between the male WT and Pyk2-KO mice 

























Figure 9. Effect of 17β-estradiol supplementation on bone volume in Pyk2-
KO mice. 
(A) Representative images of μ-CT analysis of femoral trabecular bone of OVX 
mice with or without OVX and 17β-estradiol (E2) supplementation (167 ng/day) at 
4 weeks post-operatively. OVX Pyk2-KO + E2 exhibited the highest increased 
BV/TV% among groups. (B) The relative change in BV/TV% of OVX Pyk2-KO + 
E2 (#) relative to OVX ($) was significantly higher than the change in BV/TV% of 








Figure 10. Chemical structures of the Pyk2 inhibitors. 
(A) PF-431396 (C22H21F3N6O3S · xH2O) is a dual FAK/Pyk2 inhibitor with IC50 
values of 1.5 nM of FAK and 11-32 nM of Pyk2. (B) PF-4618433 (C24H27N7O2) is 
a Pyk2-targeted inhibitor that has IC50 values of 100 nM for Pyk2 and 10,000 nM 
















Figure 11. Chemical structures of PEG, PEGDA, and PEGDM.  
PEG diacrylate (PEGDA) or PEG dimethacrylate (PEGDM) are PEG-based 
macromers with reactive termini that highly used in hydrogel fabrication due to the 
controllable material properties and the simplicity of synthesis. (Adapted from Lin 
and Anseth 2009).  
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Figure 12. Pyk2 and Pyk2-S expression constructs.  
(A) Schematic representation of the plasmid vector for Pyk2/Pyk2-S expression 
constructs is shown. The vector was tagged with histidine (His) and V5. (B) The 
domain structures of Pyk2/Pyk2-S are shown. Pyk2-S lacks 42 amino acids 
compared to the full-length Pyk2 as indicated.   
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Figure 13. Effect of media and FBS concentration on OB number. 
(A and B) An equal number of WT and Pyk2-KO OBs were cultured in α-MEM or 
phenol red free α-MEM plus 10% FBS, or (C and D) in α-MEM or phenol red free 
α-MEM plus 2% FBS. Cells were cultured for 4 days and then cell numbers 
excluding Trypan blue were counted (N=6/group). The data are shown as mean 
and SEM of six samples. Asterisks (*) indicate statistical significance between WT 


















Figure 14. Effect of Pyk2-deletion and estrogen on OB proliferation and 
number.  
(A). Calvarial WT and Pyk2-KO OBs were cultured for 1 or 4 days in the presence 
or absence of 100 nM E2. At days 1 and 4, cells from each group were trypsinized 
and counted under a microscope using a hemacytometer. (B) Calvarial WT and 
Pyk2-KO OBs were cultured for 24 hours then treated with or without 100 nM E2 
for 12 hours, and an MTS assay was performed for 0 to 6 hours. The data shown 
as mean and SEM of triplicate samples. Experiments were performed a minimum 
of three times and representative data are shown. Asterisks (*) indicate statistical 
significance between WT and Pyk2-KO, WT and Pyk2-KO with E2, and WT with 
E2 and Pyk2-KO for the proliferation activity (p<0.05). For cell number, statistical 
significant differences were found between WT and Pyk2-KO, WT and WT with 
E2, and WT with E2 and Pyk2-KO (p<0.05).   
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Figure 15. Effect of Pyk2-deletion and estrogen on markers of OB activity.  
WT and Pyk2-KO calvarial OBs were cultured for 4-28 days with or without 100 
nM E2 supplementation, and QPCR analysis was used to determine mRNA 
expression of osteoblastic genes. On day 4, (A) c-fos, (B) collagen type I, (C) ALP, 
and (D) OCN mRNA expression levels were evaluated. In addition, (E) ALP, and 
(F) OCN mRNA levels on day 28 were examined. 18S was used as the 
housekeeping control to normalize the amount of the mRNA transcript under 
investigation. The data are shown as mean and SEM of triplicate samples. 
Experiments were performed a minimum of three times and representative data 
are shown. Asterisks (*) indicate statistically significant difference (p<0.05) 
between WT and Pyk2-KO OBs, whereas pound signs (#) indicate statistical 
significance of estrogen supplementation ((p<0.05).   
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Figure 16. Effect of Pyk2-deletion and estrogen supplementation on ALP 
activity during OB differentiation.  
WT and Pyk2-KO calvarial OBs were cultured for 4-28 days under osteogenic 
conditions containing ascorbic acid and β-GP with or without 100 nM E2 
supplementation. (A) Results of quantitative ALP activity assay on day 4, (B) and 
days 14 to 28 are shown. Asterisks (*) indicate statistically significant difference 
(p<0.05) between WT and Pyk2-KO OBs, whereas pound signs (#) indicate 













Figure 17. Mineralization of WT and Pyk2-KO OBs in the presence or absence 
of E2.  
WT and Pyk2-KO calvarial OBs were cultured for 14-28 days under osteogenic 
conditions containing ascorbic acid and β-GP with or without 100 nM E2 
supplementation. Results of quantitative Alizarin Red S staining are shown. 
Asterisks (*) indicate a statistically significant difference (p<0.05) between WT and 
Pyk2-KO OBs, whereas pound signs (#) indicate statistical significance of estrogen 
supplementation ((p<0.05).  
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Figure 18. The effect of raloxifene on ALP activity and mineralization in WT 
and Pyk2-KO OBs.  
WT and Pyk2-KO calvarial OBs were cultured for 28 days under osteogenic 
conditions containing ascorbic acid and β-GP with or without 0.1 nM, 1 nM and 10 
nM raloxifene. (A) Results of quantitative ALP activity assay, (B) and quantitative 
Alizarin Red S staining are shown. The data are shown as mean and SEM of 
triplicate samples. Experiments were performed three times and representative 
data are shown. Asterisks (*) indicate statistical significance (p<0.05) between WT 
and Pyk2-KO OBs, whereas pound signs (#) and dollar signs ($) indicate statistical 
significance of raloxifene supplementation ((p<0.05) in Pyk2-KO and WT OBs, 
respectively.   
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Figure 19. ERα and ERβ mRNA levels in WT and Pyk2-KO OBs in the 
presence or absence of E2.  
WT and Pyk2-KO calvarial OBs were cultured for 4 (A and B) and 28 (C and D) 
days with or without 100 nM E2 supplementation. ERα and ERβ mRNA 
expressions were determined using QPCR analysis. 18S was used as the control 
to normalize the amount of the mRNA transcript under investigation. The data are 
shown as mean and SEM of triplicate samples.   
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Figure 20. ERα and ERβ protein levels in WT and Pyk2-KO OBs in the 
presence or absence of E2. 
WT and Pyk2-KO calvarial OBs were cultured for 4 (A and B) and 28 (C and D) 
days with or without 100 nM E2 supplementation. Western blotting was performed 
to determine ERα and ERβ protein expressions. Cells were lysed with mRIPA 
buffer, and then sonicated. The ratio of ERα or ERβ to β-actin was determined by 
densitometry using ImageJ software. Experiments were performed 4 times in a 4-
day experiment and twice in a 28-day experiment and representative data are 
shown.  
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Figure 21. Effect of MG-132 on the subcellular distribution of ERα.  
WT and Pyk2-KO calvarial OBs were cultured for 4 days, then a proteasome 
inhibitor, MG-132 (20 μM), was added for the final 3 hours of culture. Cells were 
lysed with mRIPA buffer and the soluble fraction was separated from the insoluble 
pellet fraction. Forty μg of soluble proteins and 20 μg of proteins from the pellet 
fraction were resolved by SDS-PAGE. Western blotting and densitometry was 
performed to determine the ratio of ERα/β-actin in WT and Pyk2-KO OBs in the 
presence or absence of MG-132. Experiments were performed twice and 


















Figure 22. The effect of the activation of ERα and ERβ on OB mineralization.  
WT and Pyk2-KO calvarial OBs were cultured under osteogenic conditions for 21 
days. An ERα-specific agonist (PPT; 0.04, 0.1, and 0.4 μM) or an ERβ-specific 
agonist (DPN; 0.1, and 0.4 μM) was added for the whole culture time. The effects 
of (A) PPT and (B) DPN on mineralization levels are shown. Experiments were 
performed twice, in triplicate, and representative data are shown. Asterisks (*) 
indicate statistical significance (p<0.05) between WT and Pyk2-KO OBs, whereas 
pound signs (#) indicate statistical significance of PPT or DPN supplementation 
((p<0.05).   
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Figure 23. The effect of Pyk2-deletion and E2 on ERK and AKT 
phosphorylation in undifferentiated OBs.  
WT and Pyk2-KO calvarial OBs were cultured for 4 days with or without 100 nM 
E2 supplementation, and then cell pellets were lysed with mRIPA buffer. Western 
blotting was performed to determine pERK, ERK, pAKT, AKT, and actin protein 
levels. The ratio of p-ERK/ERK, ERK/actin, pAKT/AKT, and AKT/actin are shown. 
Experiments were performed twice and representative data are shown. An 
additional band approximating the molecular weight of p-p38 and p38 was also 
detected with the p-ERK antibody, although the identify of this protein remains to 





















Figure 24. The effect of Pyk2-deletion and E2 on ERK phosphorylation in 
differentiated OBs for 21 days.  
WT and Pyk2-KO calvarial OBs were cultured under osteogenic conditions for 21 
days with or without 100 nM E2 supplementation, and then cell pellets were lysed 
with mRIPA buffer. Western blotting was performed to determine pERK, ERK, and 
actin protein levels. The ratio of p-ERK/ERK and ERK/actin are shown. 


















Figure 25. Pyk2 and Pyk2-S expression in primary OBs and MC3T3-E1 cells.  
(A) Schema of Pyk2 and Pyk2-S isoforms. (B) Calvarial OBs and MC3T3-E1 cells 
were cultured for 0-7 days. Ethidium bromide-stained gel shows the expression of 
Pyk2 and Pyk2-S mRNA expressions in calvarial OBs and MC3T3-E1 by RT-PCR. 
β-actin was used as the housekeeping control. Molecular weight standards are 
shown.   
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Figure 26. The effect of Pyk2 and Pyk2-S on OB proliferation, differentiation, 
and mineralization.  
MC3T3-E1 cells were transiently transfected with expression constructs for Pyk2 
or Pyk2-S. (A) Equivalent expression of Pyk2 and Pyk2-S proteins in MCT3-E1 
cells was confirmed by Western blotting. (B) Results of MTS assay after 2 days of 
transfection, (C) Quantitative ALP activity assay of MCT3-E1 cells expressing Pyk2 
or Pyk2-S cultured for 3 days in osteogenic media. (D) Alizarin Red S staining to 
determine quantitative mineralization after 3 days are shown. Experiments were 
performed three times and representative data are shown. Asterisks (*) indicate 



















Figure 27. Expression of phospho-Y402 and Pyk2 isoforms in 
undifferentiated and differentiated OBs treated with E2 for 6 hours. 
WT calvarial OBs were cultured under osteogenic conditions for 0 or 14 days and 
100 nM E2 was added for the final 6 hours of culture. Western blotting was 
performed for Pyk2-Y402 phosphorylation (p-Y402) and total Pyk2. β-actin was 
used to normalize for protein loading. Densitometry was performed using ImageJ 
software and used to calculate the ratio of p-Y402/Pyk2, p-Y402/Pyk2-S, 
Pyk2/Actin, and Pyk2-S/Actin. Studies were replicated twice and representative 
data are shown. The two molecular weight isoforms of Pyk2 are indicated.  
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Figure 28. Expression of phospho-Y402 and Pyk2 isoforms in 
undifferentiated and differentiated OBs treated with E2 for 4 and 28 days.  
(A) WT calvarial OBs were cultured in the presence or absence 100 nM E2 for 4 
days. (B) WT calvarial OBs were differentiated in osteogenic media with or without 
100 nM E2 for 28 days. Western blotting was performed for Pyk2-Y402 
phosphorylation (p-Y402), total Pyk2 and β-actin. Densitometry was performed 
using ImageJ software and used to calculate the ratio of p-Y402/Pyk2, p-
Y402/Pyk2-S, Pyk2/Actin, and Pyk2-S/Actin. Studies were replicated twice and 
representative data are shown. MC3T3-E1 cells expressing Pyk2 or Pyk2-S  were 
used as a positive control for Western blotting.  
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Figure 29. Working model for the mechanism of action of Pyk2 and E2 in 
OBs. 
Pyk2 protects ERα protein degradation by the ubiquitin-proteasome pathway. In 
addition, Pyk2 inhibits ERK phosphorylation which consequently suppresses OB 
proliferation and differentiation. Pyk2 integrates to E2-ERα/ERβ signaling cascade 
via ERK pathway. Overall, our findings suggest Pyk2 negatively affects E2, ERα 
and ERK signaling in OBs. Thus, Pyk2 deletion combined with E2 stimulation has 
a positive effect on matrix formation and mineralization of OBs, resulting in a 
further increase in bone mass. Pyk2 and Pyk2-S (not shown) may exert unique 





























Figure 30. The efficacy of Pyk2 inhibitors, PF-43 and PF-46, on the activity of 
bone marrow derived MSCs. 
(A) MSCs were treated with a dual FAK/Pyk2 inhibitor (PF-43) or a Pyk2-targeted 
inhibitor (PF-46) at 0.1 and 0.3 μM for 24 hours, and then proliferation activity was 
determined using the MTS assay. (B; C) MSCs were differentiated into mature 
OBs under osteogenic conditions for 7 or 21 days in the presence or absence of 
PF-43 or PF-46, and the ALP activity and mineralization assays were performed, 
respectively. The data are shown as mean and SEM of triplicate samples. 
Experiments were performed a minimum of three times and representative data 























Figure 31. The efficacy of Pyk2 inhibitor, PF-46, on calvarial OB activity. 
Calvarial OBs were differentiated under osteogenic conditions for 7 or 21 days in 
the presence or absence of a Pyk2-targeted inhibitor, PF-46, at 0.0125 and 0.05 
μM. (A) The quantitative ALP activity assay and (B) the mineralization assay were 
performed. The data are shown as mean and SEM of triplicate samples. 
Experiments were performed three times and representative data are shown. 



























Figure 32. The dynamic viscosity of PEGDA and PEGDA-gelatin hydrogels.  
The dynamic viscosity of P600, P600:G5, P1000, and P1000:G10 prepolymer 
solutions was measured using a digital rheometer (viscometry mode) at room 
temperature. The plots of (A) viscosity vs. shear rate, and (B) shear stress vs. 


































Figure 33. The gelation times of PEGDA and PEGDA-gelatin hydrogels.  
(A) P600, P600:G5, P1000, and P1000:G10 prepolymer solutions were prepared 
and pipetted into a disk-shaped mold of 5 mm in diameter and 3 mm in thickness 
and exposed under visible light at room temperature. Gelation times were 
determined using a periodontal probe to verify the hardened material surfaces. The 
data are shown as mean and SEM of five samples (N=5). Asterisks (*) indicate 
statistical significant differences between different molecular weights of PEGDA, 
while the pound sign (#) shows significance for the effect of gelatin (p<0.05). (B to 
E) The in situ photorheometry was performed in four groups of prepolymer 
solutions using a digital rheometer with a light cure attachment at room 
temperature. Gelation times were defined as the time when storage modulus (G′) 
crossover loss modulus (G″), and the plots of log G’ and G” moduli vs. time of a 























Figure 34. The swelling ratio and degradation of PEGDA-gelatin hydrogels.  
(A) P600:G5 and P1000:G10 gels were prepared and dried under the vacuum for 
48 hours before soaking gels in PBS at 37°C and weight measuring up to 25 days. 
(B) The degradation of P600:G5 and P1000:G10 gels were also evaluated using 
the same method as the swelling experiment. The data are shown as mean and 
SEM of five samples (N=5). Experiments were performed twice and representative 















Figure 35. The loading efficiency of 7-amino-4-methylcoumarin in hydrogels. 
7-amino-4-methylcoumarin was used as a representative of PF-46 and loaded into 
P600:G5 or P1000:G10 prepolymer solution before photopolymerization, or were 
dripped on collagen sponge (control) (N=5). Samples were then incubated in PBS 
at 37°C for 24 hours, and then were completely disrupted using a sonicator. The 
































Figure 36. The release profiles of 7-amino-4-methylcoumarin loaded PEGDA-
gelatin hydrogels.  
7-amino-4-methylcoumarin was used as a representative of PF-46 and loaded into 
P600:G5, P1000:G10, or collagen sponge (control) (N=5). Carriers were then 
incubated in PBS at 37°C, and eluted dye was collected every 30 minutes up to 4 
hours and at days 1, 2, 3, 5, 10, 15, 20, and 25. (A) The cumulative amount of dye 
released from carriers is shown. (B) The plots of % cumulative release vs. time 
square root of the three candidate carriers are shown for the whole period of 
release. The insert shows the plot of the first 60% cumulative release vs. time 
square root of all carriers. The correlation efficient (R2) and slope (y) for each 














Figure 37. In vitro cytotoxicity of PEGDA-gelatin containing eluates.  
P600:G5, P1000:G10 and collagen sponge disks were prepared and immersed in 
α-MEM supplemented with 10% FBS and 1%P/S at 37ºC for 24 hours, and eluates 
were collected. MC3T3-E1 cells were then cultured in the presence or absence of 
eluates for 24 hours and MTS assay was performed to determine the cytotoxicity 
of eluates. Non-treated MC3T3-E1 cells were used as a positive control. The data 
are shown as mean and SEM of five samples (N=5). Experiments were performed 



















Figure 38. Inhibition of Pyk2 tyrosine kinase activity by the released PF-46.  
PF-46 loaded P1000:G10 gels were immersed in α-MEM supplemented with 10% 
FBS and 1%P/S at 37ºC for 24 hours, and released PF-46 were collected. 293 
VnR cells were transfected with Pyk2 cDNA for 3 days and then treated with 
released PF-46 at different concentrations for 2 hours. (A) Pyk2 
immunoprecipitates (IP) from cells were immunoblotted for Pyk2 as controls. (B) 
The effect of released PF-46 on the intracellular Pyk2 tyrosine kinase activity was 
examined using Universal Tyrosine Kinase Assay Kit. The data are shown as 
mean and SEM of five samples (N=5). Experiments were performed twice and 
representative data are shown. Asterisks (*) indicate statistically significant 
















Figure 39. Effect of released PF-46 on ALP activity in OBs.  
PF-46 loaded P1000:G10 gels were immersed in α-MEM supplemented with 10% 
FBS and 1%P/S at 37ºC for 24 hours, and released PF-46 were collected. Bone 
marrow derived MSCs were differentiated into mature OBs under osteogenic 
conditions for 7 days in the presence or absence of released PF-46 at various 
concentrations, and ALP activity assay was performed. Fresh PF-46 was used as 
positive controls, and untreated cells were used as the negative control. The data 
are shown as mean and SEM of five samples (N=5). Experiments were performed 
twice and representative data are shown. Asterisks (*) indicate statistically 




Figure 40. Schema of Pyk2-inhibitor loaded hydrogel preparation and 
utilization. 
The PEGDA-gelatin prepolymer solution exhibits high viscosity, yield stress, and 
shear-thinning behavior, which is suitable for injectable delivery, keeping the 
solution within the defect site prior to photopolymerization. Importantly, a Pyk2-
targeted inhibitor incorporated into PEGDA-hydrogel enhances OB activity, which 
strongly supports the use of a Pyk2 inhibitor-loaded hydrogel for future bone 































Figure 41. Schematic illustrating the key findings from Chapter 3 and 
Chapter 4 and the potential clinical applications. 
A Pyk2-targeted inhibitor loaded PEGDA-gelatin hydrogel inhibits Pyk2 activity and 
enhances OB activity. We propose the Pyk2 inhibitor will act in a similar manner 
as genetic deletion of Pyk2 to augments bone formation. Thus, the inhibition of 
Pyk2 locally with hydrogel delivery may be a therapeutic tool for bone regeneration 
at sites of craniofacial bone and the other skeletal defects. Furthermore, 
therapeutic strategies that target Pyk2 at the systemic level, with or without with 
estrogen or raloxifene supplementation may improve bone mass in low bone mass 
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